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ABSTRACT 
Dry powder aerosols have attracted increasing attention for the treatment of 
pulmonary diseases due to their capability of providing direct and effiCient drug 
delivery to the lungs. Unfortunately, barriers exist in the implementation of dry 
powder pulmonary delivery systems, including: (1) dry powder aerosols with 
aerodynamic diameters smaller than 1 µm will often be exhaled; (2) particles with 
aerodynamic diameters above 5 µm tend to deposit in the mouth, throat or upper lung 
mucosa and will then be eliminated due to mucosal clearance mechanisms; and (3) 
particles larger than 1 µm that deposit in the deep lung area may be cleared from the 
alveoli via macrophages. Spray-dried nanocomposite microparticles (nCmP), 
combining the advantages of nanoscale and microscale carriers, can be employed to 
overcome these issues. Microscale powders facilitate effective deep lung deposition 
while the embedded nanoscale carriers can provide multiple functions such as the 
protection of active ingredients from degradation, enhancement of the solubility of 
drugs, controlled drug release, and reduction of systemic side effects. Several nCmP 
systems have been developed for various applications, but few comprehensive studies 
have been completed to illustrate how to effectively engineer optimal nCmP systems 
with desired properties including: targeted deposition in airways, controlled release of 
payloads, ability of overcoming physiological barriers, and favorable formulation 
stability. 
This dissertation focuses on the development, characterization, and 
optimization of various dry powder aerosol nanocomposite microparticle systems for 
the treatment of pulmonary diseases. In the production of nCmP, acetalated dextran 
(Ac-Dex) nanoparticles loaded with therapeutics are synthesized, suspended in an 
excipient solution or DI water, and transformed into microscale dry powder 
microparticles via spray drying. Upon pulmonary administration, the nCmP will 
deposit on the surface of the mucosal layer of the lungs and decompose into free NP, 
allowing the nanoparticles to reach the mucus and/or cell epithelium and then release 
drug(s) at sustained rate. Nanoparticles were prepared using Ac-Dex with different 
degradation rates to control the drug release profiles. In this work, various therapeutics 
were encapsulated in nanoparticles, and subsequently nCmP, for applications in the 
treatment of cystic fibrosis-related lung infections or pulmonary arterial hypertension. 
The physical properties of the nanoscale carriers in terms of size, size distribution, and 
surface properties were modified by manipulating the parameters of the nanoparticle 
preparation process. Dry powder aerosols embedded with nanoparticles were 
formulated using spray drying. The aerosol performance was optimized by 
manipulating the composition of feed solution and spray drying parameters. The 
optimal parameters to form nCmP with deep lung and whole lung deposition were 
studied. Furthermore, the favorable drying conditions necessary to achieve high 
therapeutic stability and formulation stability of the particles was also evaluated. 
Overall, dry powder aerosol nanocomposite microparticles have the ability to 
provide pulmonary drug delivery systems with tunable properties to fit a wide variety 
of desired applications. These general-purpose systems exhibit promising potential in 
the improved treatment of pulmonary diseases through particle engineering and design. 
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PREFACE 
This thesis is written in manuscript format. The first chapter is an instruction 
of the entire dissertation. The second chapter, entitled "Nanocomposite Microparticles 
(nCmP) for Pulmonary Drug Delivery Applications," was accepted as a chapter in the 
book, "In Strategies of Nanotechnology in Drug Delivery". The third chapter, entitled 
"Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the 
Treatment of Cystic Fibrosis-Related Infections," is published in Pharmaceutical 
Research. The third chapter entitled, "Nanocomposite Microparticles (nCmP) for the 
Delivery of Tacrolimus in the Treatment of Pulmonary Arterial Hypertension," is 
published in the International Journal of Pharmaceutics. The fourth chapter, entitled 
"Optimization of Nanocomposite Microparticles (nCmP) for Deep Lung Delivery of 
Therapeutics via Spray Drying," was submitted to Powder Technology in October 
2016. The fifth chapter, entitled "Development and Physicochemical Characterization 
of Acetalated Dextran Aerosol Particle Systems for Deep Lung Delivery," was 
submitted to International Journal of Pharmaceutics in October 2016. The seventh 
chapter includes the conclusions and future work related to this dissertation. 
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CHAPTERl 
Introduction 
1.1 Motivation 
Pulmonary drug delivery has exhibited promising potential in the effective 
treatment of lung diseases, as it allows for the delivery of a wide range of therapeutics 
directly and efficiently to the lungs, thereby increasing local drug concentration, 
reducing systemic side effects, providing a rapid onset of pharmaceutical action, and 
avoiding the first-pass metabolism associated with the liver (1-4). As a result, various 
therapeutics such as antibiotics, proteins, peptides, anti-cancer drugs (5), plasmid 
DNA (6), siRNA (7), and anti-tuberculosis (TB) drugs have been employed in 
inhalation formulations for the treatment of pulmonary diseases such as asthma, 
chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF)-related 
pulmonary infections, and lung cancer (5, 8). In comparison to liquid aerosol 
formulations, aerosols based on dry powders offer additional benefits such as 
enhanced stability of the formulations, controllable particle size for targeting specific 
regions of the lung, and increased drug loading of hydrophobic or lipophilic payloads 
(9, 10). Unfortunately, barriers exist in the implementation of dry powder pulmonary 
delivery systems, including: (1) dry powder aerosols with aerodynamic diameters 
smaller than 1 µm will often be exhaled; (2) particles with aerodynamic diameters 
above 5 µm tend to deposit in the mouth, throat or upper lung mucosa and will then be 
eliminated due to mucosal clearance mechanisms; and (3) particles larger than 
1 µm deposited in the deep lung area may be cleared from the alveoli via macrophages 
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(10-12). Spray-dried nanocomposite microparticles (nCmP) can be employed to 
overcome these issues, as the integration of nanoscale and microscale carriers 
combines the benefits of both types of systems. Microscale powders (1 - 5 µm) 
facilitate effective deep lung deposition (12) while the embedded nanoscale carriers 
can provide multiple functions such as the protection of drugs from degradation, 
enhancement of the solubility of drugs, provision of controlled drug release, and 
reduction of systemic side effects (2, 13, 14). Although many nCmP systems have 
been developed, few comprehensive studies have been completed to illustrate the 
effective engineering of optimal nCmP systems for the pulmonary delivery of 
therapeutics. 
To this end, the purpose of this work was to develop and optimize several dry 
powder aerosol nanocomposite microparticle systems for the treatment of pulmonary 
diseases. In the production of nCmP, acetalated dextran (Ac-Dex) nanoparticles 
loaded with therapeutics were prepared using nanoprecipitation (Figure 1.1) or 
emulsion evaporation (Figure 1.2). The resulting nanoparticle were suspended in an 
excipient solution or DI water, and transformed into microscale dry powder 
microparticles via spray drying (Figure 1.3). Upon pulmonary administration, the 
nCmP will deposit on the surface of the mucosal layer of the lungs and decompose 
into free NP, allowing the nanoparticles to penetrate the mucus and then release drug 
at sustained rate. The polymer Ac-Dex was applied to form drug-loaded nanoscale 
carriers with simply tunable release profiles. Various drugs were encapsulated in the 
nanoparticle matrices for the treatment of different pulmonary diseases. Vitamin E 
poly( ethylene glycol) 5000 (VP5k) or polyvinyl alcohol (PV A) coating was used to 
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improve the surface properties of the nanoparticles. Mannitol was employed as 
excipient at various ratios to improve the particle properties in terms of aerosolization 
and storage. The spray drying process parameters were manipulated to optimize the 
aerosol performance of the resulting nCmP and to maintain the desirable properties of 
original nanoparticles. 
Drug and Ac-Dex 
dissolved in lml Ethanol 
Solvent diffusion 
1.65% VPSk in Centrifuge and lyophilize 
to collect nanoparticles 40 ml stirring PBS 
Figure 1.1. Schematic of nanoparticle formulation via nanoprecipitation. 
i= 
PVAinPBS I 
Drug and Ac-Dex 
in DCM 
Sonication 
Solvent 
evaporation 
Centrifuge and lyophilize 
to collect nanoparticle 
Figure 1.2. Schematic of nanoparticle formulation via emulsion evaporation. 
3 
Small particles and air 
---·,' H 
"U 
Big particles 
Figure 1.3. Schematic of nanocomposite microparticle formulation via spray drying. 
1.2 Significance of This Study 
This is a comprehensive study on the development, characterization, and 
optimization of nCmP systems for the treatment of pulmonary diseases. The 
significance of the research discussed in this dissertation is summarized as the 
following: 
1. The nCrnP system can provide a simply tailorable drug release profile of payloads 
by adjusting the synthesis of Ac-Dex polymer that is used for nanoparticle 
preparation. 
2. The nCrnP system can be design to primarily deposit at a targeted location in the 
airways by manipulating the nCmP formulation process parameters. 
3. The nCmP system can overcome various physiological barriers by tuning the 
physical properties of nanoparticles, thus providing effective delivery of 
therapeutics for the treatment of pulmonary diseases. 
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1.3 Objectives of This Research 
The overall objective of this dissertation was to develop, characterize, and 
optimize multipurpose dry powder aerosol nanocomposite microparticle systems for 
the treatment of pulmonary diseases. This involved four projects and the specific 
objectives of these are outlined as follows: 
1. "Synthesis and characterization of nanocomposite microparticles (nCmP) for the 
treatment of cystic fibrosis-related infections": 
a) Prepare azithromycin or rapamycin-loaded nanoparticles with capable of 
mucus penetration and sustained release of therapeutics. 
b) Formulate nanocomposite microparticles capable of delivering therapeutics 
to the deep lung. 
c) Evaluate the physicochemical and aerosol dispersion properties of the 
particulate systems. 
2. "Nanocomposite microparticles (nCmP) for the delivery of tacrolimus m the 
treatment of pulmonary arterial hypertension": 
a) Prepare tacrolimus-loaded nanoparticles capable sustained release. 
b) Formulate nanocomposite microparticles capable of delivering therapeutics 
to the deep lung. 
c) Evaluate the physicochemical and aerosol dispersion properties of the 
particulate systems. 
3. "Optimization of nanocomposite microparticles (nCmP) for deep lung delivery of 
therapeutics via spray drying": 
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a) Identify the optimal spray drying condition in order to prepare 
nanocomposite microparticles with favorable properties including: ability 
of deep lung deposition, desirable nanoparticle re-dispersity, high drug 
loading, and low water content 
4. "Development and Physicochemical Characterization of Acetalated Dextran 
Aerosol Particle Systems for Deep Lung Delivery": 
a) Develop and characterize pulmonary delivery systems based on spray-dried 
Ac-Dex particles with the capability of delivering therapeutics to the deep 
lung, targeting to desired location, and releasing therapeutics in controlled 
rate. 
1.4 Dissertation Organization 
This dissertation will be organized as follows: 
Chapter 2 provides the background information on nanocomposite microparticle 
systems for pulmonary drug delivery applications including an introduction of 
pulmonary delivery of dry powder particle-based therapeutics, a review of 
nanocomposite microparticles for pulmonary delivery, and a discussion of 
nanocomposite microparticles preparation, optimization, and applications. 
Chapter 3 presents the project "Synthesis and characterization of nanocomposite 
microparticles (nCmP) for the treatment of cystic fibrosis-related infections," which 
involves the development of nanocomposite microparticle systems for the delivery of 
antibiotics through viscous lung mucus caused by cystic fibrosis . 
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Chapter 4 includes the project "Nanocomposite microparticles (nCmP) for the delivery 
of tacrolimus in the treatment of pulmonary arterial hypertension (PAH)," which 
involves the development of nanocomposite microparticles for the deep lung delivery 
of tacrolimus, a novel treatment regime for P AH. 
Chapter 5 includes the project "Optimization of nanocomposite microparticles (nCmP) 
for deep lung delivery of therapeutics via spray drying," which discusses the 
optimization strategy necessary in order to prepare nanocomposite microparticles with 
favorable properties including: deep lung deposition, desirable nanoparticle re-
dispersion, high drug loading, and low water content. 
Chapter 6 focuses on the project "Development and Physicochemical Characterization 
of Acetalated Dextran Aerosol Particle Systems for Deep Lung Delivery," which 
involves the development of Ac-Dex particles for targeted delivery and controlled 
release of therapeutics to the deep lung region. 
Chapter 7 concludes the dissertation and also discusses the future directions in the 
development and optimization of multipurpose dry powder aerosol nanocomposite 
microparticle systems for the treatment of pulmonary diseases. 
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2.1. Introduction 
2.1.1. Pulmonary delivery of dry powder particle-based therapeutics 
Aerosols in their dry and wet forms, including steam, gas, and smoke, have 
been used for medical purposes for decades. In 1956, the first metered-dose inhaler 
became available and in 1970 the first dry powder inhaler reached the market ( 1 ). 
Such aerosol systems have been used for many therapeutic applications including local 
administration of chemopreventive agents (2), activators of the local immune system 
(3, 4), and antibiotics, among others. Aerosol delivery of therapeutics to the lungs 
offers an attractive way to deliver high drug concentrations directly to the site of 
disease, reducing toxicity while improving the therapeutic potential. Pulmonary 
delivery is also an attractive route for systemic administration with a more rapid onset 
of action than is traditionally seen when given orally. The rapid onset is due to fast 
absorption of the therapeutic by the massive surface area of the alveolar region, 
abundant pulmonary vasculature, thin air-blood barrier, high solute permeability, and 
the avoidance of first pass metabolism, which degrades many proteins that have shown 
promise for use as biotherapeutics (5, 6). 
There is great promise for advances in pulmonary drug delivery using inhaled 
aerosols for the targeted treatment of respiratory diseases such as chronic obstructive 
pulmonary disease (COPD), asthma, cystic fibrosis, lung cancer, and infectious 
diseases (e.g. tuberculosis) (7). To date, several types of particle-based aerosol 
therapeutics have been developed including nanoparticulates suspended in aqueous 
form from inhalers and nebulizers as well as microparticle-based liquid and dry 
powder formulations. Both nanoparticle and microparticle-only formulations exhibit 
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limitations that will be discussed in detail later, leading to a need in the development 
of advanced formulations using particle engineering techniques. In particular, it has 
been shown that solid drug-loaded nanoparticles can be effectively delivered to the 
lungs when they are encapsulated in a carrier system that dissolves after coming in 
contact with the aqueous environment of the lung epithelium. These so-called 
nanocomposite microparticles (nCmP) can enhance the delivery of therapeutics via the 
aerosol route as described in the following sections. In this chapter, a general overview 
of pulmonary delivery and the current state-of-the-art related to nCmP will be 
followed by an overview of current nCmP systems and their design considerations. 
2.1.2. Dry powder aerosol delivery devices 
The most common inhaler devices are nebulizers, pressurized metered-dose 
inhalers (MDI), and dry powder inhalers (DPI). Nebulizers deliver liquid medication 
in a steady steam of tiny droplets, do not require patient coordination, and can deliver 
larger doses compared to the other devices (5). MDis are the most popular devices 
used to treat local respiratory diseases and their mechanism utilizes a valve designed 
to deliver a precise aerosol amount each time the device is actuated (8, 9). DPis are 
portable devices that deliver medication in the form of a dry powder directly to 
airways (10). Traditional dry powder blends are typically comprised of micronized 
drug particles with a mass median aerodynamic diameter (MMAD) less than 5 µm 
blended with inactive excipients of larger sizes (11-13). The drug is delivered when a 
patient inhales, pulling air through a punctured capsule, blister, or reservoir. 
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Advantages of DPis are that they are portable, compact, and have multi-dose 
functionality. DPis are breath-activated and unlike MDis do not require any outside 
energy source or propellant, eliminating the need to coordinate actuation and 
inhalation (14). Another practical advantage of using a dry powder system is the far 
slower degradation of drugs in the dry state as compared to their suspension in a liquid 
form, resulting in higher long-term stability and sterility (6). Dry formulations of 
nanoparticles also reduce inter-particle attractive forces as does blending with larger 
carrier molecules, which improves aerodynamic performance (15). The use of 
biodegradable particles in DPis may increase the bioavailability of therapeutic agents 
and change the pharmacokinetic plasma profile, making the agent more suitable for 
pulmonary delivery (16). 
DPis have many advantages with respect to medication delivery; however, 
they are not without their disadvantages. These disadvantages include poor deposition 
in the lower bronchioles and alveoli as well as the limited availability of drugs from 
the device itself. In many cases, DPis are a relatively new technology still in the 
development stage, in comparison to the more established nebulizer and MDI 
technology. A more detailed overview of aerosol delivery devices can be found 
elsewhere (17-20). Overall, the ease of use and powder storage advantages discussed 
further in this chapter provide strong reasoning for the application of DPis to deliver 
advanced dry powder formulations. 
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2.1.3. Overview of current dry powder aerosol therapeutics 
As seen in Table 2.1, diseases that most commonly incorporate DPis in 
treatment regimens are asthma and chronic obstructive pulmonary disease (COPD). 
COPD affects over 5% of the U.S. population and kills 120,000 individuals each year, 
ranking it as the third-leading cause of death. Management for asthma and COPD 
consists of short-acting bronchodilators for acute exacerbations and in more severe 
disease, daily maintenance therapy with bronchodilators and anti-inflammatory 
medications. Tiotropium bromide is an anticholinergic bronchodilator given to COPD 
patients via DPI in the U.S. A meta-analysis of various clinical trials found tiotropium 
to significantly improve mean quality of life and significantly reduce the number of 
participants suffering from exacerbations (21 ). 
Combination therapy with an umeclidinium-vilanterol DPI is approved for 
once-daily use for COPD patients in the U.S. Compared to individual agents, this 
formulation results in greater increases in forced expiratory volume over I-second 
(FEVI) at both trough and mean peak levels (22). In addition, a once-daily 
fluticasone-salmeterol DPI is FDA approved for COPD treatment (23). While not yet 
FDA-approved, a once-daily DPI containing glycopyrronium and indacaterol is 
approved for use in Europe and Japan (24). Also, a twice-daily combination DPI 
comprised of aclidinium-formoterol is approved for use in Europe, the United 
Kingdom, and Canada (25). 
Asthma maintenance therapy is often similar to that seen in COPD with the 
goals of bronchodilation and reduction in inflammation. Some examples of these DPis 
can be seen in Table 2.1. Recently, in April 2015, the FDA approved a new DPI 
14 
device for albuterol sulfate administration. Albuterol, traditionally delivered via MDI, 
is a short-acting beta-agonist (SABA) that is commonly used as a rapid and effective 
treatment for acute asthma exacerbations, in which the throat and airways can 
eventually close off if left untreated. In a news release, David I. Bernstein was quoted, 
"ProAir RespiClick is the first and only breath-actuated dry-powder rescue inhaler to 
be approved by the FDA for the treatment of acute asthma symptoms (26). In addition 
to the treatment of reactive airway diseases, DPis can also be used in diagnostic 
applications. Aridol is a DPI that delivers mannitol, a sugar alcohol, to the lungs to 
assess for hyperresponsiveness, which indicates whether or not a patient has asthma. 
Research has been conducted to develop particles for DPis including theophyllyne 
with sodium stearate and salmeterol xinafoate with lactose, both for the treatment of 
asthma. 
Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) protein. Current U.S. 
guidelines suggest treating all CF patients older than 6 years with chronic pulmonary 
infections with inhaled antibiotics, first tobramycin, then aztreonam, and finally 
colistin. Aerosolized antibiotic therapy is traditionally given through a nebulizer; 
however, in March 2013 the TOBI Podlialer was approved as a DPI alternative for 
inhaled tobramycin. A trial comparing the tobramycin-inhaled powder (TIP) versus 
nebulized solution found that TIP was generally well tolerated, provided a 
significantly more convenient treatment option, and resulted in a higher 
discontinuation rate (27-29). Colistin, while considered third-line by U.S. guidelines, 
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is frequently used as first choice in Europe for CF patients (30). The DPI form of 
colistin (Colobreathe) is approved for use in Europe. 
Antibiotic DPI formulations including vancomycin and clarithromycin with 
dipalmitoylphosphatidylcholine have been developed for the treatment of pulmonary 
infections (31 ). In addition, azithromycin microparticles have been developed 
successfully in an inhalable aerodynamic range(< 10 µm) (32). 
Table 2.1. Current dry powder inhaler (DPI) formulations approved by the FDA 
including the approval date, brand date, active pharmaceutical ingredient (API), 
disease, and company. 
Date Brand Name API Disease Company 
2015 Pro Air Albuterol sulfate Asthma Teva 
Respiclick 
2014 Amuity Fluticasone furoate Asthma GlaxoSmithKline 
Ellipta 
2014 Incruse Ellipta Umeclidinium COPD GlaxoSmithKline 
2013 Tobi Podhaler Tobramycin Cystic fibrosis Novartis 
2013 Breo Ellipta Fluticasone furoate, COPD GlaxoSmithKline 
vilanterol 
2013 Anoro Ellipta Umeclidinium, COPD GlaxoSmithKline 
vilanterol 
2012 Tudorza Aclidinium bromide COPD Forest Labs 
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Pressair 
2011 Arcapta Indacaterol COPD Novartis 
2010 Aridol Mannitol Asthma (testing) Pharmaxis 
2006 Pulmicort Budesonide Asthma Astrazeneca 
Flexhaler 
2005 Asman ex Mometasone furoate Asthma Merck 
Twisthaler 
2004 Spiriva Tiotropium COPD Boehringer 
Ingelheim 
2001 Foradil Formoterol fumarate Asthma, COPD Novartis 
Aerolizer 
2000 Advair Diskus Fluticasone Asthma, COPD Glaxo 
propionate, 
salmeterol xinafoate 
2000 Flovent Diskus Fluticasone Asthma GlaxoSmithKline 
1999 Relenza Zanamivir Influenza GlaxoSmithKline 
1986 Provocholine Methacholine Diagnosis of Methapharm 
Chloride bronchial airway 
hyperreactivity 
2.1.4. Obstacles in pulmonary delivery of particle-based therapeutics 
The human lungs have the innate ability to remove aerosolized particulates, 
which can decrease the delivered aerosol drug load. The natural removal mechanisms 
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include mucociliary clearance, phagocytosis, and enzymatic degradation. Mucociliary 
clearance is a critical host defense mechanism of the airways to clear locally produced 
debris, excessive secretions, or unwanted inhaled particles. It consists of ciliated 
epithelial cells present from the naso/oropharynx and the upper tracheobronchial 
regions down to the most peripheral terminal bronchioles (33). Effective mucociliary 
clearance requires appropriate mucus production and coordinated ciliary activity (34 ), 
including the "mucociliary escalator," where ciliated epithelia sweep particles in the 
upper airways away from the lungs towards the mouth (35). 
Phagocytosis occurs primarily in the deep lungs where alveolar sacs rich in 
macrophages play a key role in innate immune defense. Particles 1 - 5 µm in size are 
typical of bacteria and are readily engulfed via phagocytosis, thereby limiting the 
bioavailability of therapeutics (36). Phagocytic activity is maximized for particles 1-
2µm in diameter and less so for smaller or larger particles outside of this range (37). 
The contribution of pulmonary endocytosis to the overall lung clearance is determined 
by the particle size and shape, solubility, particle burden, and chemical nature of the 
inhaled aerosols. 
Macromolecular drugs are also susceptible to enzymatic degradation. The 
contribution of drug breakdown along with other pulmonary clearance mechanisms is 
minimal in comparison with the gastrointestinal tract; however, it requires 
consideration in enzyme-sensitive compounds. Therefore, to protect from rapid 
clearance or degradation and achieve sustained release within the lung, encapsulation 
into nanoparticles or microparticles has been pursued. 
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Systemic diseases can be treated via pulmonary delivery as formulations and 
their released drugs can translocate from lung tissue to the cardiovascular endothelium. 
The mechanisms by which therapeutics are translocated from the lung occurs by either 
transcellular or paracellular transport. In transcellular transport, absorption of the 
therapeutic typically occurs through receptor/carrier-mediated endocytosis. This is a 
slow process (hours to days) and occurs for larger particles (>5-6 nm) having 
molecular weights of more than 40 kDa (36). Transcellular transport involves the 
internalization of caveolin-1, transcellular channels, and vesicular trafficking. 
Paracellular transport involves diffusion of drug through alveoli, which is a fast 
process (5 to 90 minutes) and happens in the case of smaller molecules (<5-6 nm). 
Several studies have evaluated the mechanisms of nanoparticle interaction with the 
lung and translocation of nanoparticles from nanocomposite microparticles through 
the epithelial barrier (38, 39). 
Nanocomposite microparticles offer the ability to overcome many of the 
barriers associated with the aerosol delivery of therapeutics. First, nCmP are typically 
an appropriate size for effective pulmonary delivery (e.g. micrometer) and thereby can 
be delivered to all locations in the lungs. While micro-sized particles are usually 
removed from the lungs via mucociliary clearance and/or phagocytosis, nCrnP can be 
designed to rapidly release nanoparticles from the nCmP bulk in a very quick fashion 
to avoid these clearance mechanisms. In addition to avoidance of pulmonary clearance, 
the nanoparticles released from nCmP offer their own advantages including the ability 
to translocate through mucus, penetrate into cells, and translocate across the 
19 
pulmonary epithelium/cardiovascular endothelium barrier ( 40, 41 ). At this point, the 
use of nCmP is the only effective way to delivery dry nanoparticle-based therapeutics. 
2.1.5. Design for pulmonary deposition of particles 
With respect to aerosol formulation and design, drug distribution and 
deposition along the respiratory tract depends on many characteristics of the inhaled 
formulation including the diameter, size distribution, shape, charge, density, and 
hygroscopicity of the particulate system. The mass median aerodynamic diameter 
(MMAD) and geometric standard deviation are what determine the site of deposition 
in the respiratory tract ( 42). 
Dry powder particle formulations used in pulmonary applications must exhibit 
specific physical properties for successful implementation. Respirable particles with 
an MMAD between 0.5 and 5 µm undergo deposition in the alveolar region, which 
can facilitate systemic bioavailability (43, 44). Particles larger than this may 
potentially be deposited in the inhaler, oropharynx, and/or larynx, or they may not 
reach the desired site within the lung due to size constraints. For example, it was 
shown that decreasing the particle size from 5.4 µm to 2.7 µm reduced the total throat 
deposition by half and increased the total lung deposition by over two-fold for 
mannitol particles ( 45). 
The process of particle deposition in human airways includes: a) inertial 
impaction, which is dominant in the upper airways where velocities are at a maximum 
and where many particles impact and stick to the pulmonary surface, b) sedimentation, 
which is predominant throughout the central and distal tract, where the particles settle 
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on the surface of the lung due to gravitational forces and air resistance, and c) 
diffusion, which is the most important for submicrometer-sized particles ( < 0.5 µm), 
which are in random motion and deposit on the lung walls via Brownian motion (33, 
42, 46). Previous studies have shown that the size and distribution site of particles 
inhaled in the lungs is as follows: particles smaller than 1 µm tend to diffuse, 
remaining suspended in the airways, and are typically exhaled; particles 1 - 3 µm in 
diameter deposit primarily in the alveolar region, 8 - 10 µm-sized particles undergo 
tracheobronchial deposition; and particle larger than 10 µm often exhibit deposition in 
the mouth (36). 
2.1.6. Long-term storage considerations 
Another major concern in the development of powder aerosols is in the storage 
of particles, which tend to agglomerate (16). In general, the more uniformly the 
particles are distributed, the more stable their shelf life is (47). Spray-drying, freeze-
drying, and spray-freeze-drying often improve long-term particle stability during 
storage for dry formulations in comparison to aqueous formulations. For example, 
freeze-dried poly(methylidene malonate) nanoparticles were stored for twelve months 
at different temperatures and showed no significant variations in pH, size, turbidity 
and cytotoxicity ( 48). Suspensions of freeze-dried PLGA microspheres, either alone or 
loaded with cyclosporine, were stored at 8°C and room temperature (RT) for six 
months. The suspensions were substantially instable while the freeze-dried particles 
showed an alternative for long-term stability at low temperatures (49). In another 
study, a poorly soluble drug, celecoxib, was formulated into solid phospholipid 
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nanoparticles and showed that the amorphous matrix generated via spray-drying and 
freeze-drying significantly enhanced the dissolution rates and apparent solubility (50). 
Another technique applied to enhance stability and solubility of particles is 
spray-drying. TIP used for the treatment of cystic fibrosis was designed and 
formulated considering the process parameters related to critical temperature 
transitions. A room temperature stable product was obtained that reqmres no 
refrigeration (51). Gentamicin particles for cystic fibrosis developed with L-leucine 
showed no significant degradation for up to 6 months of storage (52). Spray-freeze-
drying is a relatively new method of producing biopharmaceutical powder 
preparations. It combines the advantages of freeze- and spray-drying techniques in 
order to get a stable product and increase the solubility of poorly water-soluble drugs. 
This technique was used to obtain a fine stable probiotic powder of Lactobacillus 
casei in mannose and CaC03 (53). Finally, re-aggregation of palygorskite nanofibers 
containing ofloxacin was successfully overcome by freeze-drying. Comparing with the 
traditional oven-dried sample, the freeze-dried sample showed enhanced dispersion 
stability of palygorskite in deionized water (54). 
2.2. Nanocomposite microparticles: a solution for overcoming the obstacles of 
particle-based pulmonary delivery 
Nanocomposites are an emerging class of materials utilized in pulmonary drug 
delivery. Such systems are typically multiphase structures, comprised of a single 
continuous phase or matrix (e.g. polymers) with one or more discontinuous or 
dispersed phases (e.g. drugs). A formulation of nanocomposite microparticles (nCmP) 
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utilizes a combination of phase or matrix components, active pharmaceutical 
ingredients (APls), and inert components (excipients) as seen in Figure 2.1. Although 
the overall size of the nanocomposite microparticles can vary between 0.1 - 100 µm, a 
fraction of these particles having aerodynamic diameters 1-2 µm have been reported to 
be more effective in depositing into alveolar spaces (55). The properties of 
nanocomposite materials typically differ from conventional composite materials 
owing to the 'critical size' or 'nanometer range' of the dispersed drugs in the matrix, 
which enhances the properties of the nanocomposite particle. 
Drug-Loaded 
Nano particles 
Excipien.t 
Figure 2.1. Schematic of nanocomposite microparticle (nCmP) system used for 
pulmonary delivery applications. 
A list of nCmP developed for the treatment of pulmonary diseases is outlined 
in Table 2.2. The examples in this table not only cover a wide variety of pulmonary 
applications but also include different encapsulated nanoparticle (NP) systems, APis, 
and carriers. The loaded NP are primarily polymer-based, however, systems with 
metals (iron oxide) and pure drug are also present. The table encompasses a 
comprehensive overview of the current pulmonary nCmP systems that have been 
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designed and evaluated and one significant conclusion is that the majority of the 
systems were fabricated via spray drying, which is a fairly straightforward, accessible, 
and high throughput synthesis method. 
Table 2.2. Overview of nanocomposite microparticles (nCmP) systems used to deliver 
therapeutics for pulmonary applications with their active pharmaceutical ingredient 
(API), treatment application, and key findings. 
Encapsulated API/ Carrier/ Synthesis Application/ 
NP Payload Excipient Method Disease 
Treated 
Haloperidol- Doxorubicin Trehalose, Spray drying of Cancer 
bovine serum L-leucin, NP suspension 
albumin NP (56) mannitol 
Iron oxide - D- Spray drying of Thermal 
magnetic NP mannitol NP suspension treatment of 
(57) the lung 
diseases 
Poly(glycerol Antigen L-leucine Spray drying of Pneumonia, 
adipate-co-v- PspA or NP suspension delivery of 
pentadecalacton) BSA protein 
NP 
(58, 59) 
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Poly(e- Hydrocortis Poly(lacti Double emulsion Cancer 
caprolactone) one acetate c-co-
NP glycolic) 
(60) acid 
(PLGA) 
PLGANP Salmon Chitosan Spray drying Enhanced 
(61) calcitonin fluidized bed pulmonary 
granulation and absorption of 
dry powder drug 
coating 
techniques 
PLGANP and Tobramycin Lactose Spray drying of Delivery of 
alginate/PLGA NP suspension antibiotic 
NP 
(62) 
Chitosan/tripolyp Itraconazole Lactose, Spray drying of Delivery of 
hosphate (TPP) mannitol, NP suspension antifungal drug 
NP L-leucine 
(63) 
Itraconazole Itraconazole Mannitol, Spray drying of Invasive 
nanosuspension sodium NP suspension pulmonary 
(64) taurochol aspergillosis 
ate 
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PLGANP Coumarin 6 - Spray drying of Alveolar tissue 
(65) NP suspension targeting 
Chitosan/TPP Isoniazid Lactose, Spray drying of Tuberculosis 
NP mannitol, NP suspension 
(66) maltodext 
nn, 
leucine 
PLGANP Levofloxaci poly( vinyl Spray drying of Delivery of 
(67) n alcohol) NP suspension antibiotic 
(PVA), 
leucine 
Glyceryl Thymopenti Mannitol, Spray drying of Delivery of 
monostearate n leucine SLN suspension peptide 
/soybean 
phosphatidy lchol 
ine solid lipid NP 
(SLNs) 
(37) 
PLGANP siRNA Trehalose, Spray drying of Delivery of 
(68) lactose, NP suspension siRNA 
mannitol 
PLGANP Rifampicin L-leucine Spray drying of Tuberculosis 
(69) NP suspension 
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Tobramycin Tobramycin - Spray drying of Delivery of 
nano suspension NP suspension antibiotic 
(70) 
PLGANP Rifampicin Mannitol Four-fluid nozzle Tuberculosis 
formed during spray drying 
spray drying 
(71) 
PLGANP Rifampicin Trehalose, Spray drying of Tuberculosis 
(72) lactose NP suspension 
PLGA/Polyethyl Plasmid Mannitol Spray drying of Gene delivery, 
enimine (PEI) DNA nano sphere vaccination 
nanospheres (pCMV- suspens10n 
suspension Luc) directly 
(73) 
Pranlukast Pranlukast Mannitol Four-fluid nozzle Asthma 
hemihydrate hemihydrate spray drying 
particles formed 
during spray 
drying 
(74) 
Polyacrylate NP - Phospholi Spray drying of Pulmonary 
and silica NP pids NP suspension delivery 
(75-77) 
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Chitosan/TPP FITC-BSA Mannitol Spray drying of Delivery of 
NP NP suspension protein 
(78) 
Poly(butylcyano FITC- Lactose Spray drying of Pulmonary 
acrylate)(PBCA) dextran NP suspension delivery 
NP 
(79) 
PBCANP Doxorubicin Lactose Spray freeze- Cancer 
(80) drying of NP 
suspension 
Chitosan/TPP Insulin Mannitol, Spray drying of Delivery of 
NP lactose NP suspension protein 
(81) 
T erbutaline Terbutaline Glyceryl Spray drying of Delivery of 
sulphate sulphate behenate/ NP suspension drug with 
nano suspension Tripalmiti sustained 
(82) nor release 
Hydrogen 
atedpalm 
oil 
Gelatin or PBCA Dextran Lactose Spray drying of Delivery of 
NP NP suspension drugs and 
(83) diagnostics 
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Polystyrene NP - Phospholi Spray drying of Pulmonary 
(84) pids NP suspension drug delivery 
As seen in Figure 2.2, nCmP formulations exhibit a variety of morphologies 
ranging from nanocomposite microcrystals, solid nanoparticle spheres, hollow 
nanoparticles spheroids, nanoparticle agglomerates, and nanoparticles dispersed in a 
carrier. The morphology can be tuned via synthesis parameters in order to ensure 
effective API delivery, stability, and and/or targeted pulmonary deposition. 
2.3. Preparation of nanocomposite microparticles (nCmP) 
Particle engineering is a key factor in the development of nCmP systems with 
desirable properties (85). In this section, we review techniques used in the preparation 
of nanoparticles that are used in nCmP formulations as well as techniques used to 
prepare the nCmP systems themselves. 
2.3.1. Techniques used to prepare drug-loaded nanoparticles 
2.3.1.1. Solvent evaporation 
In this method, two mam strategies are used to form emulsions including 
single emulsions with oil-in-water (o/w) and double emulsions with water-in-oil-in-
water (w/o/w) phases. For single emulsion, drugs and polymers are dissolved in oil 
phase, while in double emulsion, drugs are usually in inner water phase. Volatile 
solvents such as dichloromethane, chloroform, and ethyl acetate are mostly used as oil 
phase. The emulsions are formulated using high-speed homogenization or 
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ultrasonication and converted into nanoparticle suspension by solvent evaporation in a 
spinning solution with surfactant (88). 
(1) (4) 
(2) (5) 
Figure 2.2. Representative nanocomposite microparticles (nCmP) systems imaged via 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), and 
fluorescence imaging. The nCmP systems and imaging techniques are: (l)spray-dried 
NaCl particles (SEM), (2) hollow spherical LPNP (SEM), (3) poly(styrene) (top) and 
poly(lactide-co-glycolide) (bottom) where scale bar is 1 µm (SEM), ( 4) magnetic 
nCmP (TEM), and (5) hollow fluorescently-labeled polycyanoacrylate NP 
(fluorescence microscopy) (57, 83 , 86, 87). 
2.3.1.2. Nanoprecipitation 
Nanoprecipitation, also called solvent displacement, is used to prepare 
nanoparticles by precipitating polymer at the interface between the water and the 
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organic solvent. The precipitation is driven by the diffusion of the organic solvent into 
the aqueous phase with or without surfactant. Therefore, water-miscible solvents like 
acetone, methanol, or ethanol are recommended. The nanoprecipitation method often 
results in high drug loading and encapsulation efficacy for hydrophobic drugs, 
however, it is not an efficient means to encapsulate water-soluble drugs because of the 
high diffusion rate of drug from organic solvent into water (88). 
2.3.1.3. Emulsification/solvent diffusion 
Emulsification/solvent diffusion 1s a modified vers10n of the solvent 
evaporation method. In this method, an oil phase is formed by dissolving drug and 
polymer in a partially water soluble solvent such as propylene carbonate. This mixture 
is saturated with water to ensure the initial thermodynamic equilibrium of both liquids 
and then emulsified in an aqueous solution of surfactant. The solvent will diffuse into 
the aqueous phase leading to nanoparticle or nanocapsule formation and will then be 
eliminated by evaporation or filtration, according to its boiling point. This method also 
allows a high drug loading and encapsulation efficacy for hydrophobic drugs as well 
as for hydrophilic ones (88). 
2.3.1.4. Salting out 
Salting out, regarded as the modified vers10n of emulsification/solvent 
diffusion, is based ori the separation of a water-miscible solvent from aqueous solution 
caused by a salting out effect. In this method, drug and polymer are dissolved in a 
water-miscible solvent such as acetone. The mixture is emulsified in an aqueous gel 
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containing a salting-out agent such as magnesmm chloride, calcium chloride, 
magnesium acetate, or sucrose as well as surfactant and is then diluted with a 
sufficient volume of aqueous solution to enhance the diffusion of solvent into the 
aqueous phase. Nanoparticles are formed as the result of solvent diffusion. The salting 
out agent is the key factor in the method influencing the efficacy of encapsulation but 
should be eliminated with solvent in the end. This method exhibits an advantage over 
others by avoiding high stress and increased temperature, which is suitable for protein 
encapsulation. Salting out is ineffective for hydrophobic drug and requires extensive 
washing steps (88-90). 
2.3.1.5. IJialysis 
Dialysis can be used as a simple and effective method for the preparation of 
nanoparticles of small size and narrow distribution (88). However, the mechanism of 
this method is not completely understood right now and is regarded as similar to that 
of nanoprecipitation (91). In dialysis, polymer and drug are dissolved in an organic 
solvent inside a dialysis tube with a proper molecular weight cut off. As the solvent 
displacement progresses, aggregation of polymer happens due to loss of solubility, 
thus forming a nanoparticle suspension. The properties of resulting nanoparticles are 
influenced by the type of solvent used in salting out. 
2.3.1.6. Supercriticalfluid (SCF) technology 
A supercritical fluid is defined as any substance at a temperature and pressure 
above its critical point. Supercritical fluids are defined as compressed gases or liquids 
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above their critical pressures and temperatures, which exhibit several fundamental 
advantages as solvent or non-solvent. For pharmaceutical manufacturing, supercritical 
C02 is widely used due to its low critical temperature (31.1 °C) and moderate pressure 
(73.8 bar), non-toxic inert nature, and low cost. Supercritical fluid technology offers 
an environmentally friendly way to make nanoparticles due to efficient extraction and 
separation of organic solvents in this process. The resulting nanoparticles are in pure 
dry form or as pure aqueous suspensions (92). 
2.3.1. 7. Preparation of nanoparticles from polymerization of monomers 
Nanoparticles with desired properties can be prepared by polymerization of 
monomers. This method can be subdivided into emulsion polymerization, mini-
emulsion polymerization, interfacial polymerization, and controlled/living radical 
polymerization. For this method, toxic organic solvents, surfactants, monomers and 
initiators must be removed from formed nanoparticles, which limit the use of the 
method (88). 
2.3.2. Techniques used to prepare nCmP 
The aerosol performance of nCmP is directly related to their preparation 
techniques. In this section, both traditional and more advanced methods used in the 
preparation of nCmP are discussed (93). These methods are classified into two 
categories, including top-down as milling larger particles to reduce size and bottom-up 
precipitation of nanoparticles out of solution. Techniques such as the modification of 
spray drying also show promise to prepare nCmP (94). 
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2.3.2.1. Milling 
Milling is the traditional method of drug powder micronization, which has 
been intensively studied. The milling method can involve the use of ball mills, colloid 
mills, hammer mills, and jet or fluid energy mills, in which the jet mill is applied to 
prepare most inhalation powders. Jet milling is defined as a process of micronization 
by inter-particle collision and attrition. In this method, coarse particles carried by a 
high velocity gas as milling medium pass through a nozzle into the jet mill. The 
particles are then suspended in the turbulent gas stream where they break into smaller 
particles due to inter-particle collisions. The fine particles are then taken up by the gas 
stream out through the exit, while the larger ones remain in the mill for further 
micronization by more inter-particle collision. The application of jet milling is limited 
by lack of control over resulting particle properties and the high energy in the process 
increasing the risk of degradation of therapeutics (94, 95). 
2.3.2.2. Supercritical fluid technology (SCF) 
Supercritical fluid technology can also be used for preparation of micro-size 
inhalation as discussed previously. More specific discussion of SCF could be found in 
several review articles (85, 94, 95). 
2.3.2.3. Spray drying 
Spray drying is the most commonly used method to prepare dry powders for 
inhalation (96). In spray drying, nanoparticle suspensions with or without excipients 
are atomized at the nozzle. The droplets of the suspension go through the drying 
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chamber with heated gas, resulting in evaporation of solvent and generation of nCmP. 
The resulting nCmP are separated in a cyclone separator and collected in the collector 
(97). The spray drying method provides easily tunable process conditions and high 
reproducible properties of resulting particles. However, challenges exist to determine 
optimal processing conditions to achieve desirable properties, due to the fact that the 
drying process depends on complex parameters including the solvent used, solute 
concentration, inlet temperature, outlet temperature, atomizing pressure, feed 
properties, pump rate, drying gas type, and gas flow rate (81, 96, 98, 99). 
2.3.2.4. Spray-freeze drying (SFD) 
Spray freeze-drying is a modified version of spray-drying, in which the 
suspension or solution is atomized into a cryogenic liquid such as liquid nitrogen 
generating droplets (95). The droplets are then lyophilized, resulting in porous 
spherical particles suitable for inhalation. Application of SFD is limited by several 
disadvantages such as causing irreversible damage to the proteins by drying and 
freezing stress, time consumption, and high expense (100). 
2.3.3. Materials and excipients used in the preparation of nCmP 
2.3.3.1. Drug-loaded nanoparticle materials 
The materials used in the polymer matrix of nanoparticles should exhibit 
biodegradable and biocompatible properties in themselves as well as their degradation 
products. These polymers could be natural polymers such as chitosan gelatin, sodium 
alginate, and albumin, or synthetic polymers including polylactides (PLA), 
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polyglycolides (PGA), poly(lactide-co-glycolides) (PLGA), poly(methylmethacrylate) 
(PMM), poly(cyanoacrylate) (PCA), poly(caprolactone) (PCL), and poly(ethylene 
glycol) (PEG)-conjugated- PLGA. To select a polymer as nanoparticle matrix, the 
nanoparticle formation techniques, the encapsulated drugs, the properties of polymers, 
and further nCmP preparation methods should be taken into consideration. In addition, 
the desired properties of nanoparticles are also an important concern when choosing 
polymers. Detailed discussion on the materials used for nanoparticle formation can be 
found in former reviews (6, 84, 88, 89, 101-109). 
2.3.3.2 Excipients used in nCmP synthesis 
The nCmP carriers and excipients are the inactive ingredients used to improve 
the delivery efficacy and stability of nCmP formulations for pulmonary delivery. The 
excipients have no therapeutic effects, but still have a significant role to form a desired 
delivery system of therapeutics by enhancing the mechanical properties of dry powder, 
physical or chemical stabilization of drug, and improving redispersion and dissolution 
properties of encapsulated nanoparticles (94). The Food and Drug Administration 
(FDA) recommends the use of excipients that are either commercially established or 
"generally recognized as safe" (GRAS). Hence, the choice of excipients used for 
nCmP formation is limited since the current excipients approved for pulmonary drug 
delivery are very limited in number (110). Detailed discussion on the excipients used 
for inhalation application can be found in other review and research articles (43, 94, 
111, 112). 
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2.4. Optimization of nCmP manufacturing via spray drying 
While there are obviously many methods available for the synthesis of nCmP, 
spray drying has been the primary method to date. Spray drying is a straightforward 
and high throughput method allowing for easy reproduction of nCmP and thus the 
remaining sections of this book chapter will focus on the optimization of nCmP via 
spray drying. In a spray drying process, several parameters can be optimized to 
achieve desirable properties for nCmP formulations. In this section, these parameters 
are classified into two major categories: 1) spray drying conditions and 2) feed 
solution composition. The spray drying conditions include the inlet temperature, 
aspirator, spray gas flow, feed speed (pump rate), which can be easily tuned through 
the control panel of spray dryer, and humidity of drying gas, which can be modified by 
incorporating a dehumidifier or using dry nitrogen or compressed air. The feed 
solution composition covers the ratio of nanoparticles to carriers ( excipients ), solid 
concentration (concentration of total dry materials), properties of carriers, properties 
of nanoparticles, and solvent composition (18, 113-115). 
The relevant parameters for the spray process correlate with and depend on 
each other. Therefore, to design an optimal nCmP system with parameters suitable for 
desirable resulting particles, a comprehensive evaluation of all parameters should be 
taken. However, difficulties exist in the selection of the process conditions, lying in 
the facts that: 1) a single change in parameter may influence several other properties 
of spray drying products; 2) several parameters may influence one property of spray 
drying products and these parameters depend on each other; and 3) a parameter may 
have positive effects on products in one range and negative effects or no influence in 
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another range. In summary, there is no best spray drying condition for any given 
system, but only an optimal condition that is most suited for a product intended for a 
certain therapeutic application. This section aims at providing a strategy in the design 
of optimal process conditions and to aid in the understanding of the internal 
relationship between the process parameters and corresponding properties of resulting 
particles. 
2.4.1. How spray dryer settings influence dry powder formulations 
There are many spray dryer settings that influence the characteristics of dry 
powder formulations like nCmP (116, 117). These settings include the inlet 
temperature, aspiration rate, feed (pump) rate, spray-drying gas flow rate, composition 
of feed solution, and other external parameters discussed below. 
The inlet temperature is directly proportional to outlet temperature, which is 
the actual temperature at which the spray-dried materials are exposed. A higher inlet 
temperature is able to reduce the relative humidity in the drying gas, resulting in dryer 
and less sticky powders, thus increasing the powder yield. Aspiration, which provides 
a gas flow depending on the pressure drop of the overall system, reflects the drying 
energy that the system exerts on the drying process. The aspiration rate leads to a 
positive effect on increasing outlet temperature, reducing the amount of residual 
moisture in the product, and thus improving the degree of product separation in the 
cyclone. The feed rate affects the amount of time that materials undergo the drying 
process. A higher feed rate results in larger droplet dispersion in the drying chamber, 
which decreases the outlet temperature. An increase in the feed rate also increases the 
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moisture content in the gas, resulting in more humid or moist products that could 
adhere to the glassware (cyclone or collector), thereby decreasing the yield. The spray-
drying gas flow rate is another parameter that affects the products. Higher gas leads to 
a reduction in outlet temperature and reduces the droplet size, thus decreasing the size 
of resulting particles. 
While the previous parameters can be tuned through the control panel of the 
spray dryer, the feed composition of the spray-dried solution can also affect the final 
powder product. A direct result of increasing the feed concentration is a decrease in 
the solvent amount, which results in less liquid evaporation, leading to higher outlet 
temperature. An increase in the feed concentration also reduces the partial pressure of 
solvent in the gas, leading to less water in the final product. The feed concentration 
exerts a positive influence on the particle size due to an increase of solid in droplets 
and a higher yield contributes to the ease in the collection of larger particles. The use 
of an organic solvent for the feed solution will result in smaller particles due to lower 
surface tension of these solvents. The organic solvent also requires less energy to 
vaporize, leading to higher outlet temperatures, thus resulting in dry products. Finally, 
the humidity of the drying gas can be reduced through the use of a dehumidifier or 
using ultra dry nitrogen, and this has a negative influence on the vapor uptake 
capability in the gas stream, resulting in positive effects on outlet temperature. As a 
result, higher drying gas humidity leads to higher humidity of the final products with 
lower yield. 
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2.4.2. A theoretical framework of nanocomposite microparticle (nCmP) 
formation 
After a greater understanding of how spray dryer parameter settings influence 
the spray-drying process and resulting materials, we can move on to the more 
complicated spray-drying process with nanoparticles. Nanoparticles with various 
properties add complexity into the drying process in the droplet of feed solution 
dispersed in the drying chamber, while the formation process of droplet is affected by 
parameters such as the feed speed, aspirator speed, and drying gas flow rate. The 
engineering of nCmP formation requires an overall understanding of microbiology, 
chemistry, formulation science, colloid and interface science, heat and mass transfer, 
solid state physics, aerosol and powder science, and nanotechnology (18). 
Figure 2.3 shows nCmP formation from a droplet of feed solution in the spray-
drying process. Unlike traditional spray-dried formulations, where particle formation 
is due to the micronization and drying process of dry materials in feed solution, novel 
nCmP systems exhibit sophisticated inner attributes and substructures. During nCmP 
formation, the feed solution is atomized through the nozzle, forming droplets of the 
nanoparticle suspension in the carrier solution. In ideal conditions, the nanoparticle 
dispersion remains stable, where the carrier molecules and nanoparticles are dispersed 
uniformly in the solvent. Once the droplets come into contact with hot drying air, 
evaporation of the solvent at the droplet surface will occur. Accompanied by the 
shrinkage of the droplets, two driving forces are generated, which in combination are 
responsible for the separation of the components in the droplets. The first driving force 
is the local temperature gradient created at the droplet surface contributed by the flux 
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of heat caused by water evaporation from the surface of the droplet into the gas stream. 
As a result, thermophoresis of the nanoparticles occurs, leading to their movement 
towards the surface of the droplets (18, 118, 119). A detailed mathematical model of 
this phenomenon can be found in Ferry Iskandar's research (118, 120). 
The other driving force is caused by the concentration gradients in the droplet. 
The evaporation of solvent at the droplet surface increases the concentration of 
components in the same plane, causing diffusion of the solute and nanoparticles 
towards the droplet center (shown in Figure 2.3) (18, 121, 122). For the solute or 
nanoparticles that diffuse fast enough compared to the shrinkage of droplet caused by 
evaporation, their concentration gradient along the droplet radius will be insignificant, 
resulting in relatively uniform distribution of the dry materials in the nanoparticles. 
However, if the diffusion is slower than the surface shrinkage, there will be a higher 
concentration of solute or nanoparticles at the droplet surface compared to the droplet 
center, resulting in a shell of particles. The ratio of evaporation rate to diffusion rate 
can be described by the dimensionless Peclet number, which is an important factor 
influencing the size, shape, surface morphology, and component distribution of 
resulting particles. The Peclet number is well discussed in other review and research 
articles (18, 121, 123) and can be used to explain how the inlet temperature influences 
the properties nCmP. In the final step during nCmP formation, solvent evaporation 
finalizes, and the particles undergo changes in morphology and thermal states. 
Crystallization or re-crystallization may occur, resulting in crystals with different sizes 
located inside or at the surface of resulting particles. Whether nCmP exhibit spherical 
or wrinkled morphology is also determined in this final step (18, 123, 124). 
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2.4.3. Influence of spray drying parameters on nCmP formation 
After covering the basics on how spray drying parameters influence the 
properties of nCmP and an overall theoretical framework of nCmP formation, we can 
continue with a detailed discussion of these parameters. As previously mentioned, the 
parameters relevant to the spray process correlate with and depend on each other. In 
this section we discuss the influences of these parameters in terms of primary 
parameters, secondary parameters, physicochemical properties, and application 
properties (desirable properties). It is assumed that while discussing a given parameter, 
that the others remain constant. 
=Solvent \ = carrier/Excipient 
•= Encapsulated NP 
Droplet Shrinkage w/ 
Shell Formation a nCmP w/ Spherical 
... NP Shell 
" 
nCmP w/ Wrinkled 
NP Shell 
nCmPw/NP 
Dispersed 
Throughout 
Figure 2.3. Schematic of nanocomposite microparticle (nCmP) formation during 
spray drying from a droplet of feed solution of nanoparticles (NP) and excipients in a 
solvent. 
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2.4.3.1. Influence of inlet temperature 
The inlet temperature proportionally determines the outlet temperature, which 
is close to the actual temperatures that spray-dried materials are exposed to. At high 
spray drying temperatures evaporation is rapid, resulting in a higher Peclet number 
thus indicating a fast increase of the solute or nanoparticle concentration at the droplet 
surface. Once a critical concentration is reached at the surface, precipitation will take 
place. Early precipitation results in smaller differences between the solid particle shell 
and the initial droplet size, producing larger shells. In the preparation of nCmP, 
suspended nanoparticles will form a composite shell in early processes and insufficient 
solids remain to fill the internal space of the shell, thus forming large and hollow 
nCmP. On the contrary, lower temperatures lead to slower evaporation that may lag 
behind the solid diffusion rate, causing delayed shell formation and smaller nCmP. In 
general, higher inlet temperature leads to higher processing temperature, improving 
the formation of larger and hollow particles, which tend to exhibit favorable aerosol 
performance. However, exceptions have been reported indicating that temperature 
may not influence the particle size (125). In that case, a wider temperature range could 
be applied for study on influence of temperature (123). In another study, temperature 
firstly has a negative effect on size of nCmP, then presents a positive effect (72). In 
that case, an optimal inlet temperature should be chosen based on comprehensive 
consideration on other parameters. 
The inlet temperature also influences the crystallization of carrier molecules 
during solvent evaporation at the droplet surface, thereby changing the surface 
roughness of the resulting particles. At very high temperatures, carriers may not have 
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enough time to crystallize during the precipitation process, thus forming into an 
amorphous state. Given enough time for crystallization, lower temperatures ensure 
larger crystals due to low nucleation rates from the solution, resulting in more 
roughness at particle surfaces. On the contrary, spray drying at higher temperatures 
leads to higher nucleation rates with more nuclei, resulting in smaller crystals and 
smooth surfaces. However, converse results have also been reported, in which higher 
temperature leads to larger crystals, while at lower temperature smaller crystals are 
produced. This latter case usually happens in the spray drying of small droplets at lab 
scale, where high temperature results in higher possibility of supersaturation at the 
surface than in large droplets. Therefore, delayed crystallization from a highly 
supersaturated viscous liquid or even water-free melt may occur, leading to larger 
crystals and rougher surfaces. In summary, temperature is able to influence the 
crystalline states of carrier molecules, which may further affect the performance of 
pulmonary delivery (126, 127). More detailed discussions on the influence of 
temperature on crystalline states of spray-dried particles can be found elsewhere (115, 
125, 128, 129). 
Another consideration with process temperature is its influence on the 
bioactivity of the powder products. Although therapeutics are encapsulated and 
protected by nanoparticles and microcarriers, the process temperature should be run at 
a safe range to keep bioactivity of the payloads (68, 73, 113, 114). In addition, 
temperature can impact the redispersion of the nanoparticles from the dissolved nCmP. 
At high temperatures, the melting of dry materials can occur, which will lead to the 
fusion of nanoparticles when they diffuse towards the droplet center and form a 
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nanocomposite shell. Poor redispersion can cause nanoparticles to lose their favorable 
properties as drug delivery systems and impair the efficacy of nCmP. 
2.4.3.2. Influence of ratio and properties of nanoparticles 
In the absence of other driving forces, the freely soluble carrier molecules 
driven by diffusion exhibit even distribution in the droplet during the evaporation. The 
initial saturation of carriers is small and the characteristic time for precipitation at the 
droplet surface is close to the droplet lifetime. Given that no nanoparticles are 
included, solid particles with a density close to the true density of the dry materials 
tend to form (115, 116, 123, 125, 126, 130-134). In the case of when a system with 
lower ratio of nanoparticles to carrier molecules mixture is spray-dried, nanoparticles 
in the droplet may not be able to form a shell (135). When the nanoparticles account 
for a larger part in the dry materials, a nanocomposite shell is able to form and this 
determines the shape and size of resulting nCmP. Although the formation of nCmP is 
initiated from the same initial droplet solidification at surface, the morphology varies 
significantly. For nanoparticles capable of building rigid shells quickly, solid hollow 
spherical nCmP are formed. Otherwise, dimpled or wrinkled particles are formed. This 
difference may be caused by the properties of the suspended nanoparticles and thus it 
varies significantly in different spray drying conditions and feed solutions. No 
universal conclusion can be elucidated from this conclusion, yet optimization should 
be performed based on specific conditions by referring to former studies. Extensive 
studies have been done reporting or discussing the variety in the morphology of spray-
dried nCmP (68, 76, 84, 136-140) or particles based on other colloids (114, 135, 141-
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145). The ratio of nanoparticles to carriers also influences the redispersion of the 
nanoparticles from nCmP, as well as the particle size (72). Properties of nanoparticles 
including particle size and surface properties can influence the properties of resulting 
nCmP. No overall review of this field has been performed and thus further studies may 
be warranted (6, 17, 57, 62, 68, 72, 103, 105, 106, 109, 146, 147). 
2.4.3.3. Influence of excipients 
Carriers (excipients) are inactive materials that are applied in spray drying to 
enhance the physical or chemical stability of the active pharmaceutical ingredient. 
Sugars are widely used as excipients of nCmP, as they provide advantages such as 
rapid dissolution in aqueous environment, leading to the immediate release of 
encapsulated nanoparticles. These excipients have been well studied in aerosol 
manufacturing processes with highly reproducible products (94, 148, 149). Safety 
should be a primary consideration in choosing the carrier excipient for nCmP. Many 
excipients that can be used in drug formulations for delivery in non-pulmonary routes 
may not suitable for pulmonary delivery due to their potential to injure the lungs (149). 
Excipients approved for pulmonary delivery or presented as interesting alternatives for 
DPI formulations should be considered in high priority. Carriers also have significant 
impact on properties of nCmP, including the size, surface morphology, water content, 
and redispersion potential of nanoparticles. Comparisons of the influence of different 
excipients on dry powder formulation that can provide insight into how the excipient 
properties will affect nCmP have been studied (43, 94, 111). 
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2.4.3.4. Summary 
Several parameters m the spray drying process can be tuned to achieve 
desirable properties of nCmP. These parameters, which correlate with and depend on 
each other, should be considered comprehensively to design optimized particles. Some 
parameters may have variable effects on the nCmP systems, and not all will be 
regarded as favorable. In this case, some of the properties may be abandoned in an 
overall consideration. 
2.4.4. Optimization of nCmP formation process 
Pulmonary delivery of therapeutics using nCmP is increasingly recommended 
for the treatment of lung disease due to their high efficacy of delivery, more 
convenient administration, and more flexible storage conditions. These advantages are 
a result of effective particle engineering of the delivery system, which includes 
optimal aerodynamic size, stability, and recovery of primary nanoparticles. In this 
section, strategies to achieve these favorable properties are discussed. 
2.4.4.J. Optimization of aerodynamic size and morphology 
A schematic showing the parameters involved in optimization of aerodynamic 
size of nCmP is shown in Figure 2.4. The proper aerodynamic diameter will be 
dependent on the delivery strategy and final particle location for a given application. 
Since higher temperatures may impair the redispersion of nanoparticles and bioactivity 
of encapsulated therapeutics, relatively lower temperature should be given priority if 
possible. A way to prepare nCmP with small aerodynamic sizing is to prepare particles 
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with small geometric s1zmg, smce these sizes are positively proportional to one 
another. This goal can be achieved by reducing the feed speed and feed solution 
concentration during spray drying. The former way results in smaller droplet size with 
lower dry material content, while the latter one decreases the dry materials in droplet 
directly, thus leading to smaller particles. nCmP can be designed with rough surface 
morphology and low water content to allow for high aerosol dispersion and low 
cohesion of the resulting nCmP. Overall, the aerodynamic diameter can be influenced 
by the geometric diameter, structure, processing conditions, and materials used in the 
preparation of nCmP. 
Figure 2.4. Schematic of processing parameters affecting the aerodynamic diameter of 
nanocomposite microparticles (nCmP). 
2.4.4.2. Optimization of stability 
Figure 2.5 is a schematic outlining the factors important in the stability of 
nCmP. The stability of pulmonary delivery systems based on nCmP includes not only 
activity of encapsulated therapeutics, but also the integrated structure of the delivery 
48 
system. The drying temperature should be set to maintain the activity of therapeutic(s). 
Minimum water content should be a target to enhance stability of the structure of 
nCmP so that the favorable amorphous state of the nCrnP is maintained. 
2.4.4.3. Optimization of primary nanoparticle recovery 
A schematic outlining the optimization of nanoparticle recovery from nCmP is 
shown in Figure 2.6. To combine the advantages of both nanoparticle and 
microparticle systems, recovery of primary nanoparticles plays a significant role. An 
increase in the amount of nanoparticles released from nCmP can be achieved by 
increasing the ratio of nanoparticles to carrier ( excipient). Meanwhile, the high 
redispersion of nanoparticles can be achieved by applying a suitable coating on the 
nanoparticles and by using a lower drying temperature. At last, improvement of 
overall nCmP yield may be regarded as an indirect way to obtain higher primary 
nanoparticle recovery. 
Figure 2.5. Schematic outlining the parameters that can influence the stability of 
nCmP. 
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Figure 2.6. Schematic of the parameters that affect the recovery of redispersed 
nanoparticles from nCmP. 
2.5. Drug release behavior from nanocomposite microparticle (nCmP) systems 
As with many other drug delivery systems, nCmP is comprised of mainly 
carriers and APL The carrier often serves as the most important component for 
successful and targeted drug delivery. Significant amounts of research has been 
underway to explore the potential of nanoparticles as drug delivery carriers as they 
offer several advantages including enhanced cellular uptake, increased drug stability, 
decreased side-effects and prolonged drug release (150). Drugs encapsulated in a 
carrier are released from the nanoparticles by various physicochemical processes such 
as diffusion, dissolution, osmosis, magnetically controlled and targeted delivery, and 
the mechanism of drug release depends on the selection of carrier system and the 
solubility of the drug. The general physicochemical process for drug release from NP 
in nCmP are discussed as follows: 
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1. Diffusion: As a result of hydration, polymeric NP swell and release drugs through 
diffusion. The rate of drug release from the inner core of the water insoluble 
polymeric material follows Fick's law of diffusion (151-153). The diffusion of 
drug from the nanoparticle depends on the type of polymer, thickness of polymer 
coating, solution-diffusion membrane, and rate of permeation. 
2. Dissolution: NP dissolution is a process that involves three steps: 1) release of 
drugs from the surface, 2) slight degradation of the polymer entrapping the 
remaining drugs, and 3) complete disintegration of polymer membrane, resulting 
in the rapid release of the entrapped drug. The degradation of the polymer 
membrane can be achieved using chemical or enzymatic reaction (154). 
3. Solvent controlled (osmosis): When semipermeable polymers are used to 
encapsulate drug molecules, water crosses the polymer membrane and dissolves 
the encapsulated drug since the osmotic pressure builds up in the NP interior and 
drugs are forced to dissociate from the polymer and release outside of the particles 
(154). 
4. Magnetically controlled: If a component of the nCmP is comprised of 
superparamagnetic nanoparticles (Fe30 4) , a high frequency alternating magnetic 
field can be used to release the encapsulated drugs. Stocke et al. demonstrated the 
incorporation of iron oxide magnetic nanoparticles in magnetic nCmP (MnMs ), 
which could enhance drug release with the presence of an alternating magnetic 
field (57). 
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2.6. Therapeutic applications of nanocomposite microparticles: Impact in 
pulmonary and non-pulmonary diseases 
Over the past few years, research in the field of pulmonary drug delivery has 
gained momentum for treatment of pulmonary and non-pulmonary diseases. 
Pulmonary route for drug delivery is an attractive target, yet it poses serious 
challenges for investigation. Particles are being engineered in such a way to overcome 
the lung clearance mechanism, targeting specific regions of the lungs and being 
retained in the lung for longer time period. The nCmP formulations form an attractive 
interdisciplinary area that brings together polymer/material science, nanotechnology 
and biology for a multitude of biomedical applications. These are 'intelligent' systems 
widely used to deliver small molecules, genes, protein/peptides or drug nanoparticles 
to various targeted locations in the body. nCmP help in protecting them from 
degradation during delivery, targeting them to specific sites and regulating their 
release properties with respect to time. There are various nCmP that have been used to 
deliver therapeutic agents to the lungs (pulmonary drug delivery) and other body parts 
(non-pulmonary drug delivery) with their key findings discussed in Table 2.1 and 
Table 2.2. 
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ABSTRACT 
Purpose: Pulmonary antibiotic delivery is recommended as maintenance therapy for 
cystic fibrosis (CF) patients who experience chronic infections. However, abnormally 
thick and sticky mucus present in the respiratory tract of CF patients impairs mucus 
penetration and limits the efficacy of inhaled antibiotics. To overcome the obstacles of 
pulmonary antibiotic delivery, we have developed nanocomposite microparticles 
(nCmP) for the inhalation application of antibiotics in the form of dry powder aerosols. 
Methods: Azithromycin-loaded and rapamycin-loaded polymeric nanoparticles (NP) 
were prepared via nanoprecipitation and nCmP were prepared by spray drying and the 
physicochemical characteristics were evaluated. 
Results: The nanoparticles were 200 nm in diameter both before loading into and after 
redispersion from nCmP. The NP exhibited smooth, spherical morphology and the 
nCmP were corrugated spheres about 1 µm in diameter. Both drugs were successfully 
encapsulated into the NP and were released in a sustained manner. The NP were 
successfully loaded into nCmP with favorable encapsulation efficacy. All materials 
were stable at manufacturing and storage conditions and nCmP were in an amorphous 
state after spray drying. nCmP demonstrated desirable aerosol dispersion 
characteristics, allowing them to deposit into the deep lung regions for effective drug 
delivery. 
Conclusions: The described nCmP have the potential to overcome mucus-limited 
pulmonary delivery of antibiotics. 
KEYWORDS 
Nanocomposite microparticles, pulmonary delivery, cystic fibrosis, spray drying 
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3.1 Introduction 
Cystic fibrosis (CF) is a progressive, incurable, autosomal recessive disease that 
affects around 70,000 people worldwide (1, 2). It is caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, which leads to defective 
or insufficient amounts of functional CFTR proteins. The dysfunctional proteins result 
in an absence or decrease of chloride in secretions, leading to increased sodium and 
water absorption and airway surface liquid depletion (3). CF affects various organ 
systems of patients including the sweat glands, reproductive tract, intestine, liver, 
pancreas, and respiratory tract ( 4), in which lung disease is the primary cause of 
mortality ( 4, 5). The dysfunction of the respiratory tract results in frequent pulmonary 
infections, inflammation, bronchiectasis, and eventually respiratory failure, which 
causes over 90% of deaths in CF patients (6). Pulmonary infection is one of the primary 
complications among patients with CF and these patients tend to develop chronic 
infections within a year if no treatment is implemented, which will accelerate the 
decline in lung function, resulting in earlier mortality (7, 8). 
Pseudomonas aeruginosa (P. aeruginosa) is regarded as the most prevalent 
pathogen in CF patients' lungs (7, 9). Azithromycin (AZI) is a macrolide antibiotic 
with a broad gram-negative antibacterial spectrum and is highly effective against 
planktonic, actively growing bacteria (10). AZI has been extensively studied for the 
treatment of CF-related infections due to its ability to decrease P. aeruginosa 
accumulation (10-15) as well as its pharmacokinetic advantages including high 
bioavailability, distribution, and extended half-life (13, 14). 
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Burkholderia cenocepacia (B. cepacia) infection is also considered to be a lethal 
threat to CF patients because it causes severe and persistent lung inflammation and it is 
resistant to nearly all available antibiotics ( 16). Rapamycin (RAP), also known as 
sirolimus, is an immunosuppressive macrolide that is the most commonly used 
chemical to induce autophagy (17). It has been shown that RAP can markedly decrease 
B. cepacia infection in vitro by enhancing the clearance of this bacterium via induced 
autophagy. RAP has been shown to reduce bacterial burden and decrease inflammation 
in the lungs of CF infected mice (16). 
Acetalated dextran (Ac-Dex) is an acid sensitive, biodegradable, biocompatible 
polymer that can be prepared in a one-step reaction by reversibly modifying dextran 
with acetal groups (18). This modification reverses the solubility properties of dextran 
from hydrophilic to hydrophobic, making it possible to form polymeric particles using 
standard emulsion or nanoprecipitation techniques. Drug loaded Ac-Dex nanoparticles 
exhibit sustained release profile, with the advantages of extended duration of action, 
decreased drug use, improved management of therapy, enhanced compliance and 
reduced side effects. (19, 20) In comparison to other commonly used polymers in drug 
delivery such as poly(lactic-co-glycolic acid) (PLGA) and polyesters, Ac-Dex offers 
several advantages. Most notably, the degradation rate of Ac-Dex can be tuned from 
minutes to months by modifying the ratio of cyclic and acyclic acetal groups, which 
have different rates of hydrolysis. Also, Ac-Dex degrades into dextran, a biocompatible, 
biodegradable, FDA-approved by-product, and very low levels of methanol and 
acetone (20-22). 
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Mannitol, an FDA approved, non-toxic, readily degradable sugar alcohol commonly 
used in pharmaceutical products, was applied as the excipient of nCmP due to its 
beneficial properties.(23) First, mannitol can be rapidly dissolved into an aqueous 
environment, leading to a burst release of encapsulated nanoparticles. In addition, 
mannitol can improve the fluidity of mucus, thus enhancing the mucus penetration rate 
of nanoparticles (24). Mannitol has been extensively studied as a carrier in spray-dried 
powder aerosols for pulmonary drug administration and the resulting particles have 
been shown to exhibit desirable water content, size, and surface morphology for 
successful aerosol delivery (25, 26). 
Pulmonary antibiotic delivery is increasingly recommended as maintenance therapy 
to prolong the interval between pulmonary exacerbations and to slow the progression of 
lung disease of CF patients due to the capability of these systems to achieve high drug 
concentrations at the site of infection and to minimize the risk of systemic toxicity and 
drug resistance (31-34 ). Extensive studies have been devoted to the development of 
new inhalation devices and advanced drug delivery formulations for the treatment of 
CF-related infections (35-38). Despite these advances, there has only been incremental 
improvement in the treatment of pulmonary infections. This is partly due to the 
presence of mucus in the lung airways that can trap and remove foreign particles. Also, 
the abnormally thick and viscous mucus in the respiratory tract of CF patients impairs 
efficient mucus penetration and limits the efficacy of antibiotics delivered via 
inhalation. Polyethylene glycol (PEG)-coated nanoparticles have been shown to 
significantly improve the mucus penetration of various therapeutics encapsulated in NP 
due to the formulation size, PEG coating, and protection of active pharmaceutical 
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ingredients (39). Unfortunately, aerosolized nanoparticles will be exhaled owing to 
their small size and mass and while aerosolized particles with aerodynamic diameters 
of 1-5 µm can deposit into the deep lung region, which limits their efficacy for 
targeting the infection site in mucus as aerosol drug delivery vehicles ( 40, 41 ). 
To overcome the aforementioned obstacles of pulmonary antibiotic delivery, we 
developed nanocomposite microparticles (nCmP) in the form of dry powder aerosols 
(Figure 1). This system is comprised of drug-loaded nanoparticles (NP) entrapped in 
microparticle carriers with the excipient mannitol to allow for the delivery of mucus-
penetrating NP to the lungs. The drug-loaded nanoparticles contain azithromycin or 
rapamycin as model drugs and are coated by a vitamin E poly( ethylene glycol) (MW 
5000) layer, which has shown to improve the stability and mucus penetration rate of 
nanoparticles (39). Upon pulmonary administration, the nCmP will deposit on the 
mucus in the respiratory tract, dissociate into free NP and mannitol, and allow the 
nanoparticles to penetrate the mucus and then release drug to the targeted site at 
sustained rate. This nCmP system exhibits features favorable for dry powder-based 
antibiotic delivery including targeted delivery, rapid mucus penetration, and controlled 
drug release. The goal of the described research was the initial development and 
physicochemical characterization of the nCmP systems via particle engineering. 
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NP Containing 
Therapeutic 
Mannitol 
0 = Nanoparticles = Microparticles = Epithelium 
Figure 3.1. Schematic of an aerosol nanoparticle microparticle (nCmP) system 
interacting with the pulmonary mucosa. Once the nCmP impact the surface of the 
mucus coating the pulmonary epithelium they immediately degrade to release 
nanoparticles. 
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3.2 Materials and Methods 
3.2.lMaterials 
Dextran from Leuconostoc mesenteroides (9000 - 11000 MW), pyridinium p-
toluenesulfonate (PPTS, 98%), poly(ethylene glycol) methyl ether (mPEG, Mn 5000), 
D-a-tocopherol succinate (vitamin E succinate, 1210 IU/g), N,N'-dicyclohexyl-
carbodiimde (DCC, 99%), 4-(dimethylamino) pyridine (DMAP, 2: 99%), potassium 
phosphate di basic, potassium phosphate mono basic, D-mannitol (2: 98% ), 2-
methoxypropene (2-MOP, 97%), triethylamine (TEA, 2: 99%), anhydrous dimethyl 
sulfoxide (DMSO, 2: 99.9%), deuterium chloride (DCl, 35 weight% in D20, 99 atom% 
D), deuterated chloroform (CDCb, 100%, 99.96 atom% D), TWEEN® 80, methanol 
(HPLC grade, 2: 99.9%), and acetonitrile (HPLC grade, 2: 99.9%) were obtained from 
Sigma-Aldrich (St. Louis, MO). Ethanol (anhydrous, ASC/USP grade) was obtained 
from Pharmco-AAPER (Brookfield, CT). Deuterium oxide (D20, 99.8% atom D) was 
obtained from Acros Organics (Geel, Belgium). Phosphate buffered saline (PBS) was 
obtained from Fisher Scientific. Hydranal® KF reagent was obtained from Fluka 
Analytical. Rapamycin was obtained from LC Laboratories (Woburn, MA). 
Azithromycin was obtained from AstaTech Inc. (Bristol, PA). 
3.2.2 Synthesis of Acetalated Dextran (Ac-Dex) 
Ac-Dex was synthesized as described previously (22) with mmor 
modifications. Briefly, 1 g of lyophilized dextran and 25 mg of PPTS were dissolved 
in 10 mL anhydrous DMSO. The resulting solution was reacted with 5 mL of 2-MOP 
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under nitrogen gas for 5 minutes and was quenched with 1 mL of TEA. The reaction 
mixture was then precipitated in basic water (water and TEA, pH 9), vacuum filtered, 
and lyophilized (-50 °C, 0.023 mbar) for 24 hours to yield a solid product. 
3.2.3 Synthesis of Vitamin E Poly( ethylene glycol) (VPSk) 
VP5k was prepared with some modifications to a previously described method 
(42). 0.65 g of vitamin E succinate and 7.334 g of mPEG were dissolved in 20 mL of 
DCM. 0.278 g of DCC and 15 mg of DMAP were added to the solution. The reaction 
mixture was stirred at room temperature overnight, vacuum filtered (0.45 µm), and 
concentrated under reduced pressure via a rotor evaporator (IKA-RV, Wilmington, 
NC) to obtain a crude product. The resulting crude product was dissolved at 5% (w/v) 
in DI water and centrifuged at 12000 rpm for 30 minutes. The filtrate was vacuum 
filtered (0.22 µm) and lyophilized (-50 °C, 0.023 mbar) for 72 hours to yield the final 
product. 
3.2.4 NMR Analysis of Ac-DEX and VPSk 
The cyclic-to-acyclic (CAC) ratio of acetal coverage and degrees of total acetal 
coverage per 100 glucose molecules was confirmed by 1H NMR spectroscopy (Bruker 
300 MHz NMR, MA). 10 mg of Ac-Dex was added to 700 µL of D20 and was 
hydrolyzed with 30 µL of DCl prior to analysis. The hydrolysis of one cyclic acetal 
group produces one acetone whereas one acyclic acetal produces one acetone and one 
methanol. Consequently, from the normalized integrations of peaks related to acetone, 
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methanol, and the carbon ring of dextran, the CAC ratio of acetal coverage and 
degrees of total acetal coverage per 100 glucoses were determined. 
Conjugation of mPEG to Vitamin E succinate was also confirmed by NMR 
spectroscopy. 20 mg of VP5k was dissolved in 600 µL of CDCh. The resulting 
solution was analyzed by 2D 1H-13C HMBC-GP NMR spectroscopy. Shift of the 
signal at 2.8 ppm and 178.8 ppm related to the -COOH group of vitamin E succinate 
and 2. 7 ppm and 172.2 ppm related to the ester group indicated conjugation of mPEG 
to vitamin E succinate for the successful formation ofVP5k. 
3.2.5 Preparation of Drug-loaded Nanoparticles 
Azithromycin (AZI)-loaded nanoparticles and rapamycm (RAP)-loaded 
nanoparticles were prepared via nanoprecipitation. 40 mg of Ac-Dex and 12 mg of 
AZI or 4 mg of RAP were dissolved in 1 mL of ethanol and injected into 40 mL of 
1.5 % (w/v) VP5k solution. The resulting suspension was stirred for 3 hours for 
removal of ethanol and hardening of the particles and the final solution was 
centrifuged at 12000 rpm for 20 minutes to collect the NP. The NP were washed once 
with basic water and lyophilized for 24 hours to give the final AZI-NP and RAP-NP 
systems. 
3.2.6 Preparation of Nanocomposite Microparticles (nCmP) 
nCmP were prepared via the spray drying of a AZI NP or RAP NP suspensions 
and mannitol in an aqueous solution using a Bilchi B-290 spray dryer (Bilchi 
Labortechnik, AG, Switzerland) in open mode. The spray drying conditions were as 
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follows: 1:1 (w:w) ratio of NP to mannitol in DI water; feed solution concentration of 
1 % (w/v); 1.4 mm nozzle diameter; atomization gas flow rate of414 L/h (UHP dry 
nitrogen); aspiration rate of 28 m3 /h, inlet temperature of 50 °C; pump rate of 0.6 
mL/min; and nozzle cleaner rate of 4. The resulting nCmP were separated in a high-
performance cyclone, collected in a sample collector, and stored in amber glass vials 
in desiccators at -20°C. 
3.2.7 Powder X-Ray Diffraction (PXRD) 
Crystalline states of the nCmP were examined by PXRD using a Rigaku 
Multiflex X-ray diffractometer (The Woodlands, TX) with a Cu Ka radiation source 
(40 kV, 44 mA). The samples were placed on a horizontal quartz glass sample holder 
(3 mm). The scan range was 5 - 65° in 28 with a step width of 0.02 and scan rate of 
2°/min. 
3.2.8 Differential Scanning Calorimetry (DSC) 
The thermal phase transitions of the nCmP were determined by DSC using a 
TA Q200 DSC system (TA Instruments, New Castle, DE, USA) equipped with an 
automated computer-controlled RSC-90 cooling accessory. 1 - 3 mg of sample was 
weighed into Tzero TM alodined aluminum pans that were hermetically sealed. The 
sealed pans were placed into the DSC furnace along with an empty sealed reference 
pan. The heating range was 0 - 250 °C at a heating rate of 10 °C/min. 
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3.2.9 Scanning Electron Microscopy (SEM) 
The shape and surface morphology of the NP and nCmP were evaluated by 
SEM using a Hitachi S-4300 microscope (Tokyo, Japan). nCmP samples were placed 
on aluminum SEM stubs (TedPella, Inc., Redding, CA, USA) with double-sided 
adhesive carbon tabs. Nanoparticles were dispersed in basic water (pH= 9, 10 mg/mL) 
and this suspension was dropped onto aluminum SEM stubs and then dried at room 
temperature. Both the NP and nCmP samples were coated with a thin film of a 
gold/palladium alloy using an Emscope SC400 sputter coating system at 20 µA for 75 
seconds under argon gas. Images were captured at 5 kV. 
3.2.10 Particle Size, Size Distribution and Zeta Potential Analysis 
The size, size distribution, and zeta potential of the NP systems were measured 
by dynamic light scattering (DLS) using a Malvern Nano Zetasizer (Malvern 
Instruments, Worcestershire, UK). The NP were dispersed in basic water (pH= 9, 0.3 
mg/mL). All experiments were performed in triplicate with a scattering angle of 173° 
at 25 °C. The mean size and standard deviation of the nCmP were measured digitally 
from SEM images using ImageJ software (Systat, San Jose, CA, USA). Representative 
micrographs (5k magnification) for each sample were analyzed by measuring the 
diameter of at least 100 particles. 
3.2.11 Karl Fischer (KF) Titration 
The water content of the nCmP was quantified by Karl Fischer (KF) titration 
using a 737 KF coulometer (Metrohm, Riverview, FL). Approximately 10 mg of 
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powder was dissolved in anhydrous methanol. The resulting solution was injected into 
the KF reaction cell filled with Hydranal® KF reagent and then the amount of water 
was analyzed. Pure solvent was also injected for use as a background sample. 
3.2.12 Aerosol Dispersion Analysis 
In vitro aerosol dispersion performance of the nCmP was evaluated using a 
Next Generation Impactor™ (NGI™, MSP Corporation, Shoreview, MN) equipped 
with a stainless steel induction port (USP throat adaptor) attachment and stainless steel 
NGI™ gravimetric insert cups. The NGI™ was coupled with a Copley TPK 2000 
critical flow controller, which was connected to a Copley HCP5 vacuum pump 
(Copley Scientific, United Kingdom). The airflow rate (Q) was measured and adjusted 
to 60 L/min in order to model the flow rate in a healthy adult lung before each 
experiment. Glass fiber filters (55 mm, Type A/E, Pall Life Sciences, PA) were placed 
in the gravimetric insert cups for stages 1 through 7 to minimize bounce or re-
entrapment ( 4 3) and these filters were weighed before and after the experiment to 
determine the particle mass deposited on each stage. Approximately 10 mg of powder 
was loaded into a hydroxypropyl methylcellulose (HPMC, size 3, Quali-V®, 
Qualicaps® Inc., Whitsett, NC, USA) capsule and the capsule was placed into a 
human dry powder inhaler device (HandiHaler, Boehringer Ingelheim Pharmaceuticals, 
CT) attached to a customized rubber mouthpiece connected to the NGI™. Three 
HPMC capsules were loaded and released in each measurement and experiments were 
performed in triplicate. The NGI™ was run with a delay time of 10 sand running time 
of 10 s. For Q = 60 L/min, the effective cutoff diameters for each stage of the impactor 
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were given from the manufacturer as: stage 1 (8.06 µm); stage 2 (4.46 µm); stage 3 
(2.82 µm); stage 4 (1.66 µm); stage 5 (0.94 µm); stage 6 (0.55 µm); and stage 7 (0.34 
µm). The fine particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF), 
and emitted dose (ED) were calculated as follows: 
Fine particles dose (FPD) = mass of particles on Stages 2 through 7 
F. . 1 fr . (FPF) fine particles dose 1000/ me part1c es action = -------=---------- x ;ro 
initial particle mass loaded into capsules 
R . bl fr . (RF) mass of particles on Stages 2 through 7 1000/ esp1ra e action = x ;ro 
total particle mass on all stages 
E . d d (ED) initial mass in capsules - final mass remaining in capsules m1tte ose = x 100% 
initial mass in capsules 
The mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) for the particles were determined using a Mathematica® program 
written by Dr. Warren Finlay (43, 44). 
3.2.13 Analysis of Nanoparticle Drug Loading and Nanoparticle Loading in 
nCmP 
Drug loading and encapsulation efficacy of AZI and RAP NP and nCmP were 
determined using high performance liquid chromatograph (HPLC) (Hitachi Elite 
LaChrom, Japan). Detection of AZI was performed using the following conditions: 
C18, 5 µm x 150 mm x 4.6 mm column (XTerra™, Waters); 1.5 mL/min pump rate; 6 
minute retention time; mobile phase of 70% methanol and 30% PBS (0.03 M, pH = 
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7.4); absorbance of 215 run; and ambient temperature. Detection of RAP was 
performed using following conditions: C 18, 5 µm x 150 mm x 4.6 mm column 
(Supelco, Sigma-Aldrich, St. Louis, MO); 1 mL/min pump rate; 6 minute retention 
time; mobile phase of 65% acetonitrile and 35% DI water; absorbance of 278 run; and 
temperature of 50°C. Drug-loaded NP and nCmP were fully dissolved in their 
respective mobile phases. The experimental drug concentration in each sample was 
quantified by comparison with a standard curve of drug in its mobile phase. The drug 
loading of NP, drug loading of nCmP, NP loading in nCmP, drug encapsulation 
efficiency of NP, and NP encapsulation efficacy in nCmP were determined by the 
following equations: 
Drug loading = mass of drug loaded in nanoparticles x 1 OO% 
mass of particles 
D I . ffi (EE) mass of drug loaded in nanoparticles rug encapsu ation e 1cacy = ------"-------"-----
initial mass of drug in particle formulation 
N . 1 1 d. mass ofNPs loaded in nCmPs x 1000/0 anopart1c es oa mg = ----------- 1 1 
mass of nCmPs 
NP loading efficacy mass of NPs loaded in nCmPs 
initial mass of NPs in nCmPs formulation 
3.2.14 In Vitro Drug Release from Nanoparticles 
x 100% 
x 100% 
The in vitro release profiles of AZI or RAP from nanoparticles was determined 
via a release study of NP suspended (1 mg/mL) in modified phosphate buffer (0.1 M, 
pH= 7.4) with 0.2% (w/v) of Tween® 80. The suspension was incubated at 37 °C and 
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100 rpm. At various time points (0 to 48 h), NP samples were centrifuged at 14000 
rpm for 5 minutes at 4 °C to isolate the NP. 200 µL of supernatant was withdrawn and 
replaced by the same amount of fresh modified PBS in each sample. The withdrawn 
solutions were analyzed for drug content via HPLC using the same methods described 
in the previous section. 
3.2.15 Statistical analysis 
All measurements were performed in at least triplicate. Values are given in the form 
of means ± SD. The statistical significance of the results was determined using t-Test. 
A p-value of <0.05 was considered statistically significant. 
3.3 Results and Discussion 
3.3.1 NMR Analysis of Ac-Dex and VPSk 
Successful synthesis of Ac-Dex and VP5k was confirmed by NMR (Figure 
A.1 in Supplemental Information). Ac-Dex exhibited 68.7% cyclic acetal coverage 
(CAC) and 79.1% total acetal coverage (conversion of -OH groups). A yield of 
approximately 95% was obtained for this Ac-Dex. An increase in CAC is known to 
slow drug release due to slower degradation.(21, 22) A high total acetal coverage 
(higher than 75% according to our research) is required to stabilize the VP5k coating 
of nanoparticles, which ensures small particles size and narrow size distribution. The 
signals for ester groups were detected via NMR, indicating successful conjugation of 
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mPEG to vitamin E succinate for the successful formation of VP5k ( 45). The yield of 
VP5k was approximately 30%. 
3.3.2 Characterization of N anoparticles 
The azithromycin-loaded nanoparticles (AZI-NP), shown in Figure 3.2A, 
appear as uniform spheres with smooth surface morphology. NP size, size distribution, 
and zeta potential are shown in Table 3.1. The resulting sizes of the NP analyzed via 
DLS (approximately 200 nm) were larger than those observed from SEM micrographs 
and ImageJ analysis (approximately 100 nm) due to shrinking of the particles during 
freeze-drying from the collapse of hydrated PEGylated chains (46). Both drug-loaded 
NP systems exhibited desirable size (less than 200 nm) with narrow size distribution to 
allow for potential mucus penetration. The relative surface charge of the NP systems 
were nearly neutral, confirming PEG coverage on their surfaces ( 45). Similar results 
were obtained for drug-loaded and blank nanoparticles with respect to their size, size 
distribution, and surface charge, indicating that drug encapsulation did not affect the 
formation of the NP. 
Both AZI and RAP were successfully encapsulated into the described NP 
systems. 13.0 % of initial AZI and 25.8 % of initial RAP were effectively entrapped 
within the NP prepared using nanoprecipitation of Ac-Dex and drugs in VP5k solution. 
The low encapsulation of the drugs may be due to the improved solubility of the drugs 
in the spinning solution by VP5K micelles. RAP-NP exhibited a higher encapsulation 
efficacy as a result of the lower solubility of RAP than AZI in the aqueous spinning 
solution. 
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Results of the in vitro release of AZI-NP and RAP-NP at physiological pH and 
temperature are reported in Figure 3.3 as the percentage of drug released over time. 
Both NP systems displayed sustained release for approximately 12 hours, which 
matched the degradation profile of other Ac-Dex particle systems (43). Based on 
previous research, Ac-Dex made of lOkDa dextran and reacted for 5 minutes showed a 
maximum of degradation at 6 hours and negligible degradation after that ( 4 7). A 
possible explanation of the release profiles could be that the first release stage 
corresponds to Ac-Dex degradation as well as nanoparticle dissociation, whereas after 
6 hours the rate of drug release is controlled by drugs passively diffuse out of the 
dissociated matrix of nanoparticles following the partial degradation of Ac-Dex. 
3.3.3 Manufacturing of nCmP 
With respect to nCmP manufacturing, the outlet temperatures of AZI- and RAP-
nCmP were 30 - 31 °C and 30 - 33 °C, respectively, while the yields were 62.4% and 
60.6%, respectively. 
3.3.4 nCmP Morphology, Sizing, and Size Distribution 
As seen in the SEM images, the AZI-nCmP were mostly spherical with a 
corrugated surface (Figure 3.2B) and encapsulated nanoparticles were visible on the 
surface of the nCmP as seen in Figure 3.2C. Both RAP-NP and RAP-nCmP exhibited 
the same morphology as the AZI loaded systems (data not shown). The number 
average geometric diameters were 1.03 ± 0.46 and 1.12 ± 0.43 µm for AZI-nCmP and 
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RAP-nCmP, respectively, as determined by ImageJ analysis. Both nCmP systems 
exhibited similar morphology, geometric size, and size distribution due to the 
similarities in spray drying conditions. 
Figure 3.2. Representative SEM micrographs of azithromycin (AZI) nanoparticles 
(NP) and nanocomposite microparticles (nCmP) including: (A) AZI-NP, (B) AZI-
nCrnP, (C) Representative zoomed in image of AZI-nCmP. 
Table 3.1. Size (as measured by dynamic light scattering), polydispersity index (PDI), 
zeta potential (~), drug loading, and encapsulation efficiency (EE) of nanoparticles 
(mean± standard deviation, n = 3). 
Drug Loading 
NP Diameter PDI ~Potential (mg drug/ EE(%) System (nm) (mV) 
lOOmgNP) 
AZI- 204.7 ± 0.4 0.11±0.01 -4.62 ± 0.19 3.89 ± 2.67 13.0 ± 0.9 NP 
RAP- 189.1±1.1 0.16 ± 0.02 -2.26 ± 0.14 2.58 ± 0.04 25 .8 ± 0.4 NP 
Blank 211.4 ± 3.2 0.18 ± 0.03 -6.13 ± 0.62 n/a n/a 
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Figure 3.3. In vitro drug release profiles for azithromycin (AZI) and rapamycin (RAP) 
nanoparticle systems. 
3.3.5 Karl Fisher (KF) Titration 
The residual water contents of AZI-nCmP and RAP-nCmP were approximately 
6% (Table 3.2). This is within the range of other nCmP in our group (results not 
published) and that of previously reported inhalable dry powder formulations prepared 
by other groups (25, 48-51). Water in inhalable powders can significantly reduce their 
dispersion properties during aerosolization due to the interparticulate capillary forces 
acting at the solid- solid interface between particles (52) and also have a negative 
effect on the stability of the powders (50). Correspondingly, low water content in the 
powder is highly favorable for efficient dry powder aerosolization and effective 
particle delivery (52, 53). 
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3.3.6 Differential Scanning Calorimetry (DSC) 
Figure 3.4 shows DSC thermograms of the raw materials used in particle 
preparation and the final drug-loaded nCmP. Raw Ac-Dex, AZI, RAP, and mannitol 
displayed endothermic main phase transition peaks (Tm) near 170, 140, 180, and 
170 °C respectively, which are in accordance with previously reported values (54-56). 
The drug-loaded nCmP systems exhibited similar thermal behaviors with a main phase 
transition peak near 165 °C corresponding to the melting of Ac-Dex and mannitol. 
This melting point was lower than those of raw Ac-Dex and mannitol, indicating an 
increase in the amorphous state of these raw materials in nCmP. No glass transition or 
other phase transitions were present under 120 °C, which indicated that all the 
materials will be stable during manufacturing and storage. 
3.3. 7 Powder X-ray Diffraction (PXRD) 
X-ray diffraction diffractograms of the raw materials and drug-loaded nCmP 
are shown in Figure 3.5. Strong peaks were present for raw AZI, RAP, and mannitol 
powders. These strong peaks indicate that the raw materials are in their crystalline 
forms prior to spray drying, which is in accordance with previous research (54-56). No 
strong peaks were present for raw Ac-Dex, indicating that it is non-crystalline. This is 
quite different from commercialized polymers such as PLGA, which exhibits strong 
XRD characterization peaks (54-57). The absence of diffraction peaks in Ac-Dex is 
likely because the Ac-Dex is collected by rapid precipitation in water. XRD patterns 
of AZI-nCmP and RAP-nCmP showed the absence of any diffraction peaks, 
suggesting amorphization of raw AZI and RAP in the particle matrix. Also, the peaks 
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-characterizing mannitol were significantly reduced, indicating that mannitol is 
primarily in an amorphous state in the nCmP. The results obtained from the XRD 
diffractograms confirmed those from DSC thermograms, where raw AZI, RAP, and 
mannitol were converted into amorphous form in the nCmP manufacturing process. 
3.3.8 Drug and Nanoparticles Loading in nCmP 
HPLC was used to determine the amount of drug loading in nCmP, which can 
be used to calculate the resulting nanoparticles loading and nanoparticle encapsulation 
efficacy in nCmP. These results are shown in Table 3.2. Both AZI- and RAP-nCmP 
exhibited desirable drug loading, high nanoparticle loading, and nanoparticle 
encapsulation efficacy. In addition, standard deviations of these three values were very 
low, which indicated reproducible drug loading of the nCmP can be achieved. 
3.3.9 Nanoparticle Redispersion from nCmP 
The properties of NP redispersed from nCmP were evaluated usmg DLS 
(Table A.1 in Supplementary Material). The size and size distribution of the NP 
increased after redispersion, which is likely a result of agglomeration that occurred 
during spray drying. The NP surface charges remained neutral due to the presence of 
PEG on the surface of the NP. These parameters were all within the desirable ranges 
for effective mucus penetration. 
87 
Table 3.2. Size (as measured by SEM imaging and ImageJ analysis), water content, 
drug loading, nanoparticle (NP) loading in nanocomposite microparticles (nCmP), and 
NP loading efficacy in nCmP (mean± standard deviation, n = 3). 
Water Drug NP NP 
nCmP Diameter Content Loading (mg Loading Loading System (µm) (%) drug/100 mg (%) Efficacy 
nCmP) (%) 
AZI- 1.03 ± 0.46 5.7 ± 1.25 0.77 ± 0.08 20.47 ± 1.80 40.94 ± 3.60 
nCmP 
RAP- 1.12 ± 0.43 6.1±1.05 0.56 ± 0.02 20.14 ± 0.68 44.28 ± 1.34 
nCmP 
- AZI 
-~ - RAP 
- - Ac-Dex 
- Mann ital 
- AZl-nCmP 
- RAP-nCmP 
0 50 100 150 200 250 300 
Temperature (0 C) 
Figure 3.4. Differential scanning calorimetry (DSC) thermograms of raw 
azithromycin (AZI), raw rapamycin (RAP), raw acetalated dextran (Ac-Dex), raw 
mannitol, AZI-nCmP, and RAP-nCmP. 
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Figure 3.5. Powder X-ray (PXRD) diffractograms of raw azithromycin (AZI), raw 
raparnycin (RAP), raw acetalated dextran (Ac-Dex), raw mannitol, AZI-nCrnP, and 
RAP-nCrnP. 
3.3.10 In vitro Aerosol Performance of nCmP 
In vitro aerosol dispersion performance properties (Figure 3.6 and Table 3.3) 
of the nCmP were evaluated using a Next Generation Impactor™ coupled with a 
human DPI device. The results indicated that the formulated nCmP are favorable for 
efficient dry powder aerosolization and effective targeted delivery. The MMAD values 
of AZI-nCmP and RAP-nCmP were 3.93 ± 0.09 and 3.86 ± 0.07 µm, while the GSD 
values were 1.73 ± 0.06 and 1.78 ± 0.06 µm, respectively. The MMAD values were 
within the range of 1 - 5 µm, which is required for predominant deposition of nCrnP 
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into the deep lung region where infection persists ( 49). The GSD values were within 
those previously reported and the RF, FPF, and ED values were all higher (43, 49, 58). 
Assuming that nCmP drug loading is homogenous, fine particle doses in terms of drug 
mass of AZI-nCmP and RAP-nCmP are 110.42 ± 0.22 µg and 100.97 ± 9.19 µg. There 
is no research on the therapeutic level of rapamycin for the treatment of CF-related 
infection. Oral delivery of azithromycin requires 500 mg/week to 1500 mg/ week, but 
the bioavailability is limited.(13) The nCmP system is expected to achieve therapeutic 
effect using a low drug amount by improving the delivery efficacy. 8.1% and 9.4% of 
AZI-nCmP and RAP-nCmP deposited on stages 5 - 7, respectively, and are predicted 
to deposit in the deep lung alveolar region due to diffusion mechanisms (59) of 
deposition, while approximate 84% of both the nCmP deposited on stages 2 - 4, and 
are predicted to deposit predominantly in the deep lung regions by sedimentation due 
to gravitational settling (60-62). Overall, the nCmP exhibited desirable aerosol 
dispersion characteristics allowing them to deposit in deep lung regions for drug 
delivery. 
Summary 
Both nCmP systems exhibited similar morphology, geometric size, size 
distribution, water content, drug loading, nanoparticles loading, and nanoparticle 
encapsulation efficacy as well as outlet temperature and yield due to the fact that they 
were prepared with nanoparticles with the same spray drying conditions. 
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Figure 3.6. Aerosol dispersion performance as % deposited on each stage of the Next 
Generation Impactor™ (NGI™) for AZI- and RAP-nCmP. 
Table 3.3. In vitro aerosol dispersion performance properties including mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine particle 
dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted dose 
(ED) for nCmP (mean± standard deviation, n = 3). 
nCmP MMAD GSD FPD FPF RF ED 
system (µm) (µm) (mg) (%) (%) (%) 
AZI- 3.93 ± 0.09 1.73 ± 0.06 19.63 ± 0.59 93.9± 79.7± 98.9 ± 0.4 
nCmP 1.3 0.8 
RAP- 3.86 ± 0.07 1.78 ± 0.06 20.90 ± 0.62 92.5 ± 73.6± 99.7 ± 0.3 
nCmP 1.7 2.1 
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-3.4 Conclusions 
Both azithromycin and rapamycin were successfully encapsulated in Ac-Dex 
nanoparticles and can be released in a sustained rate. The drug-loaded nanoparticles 
were smooth spheres 200 nm in diameter with narrow size distribution and slightly 
negative surface charge, which is desirable for mucus penetration. Most nanoparticles 
maintained these properties during the nCrnP manufacturing process as shown in 
redispersion testing. The nCmP systems were corrugated spheres of 1 µm with 
observable nanoparticles present on their surfaces. The water content of the nCrnP 
systems was relatively low, which can enable efficient dry powder aerosolization and 
particle delivery. None of the raw materials underwent degradation during nCrnP 
manufacturing, indicating the stability of the therapeutics during formation. No 
crystalline structures of AZI and RAP were observed in the nCrnP, which confirmed 
that both drugs in the nCrnP were in their amorphous form. In vitro aerosol 
performance testing demonstrated desirable aerosol dispersion characteristics of nCmP, 
allowing them to deposit in deep lung regions for drug delivery. 
This nCrnP system sheds a light on dry powder-based antibiotic delivery due to 
its novel features including targeted pulmonary delivery, rapid mucus penetration 
potential, and controlled drug release. It can be applied as a promising alternative of 
the traditional antibiotic treatment by providing effective delivery of therapeutics, 
more convenient administration, more flexible storage conditions, and lower risk of 
contamination in the device. 
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ABSTRACT 
Tacrolimus (TAC) has exhibited prom1smg therapeutic potential in the 
treatment of pulmonary arterial hypertension (P AH); however, its application is 
prevented by its poor solubility, instability, poor bioavailability, and negative systemic 
side effects. To overcome the obstacles of using TAC for the treatment of PAH, we 
developed nanocomposite microparticles (nCmP) for the pulmonary delivery of 
tacrolimus in the form of dry powder aerosols. These particles can provide targeted 
pulmonary delivery, improved solubility of tacrolimus, the potential of permeation 
through mucus barrier, and controlled drug release. In this system, tacrolimus-loaded 
polymeric nanoparticles (NP) were prepared via emulsion solvent evaporation and 
nCmP were prepared by spray drying these NP with mannitol. 
The NP were approximately 200 nm in diameter with narrow size distribution 
both before loading into and after redispersion from nCmP. The NP exhibited smooth, 
spherical morphology and the nCmP were raisin-like spheres. High encapsulation 
efficacy was achieved both in the encapsulation of tacrolimus in NP and that of NP in 
nCmP. nCmP exhibited desirable aerosol dispersion properties, allowing them to 
deposit into the deep lung regions for effective drug delivery. A549 cells were used as 
in vitro models to demonstrate the non-cytotoxic behavior of TAC nCmP. Overall, the 
designed nCmP have the potential to aid in the delivery of tacrolimus for improved 
treatment of P AH. 
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4.1. Introduction 
Pulmonary arterial hypertension (P AH) is a progressive cardiovascular disease 
that leads to limited exercise capacity, right ventricular heart failure, and ultimately 
death (1). It is hemo-dynamically defined as an increased mean pulmonary arterial 
pressure higher than 25 mmHg with a pulmonary capillary wedge pressure lower than 
15 mmHg at rest (2, 3). Patients often develop PAH because of genetic and/or 
environmental insult, resulting in endothelial cell apoptosis, loss of distal vessels, and 
occlusive vascular remodeling, which causes elevated pulmonary arterial pressures. 
The primary treatment options currently available for patients with P AH are 
based on drugs with vasodilatory properties that improve cardiopulmonary function. 
Unfortunately, these drugs show no effect on prohibiting the progress of obliterative 
vascular pathology. Because of this, the only option for many patients to improve their 
health and quality of life is heart-lung transplantation. Therefore, new approaches to 
utilize compounds that focus on activating cellular mechanisms to reverse vascular 
remodeling are under investigation ( 4). Improving the function of the bone 
morphogenetic protein receptor-2 (BMPR2) signaling pathway is a potential direction 
in the development of improved P AH therapies, as the mutations of BMPR2 have 
been identified as the main cause of inherited P AH, accounting for 60 to 80% of 
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familial cases. BMPR2 mutations are also the main cause of 10 to 25% in sporadic 
PAH and 9% of PAH associated with fenfluramine use (4-8). 
Since challenges exist in the clinical application of BMPR2 gene therapy, 
tacrolimus can be applied instead, as it increases signaling through the BMPR2 
pathway. Tacrolimus (TAC) is an FDA-approved immunosuppressive drug with a 
known pharmacokinetic and toxicity profile. Previous research on the use of TAC to 
treat P AH has shown that: 1) low-dose TAC can reverse dysfunctional BMPR2 
signaling in pulmonary artery endothelial cells (ECs) from patients with idiopathic 
P AH, 2) low-dose TAC can prevent exaggerated chronic hypoxic P AH in mice with 
conditional BMPR2 deletion in ECs, and 3) low-dose TAC can reverse severe PAH in 
rats with medial hypertrophy following monocrotaline exposure and in rats with 
neointima formation following vascular endothelial growth factor receptor blockade 
and chronic hypoxia ( 4 ). 
Although TAC shows prom1smg potential in the treatment of PAH, its 
application is hindered by its poor solubility (water solubility of 1.3 µg/mL), 
instability, and limited bioavailability (9-11 ). In addition to these limiting 
pharmacokinetic properties, systemic side effects such as neurotoxicity and 
nephrotoxicity also complicate the clinical use of TAC (12). To overcome this 
problem, biodegradable polymeric acetalated dextran (Ac-Dex) nanoparticles (NP) can 
be applied to more safely and effectively deliver TAC. Ac-Dex NP can improve 
hydrophobic agent solubility, promote drug penetration into cell membranes to obtain 
higher plasma concentration, provide sustained drug release, and provide reduced 
systemic side effects. 
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Ac-Dex is an acid-sensitive, biodegradable, and biocompatible polymer that 
can be prepared in a one-step reaction by reversibly modifying dextran with acetal 
groups (13). This modification reverses the solubility properties of dextran from 
hydrophilic to hydrophobic, making it possible to form polymeric particles using 
standard emulsion or nanoprecipitation techniques. In contrast to poly(lactic-co-
glycolic acid) (PLGA) and other polyesters, which are widely applied as excipients in 
drug delivery applications, Ac-Dex shows additional advantages. Most notably, the 
degradation rate of Ac-Dex can be tuned from minutes to months to suit various 
applications. Tunable degradation rates result from the adjustment of the ratio of 
cyclic acetal groups with a slower degradation rate to acyclic acetal groups with a 
faster degradation rate, which can be easily completed by controlling the reaction time 
during the formation of Ac-Dex. Furthermore, Ac-Dex particulates show no burst 
release at physiological conditions (pH 7.4), which is necessary to maintain a steady 
drug level in the body. Finally, Ac-Dex degrades into biocompatible, biodegradable, 
FDA-approved by-products of dextran and very low levels of methanol and acetone 
(13-16). 
Pulmonary aerosols have attracted increasing attention for the treatment of 
lung diseases, as they are capable of delivering a wide range of therapeutics directly 
and efficiently to the lungs. Pulmonary delivery systems offer several advantages 
including increased local drug concentration in the lungs, reduced systemic side 
effects, rapid onset of action due to the enormous surface area and plentiful capillary 
vessels in the lung, and avoidance of the first-pass metabolism associated with the 
liver (17-22). While dry powder aerosolized nanoparticles (less than 500 nm) will be 
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exhaled owing to their small size and mass, aerosolized particles with aerodynamic 
diameters of 1-5 µm can effectively deposit into the lungs. However, this larger 
microparticle size range is also the size at which particles are commonly phagocytosed 
by alveolar macrophages, which limits their efficacy as aerosol drug delivery vehicles 
(23). To overcome these aforementioned obstacles for pulmonary TAC delivery, we 
developed nanocomposite microparticles (nCmP) in the form of dry powder aerosols 
(Figure 4.1). This system is comprised of TAC-loaded Ac-Dex NP entrapped in 
microparticle carriers comprised using the excipient mannitol to allow for the delivery 
of TAC NP to the lungs. 
Mannitol was used as the excipient of nCmP due to its beneficial properties in 
aerosol formulations. First, mannitol is highly water-soluble, which ensures rapid 
decomposition of nCmP in the aqueous environment of mucus and pulmonary 
surfactant in the lungs, leading to a burst release of NP from the nCmP system. 
Furthermore, mannitol is able to enhance mucus penetration of nanoparticles by 
increasing fluidity of mucus in the lung (24). Finally, mannitol has been extensively 
studied as a carrier in spray-dried powder aerosols for pulmonary drug administration 
and the resulting particles have been shown to exhibit desirable water content, size, 
and surface morphology for successful aerosol delivery (25-30). 
In the present nCmP system, the drug-loaded nanoparticles contain TAC as a 
therapeutic and these NP are coated by polyvinyl alcohol (PV A). Upon pulmonary 
administration, the nCmP will deposit on the mucus in the respiratory tract, 
decompose into free NP and mannitol, and allow the nanoparticles to penetrate the 
mucus barrier and then release drug to the targeted site. The goal of the described 
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research was the initial development and physicochemical characterization of the 
nCmP systems with ability of targeted delivery, improved drug solubility, and 
potential of efficient penetration of mucus barrier and of controlled release via particle 
engmeenng. 
Ac-Dex NP Containing 
Tacrolimus 
Mannitol 
• = Nanoparticles = Microparticles = Epithelium 
Figure 4.1. Schematic of an aerosol nanoparticle microparticle (nCmP) system 
interacting with the pulmonary mucosa. Once the nCmP impact the surface of the 
mucus coating the pulmonary epithelium they immediately degrade to release 
nanoparticles. 
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4.2 Materials and Methods 
4.2.1 Materials 
Dextran from Leuconostoc mesenteroides (9000-11000 MW), pyridinium p-
toluenesulfonate (PPTS, 98%), D-mannitol (.2: 98%), 2-methoxypropene (2-MOP, 
97%), triethylamine (TEA, .2: 99%), anhydrous dimethyl sulfoxide (DMSO, .2: 99.9%), 
poly(vinyl alcohol) (PVA, MW 13,000-23,000, 87-89% hydrolyzed), dichloromethane 
(DCM, anhydrous, .2: 99.8%), deuterium chloride (DCl, 35 weight% in D20, 99 atom% 
D), Tween® 80, potassium phosphate dibasic, potassium phosphate monobasic, and 
acetonitrile (HPLC grade, .2: 99.9%) were obtained from Sigma-Aldrich (St. Louis, 
MO). Deuterium oxide (D20, 99.8% atom D) was obtained from Acros Organics 
(Geel, Belgium). Phosphate buffered saline (PBS) and phosphoric acid (extra pure, 85% 
solution in water) were obtained from Fisher Scientific (Somerville, NJ). Hydranal® 
KF reagent was obtained from Fluka Analytical. Tacrolimus (FK-506) was purchased 
from LC Laboratories (Woburn, MA). A549 cells were obtained from American Type 
Culture Collection (Manassas, VA, USA). Dulbecco's Modified Eagle Medium 
(DMEM), pen-strep, and fungizone® were obtained from Life Technologies (Norwalk, 
CT, USA). Sodium pyruvate was obtained from Fisher Scientific. Dimethyl sulfoxide 
(DMSO) was obtained from Wilkem Scientific (Pawtucket, RI, USA). Fetal bovine 
serum (FBS) was obtained from Atlanta Biologics (Flowery Branch, GA, USA) and 
Resazurin was obtained from Acros Organics. 
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4.2.2 Synthesis and NMR Analysis of Acetalated Dextran (Ac-Dex) 
Ac-Dex was synthesized as described previously (14) with mmor 
modifications. Briefly, 1 g of lyophilized dextran and 25 mg of PPTS were dissolved 
in 10 mL anhydrous DMSO. The resulting solution was reacted with 5 mL of 2-MOP 
under nitrogen gas for 5 minutes and was quenched with 1 mL of TEA. The reaction 
mixture was then precipitated in basic water (water and TEA, pH 9), vacuum filtered, 
and lyophilized (-50 °C, 0.023 mbar) for 24 hours to yield a solid product. 
The cyclic-to-acyclic (CAC) ratio of acetal coverage and degrees of total acetal 
coverage per 100 glucose molecules was confirmed by lH NMR spectroscopy (Bruker 
300 MHz NMR, MA). 10 mg of Ac-Dex was added to 700 µL of D20 and was 
hydrolyzed with 30 µL of DCl prior to analysis. The hydrolysis of one cyclic acetal 
group produces one acetone whereas one acyclic acetal produces one acetone and one 
methanol. Consequently, from the normalized integrations of peaks related to acetone, 
methanol, and the carbon ring of dextran, the CAC ratio of acetal coverage and 
degrees of total acetal coverage per 100 glucoses was determined. 
4.2.3 Formation of TAC-Loaded Ac-Dex Nanoparticles (TAC NP) 
Tacrolimus-loaded nanoparticles (TAC NP) were prepared via oil/water 
emulsion and solvent evaporation. 90 mg of Ac-Dex and 10 mg of TAC were 
dissolved in 1 mL of DCM over an ice bath, establishing the organic phase. 3% PVA 
in PBS, the aqueous phase, was added to the organic phase and the resulting solution 
was sonicated (Q500 Sonicator, Qsonica, Newtown, CT) for 30 seconds with a 1 
second on/off pulse at 70% amplitude. The emulsion was transferred to a spinning 
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solution of 0.3% PV A in PBS and stirred for 4 hours for evaporation of the organic 
solvent and particle hardening. The solution was then centrifuged at 12000 rpm for 20 
minutes to collect the nanoparticles. Nanoparticles were washed once with basic water, 
redispersed in 0.1 % PVA, and lyophilized (-50 °C, 0.023 mbar) for 48 hours. 
4.2.4 Formulation of Nanocomposite Microparticles (nCmP) Via Spray Drying 
nCrnP were prepared via the spray drying of TAC NP suspensions and 
mannitol in an aqueous solution using a Buchi B-290 spray dryer (Buchi Labortechnik, 
AG, Switzerland) in open mode. The spray drying conditions were as follows: 1:1 
(weight) ratio of TAC NP to mannitol in DI water, feed solution concentration of 1 % 
(w/v), 0.7 mm nozzle diameter, atomization gas flow rate of 414 L/h using UHP dry 
nitrogen, aspiration rate of 28 m3 /h, inlet temperature of 50 °C, pump rate of 0.6 
mL/min, and nozzle cleaner rate of 4. The resulting nCmP were separated in a high-
performance cyclone, collected in a sample collector, and stored in amber glass vials 
in desiccators at -20 °C. 
4.2.5 Particle Morphology and Shape Analysis via Scanning Electron Microscopy 
(SEM) 
The shape and surface morphology of the NP and nCmP were evaluated by 
SEM using a Zeiss SIGMA VP Field Emission-Scanning Electron Microscope (FE-
SEM) (Germany). nCmP samples were placed on aluminum SEM stubs with double-
sided adhesive carbon tabs. Nanoparticles were dispersed in basic water (pH = 9, 10 
mg/mL) and this suspension was dropped onto aluminum SEM stubs and then dried at 
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room temperature. Both the NP and nCmP samples were coated with a thin film of a 
gold/palladium alloy using a BIO-RAD sputter coating system at 20 µA for 60 
seconds under argon gas. Images were captured at 5 kV at various magnifications. 
4.2.6 Particle Size, Size Distribution, and Zeta Potential Analysis 
The size, size distribution, and zeta potential of the NP systems were measured 
by dynamic light scattering (DLS) using a Malvern Nano Zetasizer (Malvern 
Instruments, Worcestershire, UK). The NP were dispersed in basic water (pH= 9, 0.3 
mg/mL). All experiments were performed in triplicate with a scattering angle of 173° 
at 25 °C. The mean size (geometric diameter) of the nCmP was measured digitally 
from SEM images using ImageJ software (Systat, San Jose, CA, USA). Representative 
micrographs (5000x magnification) for each sample were analyzed by measuring the 
diameter of at least 100 particles. 
4.2.7 Analysis of Nanoparticle Drug Loading and Nanoparticle Loading in nCmP 
Drug loading and encapsulation efficacy of TAC NP and nCmP were 
determined via Ultra-Performance Liquid Chromatography (UPLC) (LaChrom, 
Hitachi, Japan). Detection of TAC was performed using following conditions: C1s, 5 
µm x 150 mm x 4.6 mm column (Ascentis, Sigma-Aldrich, St. Louis, MO), 1 mL/min 
pump rate, 6 minute retention time, mobile phase of 70% acetonitrile and 30% 
phosphoric acid aqueous solution (0.1 % ), absorbance of 215 nm, and temperature of 
50 °C. Drug-loaded NP and nCmP were fully dissolved in the mobile phase prior to 
analysis. The drug concentration in each sample was quantified by comparison with a 
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standard curve of TAC in its mobile phase. The TAC loading of NP, TAC loading of 
nCmP, NP loading in nCmP, drug encapsulation efficiency (EE) of NP, and NP 
encapsulation efficacy in nCmP were determined by the following equations: 
Drug loading = mass of drug loaded in NP x 1 OO% 
mass ofNP 
. mass of drug loaded in NP Drug encapsulation efficacy (EE) = x 100% 
initial mass of drug in NP formulation 
N . 1 1 d" mass ofNP loaded in nCmP x 1000/0 anopart1c es oa mg = ---------- ;re
mass ofnCmP 
NP l d. ffi mass ofNP loaded in nCmP oa mg e 1cacy = --------------
initial mass of NP in nCmP formulation 
4.2.8 In Vitro Drug Release from Nanoparticles 
x 100% 
The in vitro release profiles of TAC from nanoparticles were determined via 
the release of NP (1 mg/mL) in modified phosphate buffer (PB, 0.1 M, pH= 7.4) with 
0.5% (w/v) of Tween® 80. The NP suspension was incubated at 37 °C and 100 rpm. 
At various time points (0 to 24 h), NP samples were centrifuged at 12000 rpm for 5 
minutes at 4 °C to isolate the NP. 200 µL of supernatant was withdrawn and replaced 
by the same amount of fresh modified PB in each sample. The withdrawn solutions 
were analyzed for drug content via UPLC using the same methods described 
previously. 
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4.2.9 Karl Fischer Coulemetric Titration 
The water content of the nCmP was quantified by Karl Fischer (KF) titration 
using a 737 KF coulometer (Metrohm, Riverview, FL). 10 mg of powder was 
dissolved in anhydrous methanol. The resulting solution was injected into the KF 
reaction cell filled with Hydranal® KF reagent and then the amount of water was 
analyzed. 
4.2.10 Differential Scanning Calorimetry (DSC) 
The thermal phase transitions of the nCmP, NP, and their raw components 
were determined via DSC using a TA QlO DSC system (TA Instruments, New Castle, 
DE, USA) equipped with an automated computer-controlled TA instruments DSC 
refrigerated cooling system. 1 - 3 mg of sample was weighed into Tzero TM alodined 
aluminum pans that were hermetically sealed. The sealed pans were placed into the 
DSC furnace along with an empty sealed reference· pan. The heating range used was 0 
- 300 °C at a heating rate of 10 °C/min. 
4.2.11 Powder X-Ray Diffraction (PXRD) 
Crystalline states of the nCmP and its raw components were examined by 
PXRD using a Rigaku Multiflex X-ray diffractometer (The Woodlands, TX) with a Cu 
Ka radiation source (40 kV, 44 mA). The samples were placed on a horizontal quartz 
glass sample holder (3 mm). The scan range was 5 - 80° in 28 with a step width of 
0.02 and scan rate of2 °/min. 
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4.2.12 Jn Vitro Aerosol Dispersion Performance with the Next Generation 
Impactor (NGI) 
In vitro aerosol dispersion performance of the nCmP was evaluated using a 
Next Generation Impactor™ (NGI™, MSP Corporation, Shoreview, MN) equipped 
with a stainless steel induction port (USP throat adaptor) attachment and stainless steel 
gravimetric insert cups. The NGI™ was coupled with a Copley TPK 2000 critical 
flow controller, which was connected to a Copley HCP5 vacuum pump (Copley 
Scientific, United Kingdom). The airflow rate (Q) was measured and adjusted to 60 
Umin in order to model the flow rate in a healthy adult lung before each experiment. 
Glass fiber filters (55 mm, Type A/E, Pall Life Sciences, PA) were placed in the 
gravimetric insert cups for stages 1 through 7 to minimize bounce or re-entrapment 
(31) and these filters were weighed before and after the experiment to determine the 
particle mass deposited on each stage. Approximately 10 mg of powder was loaded 
into a hydroxypropyl methylcellulose (HPMC, size 3, Quali-V®, Qualicaps® Inc., 
Whitsett, NC, USA) capsule and the capsule was placed into a human dry powder 
inhaler device (HandiHaler, Boehringer Ingelheim Pharmaceuticals, CT) attached to a 
customized rubber mouthpiece connected to the NGI™. Three HPMC capsules were 
loaded and released in each measurement and experiments were performed in 
triplicate. The NGI™ was run with a delay time of 10 sand running time of 10 s. For 
Q = 60 Umin, the effective cutoff diameters for each stage of the impactor were given 
from the manufacturer as: stage 1 (8.06 µm); stage 2 ( 4.46 µm); stage 3 (2.82 µm); 
stage 4 (1 .66 µm); stage 5 (0.94 µm) ; stage 6 (0.55 µm) ; and stage 7 (0.34 µm). The 
112 
fine particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and 
emitted dose (ED) were calculated as follows: 
Fine particles dose (FPD) =mass of particles on Stages 2 through 7 
F. rt" l fr t" (FPF) fine particles dose x 100010 me pa ic es ac ion = --------"--------- ,c 
initial particle mass loaded into capsules 
R . bl fr . (RF) mass of particles on Stages 2 through 7 x 100010 esp1ra e action = ---"-----------"----....;;;;...- ,c 
total particle mass on all stages 
E . d d (ED) initial mass in capsules - final mass remaining in capsules m1tte ose = x 100% 
initial mass in capsules 
The experimental mass median aerodynamic diameter (MMADE) and 
geometric standard deviation (GSD) for the particles were determined using a 
Mathematica® program written by Dr. Warren Finlay (31, 32). 
4.2.13 Tapped Density and Theoretical Aerodynamic Diameter Analysis 
The density of the nCmP was evalulated via tapped density measurements as 
described previously with minor modifications (33). 30 - 35 mg nCmP was weighed in 
a glass tube. The tube was tapped 200 times to ensure efficient packing of the nCmP 
and then the volume occupied by the particles was measured. The density was 
determined by the following equation: 
m p=-
v 
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where p is the density of the nCmP, m is the nCmP mass, and V is the nCmP volume 
determined by measuring the height of the particles in a tube with a known diameter (5 
mm). The theoretical MMAD (MMADT) of the nCmP was calculated using the 
following equation: 
MJv1AD =dJf. T * p 
where d is the geometric diameter of the nCmP determined by ImageJ, p is the density 
of the TAC nCmP, and p* = 1 g/cm3 (polymer reference density). 
4.2.14 In vitro cytotoxicity of TAC nCmP using resazurin assay 
The in vitro cytotoxicity of TAC nCmP as well as free TAC were evaluated using the 
resazurin assay. Human adenocarcinomic alveolar basal epithelial cell line (A549, 
passage 6) was used as in vitro model to evaluate the effect of various TAC nCmP 
concentrations at different time intervals on their viability. A549 cells were 
maintained in DMEM supplemented with 10% (v/v) fetal bovine serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin, fungizone® (0.5 µg amphotericin, B, 0.41 µg/mL 
sodium deoxycholate) and 1 mM sodium pyruvate at 37°C in C02 incubator. The cells 
were trypsinized and plated at density 5 x 104 cells/ml (100 µl/well) in flat-bottomed 
96-well plate and incubated overnight at 37°C in C02 incubator. On the following day, 
the A549 cells were exposed to various sets of concentration of free TAC and TAC 
nCmP (0.00001 to 10 µM) in hexaplets for 48 hand 72 h. After respective time period 
of 48 h and 72 h exposure, 20 µl of resazurin solution ( 60 µM) was added to each well 
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and the plate was incubated for another 3 h, allowing the viable cells to convert 
resazurin to resorufin, and the fluorescence intensity of the resorufin produced by 
viable cells was detected at 520 run (excitation) and 590 run (emission) using Cytation 
3 plate reader (BioTek, Winooski, VT, USA). The wells containing complete medium 
and resazurin, without cells, were taken as blank and the wells containing cells and 
resazurin, without particles, served as control. The relative viability of each sample 
was calculated by: 
Relative Viability (%)= (Sample Fluorescence Intensity)/(Control Fluorescence 
Intensity) x 100% 
4.2.15 Statistical Analysis 
All measurements were performed in at least triplicate. Values are given in the 
form of means± SD. The statistical significance of the results was determined using t-
tests where a p-value of <0.05 was considered statistically significant. 
4.3. Results and Discussion 
4.3.1 Characterization of Ac-Dex 
Successful synthesis of Ac-Dex was confirmed by NMR. Ac-Dex exhibited 
71.5% cyclic acetal coverage and 79.2% total conversion of -OH groups. An increase 
in CAC is known to decrease the drug release rate due to slower degradation of Ac-
Dex (13, 14). A high total acetal coverage (higher than 75% according to our research) 
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is required to stabilize the PV A coating of nanoparticles, which ensures small particles 
size and narrow size distribution 
4.3.2 Characterization of N anoparticles 
4.3.2.1 NP Size, Distribution, and Surface Charge 
The tacrolimus-loaded nanoparticles (TAC NP) shown in Figure 4.2A, appear 
as uniform spheres with smooth surface morphology. NP size, size distribution (PDI), 
and zeta potential are shown in Table 4.1. The resulting sizes of the NP analyzed via 
DLS (approximately 200 nm) were larger than those observed from SEM micrographs 
and ImageJ analysis (approximately 100 nm) due to shrinking of the particles during 
freeze-drying or sputter coating and agglomeration of particles during resuspension 
into aqueous solutions (34, 35). The TAC NP system exhibited desirable size (less 
than 200 nm) with narrow size distribution to potentially allow for mucus penetration 
and pulmonary epithelial targeting. The surface charge of the NP system was slightly 
negative, which is suitable to reduce interactions with negatively charged mucin fibers, 
enhancing the particle permeation through the mucus barrier (35). 
Figure 4.2. Representative SEM micrographs of tacrolimus (TAC) nanoparticles (NP) 
and nanocomposite microparticles (nCmP) including: (A) TAC NP, (B) TAC nCmP, 
(C) representative zoomed in image of TAC nCmP. 
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Table 4.1. Diameter (as measured by dynamic light scattering), polydispersity index 
(PDI), zeta potential (~), TAC loading, and encapsulation efficiency (EE) of 
tacrolimus-loaded nanoparticles before spray drying (TAC NP) and after spray drying 
and redispersion from nanocomposite microparticles (Redispersed TAC NP) (mean± 
standard deviation, n = 3). 
Diameter ~Potential TAC Loading EE System (nm) PDI (mV) (mg drug/lOOmg (%) NP) 
TAC NP 199.7 ± 0.07± -6.33 ± 7.04 ± 0.45 69.25 ± 3.2 0.00 1.27 4.38 
Redisper 227.5 ± 0.16 ± -9.42 ± 
sed TAC 6.3 0.03 3.83 NIA NIA NP 
4.3.2.2 TAC Loading and in Vitro Release 
TAC was successfully encapsulated into the described TAC NP system. 69.25% 
of the initially loaded TAC was effectively encapsulated within the NP prepared using 
emulsion solvent evaporation of Ac-Dex and drug in PVA solution. The high 
encapsulation efficacy of the drug is due to the low solubility of TAC in the aqueous 
spinning solution. 
Results of the in vitro release of TAC NP at physiological pH and temperature 
are reported in Figure 4.3 as the percentage of drug released over time. The TAC NP 
system displayed a sustained release of 40% of its payload after 12 hours, in which 30% 
of TAC was released in the first 6 hours and 10% was released in the next 6 hours. 
Previous research showed that Ac-Dex NP made of 1 OkDa dextran and reacted for 5 
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minutes exhibited a maximum of degradation at 6 hours and negligible degradation 
after that (15). Based on these results, the TAC release profiles in this study can likely 
be explained as follows: the first release stage (up to 6 hours) corresponds to Ac-Dex 
degradation as well as nanoparticle dissociation, whereas after 6 hours the rate of TAC 
release is controlled by drugs passively diffusing out of the dissociated matrix of 
nanoparticles following the partial degradation of Ac-Dex. This two-stage release 
profile of Ac-Dex based particles matches that of other drug-loaded Ac-Dex 
nanoparticle systems in our group and other previous studies (33). 
50 
10 + 
0 • ···· 
0 5 
f • l 
10 15 20 
Time (hour) 
t 
25 
Figure 4.3. In vitro drug release profile for tacrolimus (TAC) nanoparticle system. 
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4.3.3 Nanocomposite Microparticle Characterization 
4.3.3.1 nCmP Morphology, Size, and Size Distribution 
TAC nCmP displayed a wrinkled and raisin-like surface with visibly 
encapsulated NP as seen in Figures 4.2B and 4.2C. The corrugated surface of the 
nCmP reduces their contact area, which prevents the particles from aggregating upon 
aerosolization, thus improving aerosol performance and the dispersion of the NP from 
the dry powder nCmP formulation. The cause of the raisin-like morphology of the 
nCmP may be attributed to the early formation of nanoparticle shells in droplets 
during spray drying. The formation of nanoparticle shells during spray drying 
determines the geometric size of nCmP. As the drying proceeds, the remaining water 
keeps evaporating from the droplet center, resulting in hollow particles that tend to 
shrink (36, 37). The number average geometric diameter of the TAC nCmP system 
was 2.13 ± 0.52 µm, as determined by ImageJ analysis. 
4.3.3.2 Karl Fischer Titration 
The residual water content of TAC nCmP was approximately 8% (Table 4.2), 
which is acceptable in this dry powder formulation. Water in inhalable dry powders 
can significantly reduce their dispersion properties during aerosolization due to the 
interparticulate capillary forces acting at the solid-solid interface between particles 
(3 8) and the presence of water is also responsible for the instability of the powders 
during storage (39). Correspondingly, low water content in inhalable dry powders is 
highly favorable for efficient dry powder aerosolization and effective particle delivery 
(38, 40). 
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Table 4.2. Geometric diameter (as measured by SEM imaging and ImageJ analysis), 
water content, TAC loading, nanoparticle (NP) loading in nanocomposite 
microparticles (nCmP), and NP loading efficacy in nCmP (mean± standard deviation, 
n= 3). 
Geometri Water Drug Loading NP NP Content Loading System c (mg drug/100 Loading Diameter (weight% 
mgnCmP) (%) Efficacy (µm) ) (%) 
TAC 2.13 ± 7.99 ± 0.31 3.19 ± 0.31 45.29 ± 90.59 ± 
nCmP 0.52 4.42 8.85 
4.3.3.3 Differential Scanning Calorimetry 
Figure 4.4 shows DSC thermograms of the raw materials used in particle 
preparation and the final drug-loaded nCmP. Raw Ac-Dex, TAC, and mannitol 
displayed endothermic main phase transition peaks (Tm) near 170, 135, and 167 °C, 
respectively, which are in accordance with previously reported values ( 41, 42). The 
TAC nCmP system exhibited a main phase transition peak (Tm) near 142 °C, 
corresponding to the melting of mannitol. This melting point was lower than those of 
raw mannitol, indicating an increase in the amorphous state of these raw materials in 
nCmP. No glass transitions or other phase transitions were evident under 120 °C, 
which indicated that all the materials are stable during manufacturing and storage 
conditions. 
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4.3.3.4 Powder X-ray Diffraction (PXRD) 
X-ray diffraction diffractograms of the raw materials and TAC nCmP are 
shown in Figure 4.5. Strong peaks were present for raw TAC and mannitol powders. 
These strong peaks indicate that the raw materials are in their crystalline forms prior to 
spray drying, which is in accordance with previous studies (41, 42). No strong peaks 
were present for raw Ac-Dex, indicating that it is non-crystalline. The non-crystallinity 
of Ac-Dex is quite different from commercialized polymers such as PLGA, which 
exhibits strong XRD characterization peaks ( 43-45). The absence of diffraction peaks 
in Ac-Dex is likely because the Ac-Dex was collected by rapid precipitation in water. 
XRD patterns of TAC nCmP displayed the absence of any diffraction peaks of raw 
TAC, suggesting amorphization of raw TAC in the particle matrix, which is suitable 
for the improvement of tacrolimus solubility in physiological conditions. Also, the 
peaks characterizing mannitol were significantly reduced, indicating that mannitol is 
reduced to its amorphous state in the nCmP. The results obtained from the XRD 
diffractograms confirmed those from DSC thermograms, where raw TAC and 
mannitol were converted into amorphous forms in the nCmP manufacturing process. 
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Figure 4.4. Representative differential scanning calorimetry (DSC) thermograrns of 
raw tacrolirnus (TAC), raw acetalated dextran (Ac-Dex), raw rnannitol, TAC 
nanoparticles (TAC NP), and formulated TAC nanocornposite rnicroparticles (TAC 
nCrnP). 
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Figure 4.5. Representative powder X-ray (PXRD) diffractograms of raw tacrolimus 
(TAC), raw acetalated dextran (Ac-Dex), raw rnannitol, and formulated TAC 
nanocornposite rnicroparticles (TAC nCrnP). 
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4.3.3.5 Drug and Nanoparticles Loading in nCmP 
UPLC was used to determine the amount of TAC loading in the nCmP and this 
data was used to calculate the resulting NP loading and NP encapsulation efficacy in 
the nCmP formulation as seen in Tables 4.1 and 4.2. The TAC NP exhibited desirable 
drug loading (more than 69% encapsulation efficiency), which is a result of the poor 
water solubility of tacrolimus. The TAC nCmP showed high NP loading(> 45%), and 
very high NP encapsulation efficacy (> 90% ). The high drug loading in the nCmP 
formulation is favorable to reduce the amount of particles administrated to achieve 
target therapeutic effect. 
4.3.3.6 Nanoparticle Redispersion from nCmP 
The properties of NP redispersed from nCmP dissolved in water were 
evaluated using DLS (Table 4.1). The size and PDI of the redispersed NP exhibited 
slight increases after redispersion from nCmP, which is likely a result of 
agglomeration that occurred during the spray drying process. The NP surface charge 
remained slightly negative. These parameters were all within the desirable ranges for 
effective penetration of NP through the mucus barrier, demonstrating the favorable 
properties of nanoparticles remain intact after spray drying. 
4.3.3.7 In Vitro Aerosol Dispersion Performance Using Next Generation Impactor 
(NGI) 
In vitro aerosol dispersion performance properties of the nCmP were evaluated 
using a Next Generation Impactor™ coupled with a human DPI device (Figure 4.6 
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and Table 4.3). The results indicated that the formulated nCmP aerosol properties are 
favorable for efficient dry powder aerosolization and effective targeted pulmonary 
delivery. The experimental mass mean aerodynamic diameter (MMADE) value of 
TAC-nCmP was 3.57 ± 0.17 µm, while the geometric standard deviation (GSD) value 
was 1.78 ± 0.02 µm. The MMADE value is within the range of 1 - 5 µm that is 
required for predominant deposition of nCmP into the deep lung regions ( 46), which 
would be desirable for the delivery of TAC to the periphery of the lungs. The GSD 
values were within the range of those previously reported and the respirable fraction 
(RF), fine particle fraction (FPF), and emitted dose (ED) values were all higher than 
reports from similar systems (31 , 46, 4 7). In clinical research, P AH patients are treated 
with TAC with a target blood level of 1.5 - 5 ng/mL ( 48-50). The present nCmP 
system is expected to achieve a therapeutic effect using a low amount of TAC through 
its improved delivery efficacy over current systemic methods. 9.8% of TAC nCmP 
deposited on stages 5 - 7 and it is predicted that these particles will deposit in the deep 
lung alveolar region due to diffusion mechanisms of deposition ( 51 ). Subsequently, 
71.2% of nCmP deposited on stages 2 - 4 and are thus predicted to deposit 
predominantly in the lungs by sedimentation due to gravitational settling (18, 52, 53). 
Overall, the nCrnP exhibited desirable aerosol dispersion characteristics allowing them 
to deposit in deep lung regions for effective drug delivery of TAC. 
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Figure 4.6. Aerosol dispersion performance of tacrolimus nanocomposite 
microparticles (TAC nCmP) as % particles deposited on each stage of the Next 
Generation Impactor™ (NGI™). For Q = 60 L/min, the effective cutoff diameters (D5o) 
for each impaction stage are as follows: stage 1 (8.06 µm) , stage 2 (4.46 µm) , stage 3 
(2.82 µm) , stage 4 (1.66 µm), stage 5 (0.94 µm), stage 6 (0.55 µm), and stage 7 (0.34 
µm) (mean± standard deviation, n = 3). 
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Table 4.3. In vitro aerosol dispersion performance properties including theoretical 
mass median aerodynamic diameter (MMADT) from tapped density measurements, 
experimental mass median aerodynamic diameter (MMADE), geometric standard 
deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF), respirable 
fraction (RF), and emitted dose (ED) for nCmP (mean± standard deviation, n = 3). 
System 
TAC 
nCmP 
MMADT MMADE 
(µm) (µm) 
0.79± 
0.79 
3.57± 
0.17 
GSD 
(µm) 
1.78 ± 
0.02 
FPF(%) RF(%) 
81.0 ± 
2.6 
67.6± 
3.0 
ED(%) 
96.3 ± 
1.37 
4.3.3.8 Analysis of nCmP Density and Theoretical Aerodynamic Diameter 
The density of the particles was determined via tapped density measurements. 
The TAC nCmP exhibited a relative low density value of 0.138 ± 0.001 g/cm3 
compared with the raw materials (1.5 g/cm\ which can be attributed to the raisin-like 
surface morphology and hollow structure of the nCmP. The theoretical MMAD 
calculated with the geometric diameter and tapped density was 0. 79 ± 0.19 µm, which 
was lower than the experimental result. The lower MMADT in comparison to MMADE 
can be attributed to nCmP agglomeration during aerosolization, which increased the 
geometric size (and thus aerodynamic diameter) of the dry powder formulation. 
4.3.3.9 In vitro cytotoxicity of TAC nCmP microparticles using resazurin assay 
To evaluate the response of particles on cell viability, in vitro cytotoxicity of TAC 
nCmP as well as free TAC against A549 cells were conducted. TAC nCmP and free 
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TAC were exposed to A549 cells at different concentrations for 48 h and 72 h, and the 
cell viability was analyzed using resazurin assay (Figure 4.7). For free TAC, the 
relative viability of the A549 cells remains constant for increasing drug concentrations 
at 48 h and 72 h, demonstrating that TAC is non-toxic to lung cells up to 10 µM 
concentration (Figure 4.7 (a)). TAC nCmP does not exhibit significant cytotoxic 
effect at various TAC concentrations (0.00001 - 10 µM) until 72 h, and there is no 
significant decrease in the viability of A549 cells at 48 hand 72 h (Figure 4.7 (b)). 
However, for TAC nCrnP, a slight increase in cell viability was observed at 72 has 
compared to 48 h. This might be due to the presence of mannitol in TAC nCrnP. 
Previous study suggests that an increase in glucose (mannitol) concentration can led to 
increase in the cell proliferation by upregulating heme oxygenase-1 via reactive 
oxygen species or the TGF-~1 /PBK/Akt signaling pathway. Thus, TAC nCrnP was 
not cytotoxic and could be used for the treatment of P AH, hence minimizing the 
potential negative side effects. 
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Figure 4.7. A549 cell viability measured by resazurin assay after 48 h and 72 h 
exposure to (a) free TAC, and (b) TAC nanocomposite microparticles (nCmP) (mean 
±standard deviation, n = 3). 
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4.4 Conclusions 
Tacrolimus was successfully encapsulated in Ac-Dex nanoparticles with a high 
encapsulation efficacy. The drug-loaded nanoparticles were 200 nm smooth spheres 
with narrow size distribution and slightly negative surface charge, which is desirable 
to overcome the mucus barrier in the lung. These favorable properties were maintained 
during the nCmP manufacturing process as shown in redispersion testing. The nCmP 
systems were 2 µm, raisin-like spheres with observable nanoparticles present on their 
surface. The water content of the nCmP systems was relatively low, which can enable 
efficient dry powder aerosolization and particle delivery. None of the raw materials 
underwent degradation during nCmP manufacturing, indicating the stability of the 
therapeutics during formation. No crystalline structures of TAC was observed in the 
nCmP, which confirmed that the drug in the nCmP were in their amorphous form. In 
vitro aerosol performance testing demonstrated desirable aerosol dispersion 
characteristics of nCmP, allowing them to deposit in deep lung regions for drug 
delivery. There was no significant effect in the viability of A549 cells, which 
confirmed the non-cytotoxic behavior of TAC nCmP. 
This nCmP system exhibits promising application in pulmonary TAC delivery 
for the treatment of P AH due to its novel features including targeted pulmonary 
delivery, improved solubility of tacrolimus, potential of permeation through mucus 
barrier, and of controlled drug release. In contrast to other delivery methods, this dry 
powder formulation also provides more convenient administration, more flexible 
storage conditions, and lower risk of contamination in the device. 
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ABSTRACT 
Dry powder aerosols have attracted increasing attention for the treatment of 
pulmonary diseases, as they are capable of delivering therapeutics directly and efficiently 
to the lungs. Nanocomposite microparticle (nCmP) systems, combining the advantages 
of nanoscale and microscale carriers, exhibit promising potential in the application of 
therapeutics for deep and whole lung drug delivery. Several nCmP systems have been 
developed for various applications, but few comprehensive studies have been completed 
to illustrate how to effectively engineer an optimal nCmP system for delivery of 
therapeutics to the deep (alveolar) region of the lungs. In the present research, we aimed 
to identify the optimal spray drying condition(s) to prepare nCmP with desirable drug 
delivery properties including: (a) small aerodynamic diameter, (b) effective nanoparticle 
redispersion upon nCmP exposure to an aqueous solution, ( c) high drug loading, ( d) and 
low water content. Acetalated dextran (Ac-Dex) was used as the polymer to form the 
nanoparticles, curcumin was used as a model drug, and mannitol was applied as an 
excipient in the nCmP formulation. Box-Behnken design was applied using Design-
Expert software for nCmP parameter optimization. The results indicated that the 
nanoparticle ratio (NP%) and feed concentration (Fe) are significant parameters that 
affect the aerodynamic diameters of nCmP systems. NP% is also a significant parameter 
that affects the drug loading. Fe is the only parameter that influenced the water content of 
the particles significantly. All prepared nCmP systems could be completely redispersed 
into the parent nanoparticles, indicating that none of the factors have an influence on the 
redispersion of the nanoparticles within the design range. Overall, the optimal spray 
drying condition to prepare nCmP with a small aerodynamic diameter, complete 
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redispersion of the nanoparticles, low water content, and high drug loading is that with an 
80% nanoparticle ratio, 0.5% feed concentration, and an inlet temperature lower than 
130 °C. 
KEYWORDS: 
Nanocomposite microparticles, pulmonary delivery, design of experiment, spray drying, 
particle engineering 
5.1. Introduction 
The deep lung (alveolar) region has attracted increasing attention as a target for 
drug delivery for several reasons (1). First, the alveolar surface area of the adult human 
ranges between 97 and 194 m2, providing a large surface for drug absorption. Second, the 
liquid layer over the alveoli is very thin (approximately 0.1 µm), ensuring rapid and 
unhindered drug absorption. Third, the plentiful capillary vessels situated beneath the thin 
alveolar epithelium provide efficient passive drug transport from the lungs to the 
bloodstream. Finally, the enzymatic activity in the lung is comparatively low, which 
enhances drug absorption (2, 3). As a result of the direct delivery of therapeutics to the 
lungs, aerosol drug delivery systems can provide several advantages including increased 
local drug concentration, reduced side effects, rapid onset of pharmaceutical action, and 
avoidance of the first-pass metabolism associated with the liver ( 4-6). These systems 
have been widely applied in the delivery of therapeutics such as antibiotics, proteins, 
peptides, and chemotherapeutics (7) for the treatment of diseases such as asthma, chronic 
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obstructive pulmonary disease (COPD), cystic fibrosis (CF)-related pulmonary infections 
(8), pulmonary hypertension (9) and lung cancer (10, 11). 
In comparison to liquid aerosol formulations, inhalation aerosols based on dry 
powders offer additional benefits such as enhanced stability of formulations, controllable 
particle size for targeting specific regions of the lung, and increased drug loading of 
hydrophobic or lipophilic payloads (10, 12). Unfortunately, barriers exist in the 
implementation of dry powder pulmonary delivery systems, including: (1) dry powder 
aerosols with aerodynamic diameters smaller than 1 µm will often be exhaled; (2) 
particles with aerodynamic diameters above 5 µm tend to deposit in the mouth, throat or 
upper lung mucosa and will then be eliminated due to mucus clearance; and (3) particles 
larger than 1 µm deposited in the deep lung area may be cleared from the alveoli via 
macrophages (10, 13, 14). 
The application of traditional dry powder aerosols comprised of a mixture of 
drugs and excipients may be limited by the aforementioned barriers, but fortunately 
spray-dried nanocomposite microparticles (nCmP) can be employed to solve these issues. 
In the production of nCmP (Figure 5.lA and 5.lB), polymeric nanoparticles (NP) loaded 
with a therapeutic are prepared, suspended in an excipient solution, and transformed into 
micro-scale dry powder microparticles via spray drying. Upon pulmonary administration 
(Figure 5.lC and 5.lD), the nCmP will deposit on the surface of the mucosal layer of 
the lungs and decompose into free NP and excipient, allowing the nanoparticles to 
penetrate the mucus and then release drug at sustained rate. The integration of nanoscale 
and microscale carriers combines the benefits of both types of systems. Microscale 
powders (I - 5 µm) facilitate effective deep lung deposition (14) while the embedded 
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nanoscale carriers can provide multiple functions such as the protection of drugs from 
degradation, enhancement of the solubility of drugs, provision of controlled drug release, 
and reduction of side effects (15-17). 
nCrnP systems have been widely applied in the pulmonary delivery of 
therapeutics including proteins ( 18-20), plasmid DNA (21 ), siRNA (22), antibiotics (23-
25), anti-tuberculosis (TB) drugs (26-28), anti-cancer drugs (29-31), and antifungal drugs 
(30). Small molecules such as mannitol (19, 20, 22, 26, 28, 30-37), lactose (20, 22, 25, 26, 
29, 30, 38-41), trehalose (22, 31, 38, 39), and L-leucine (18, 27, 30, 31, 42) have been 
applied as excipients to form nCmP. Biocompatible and biodegradable polymers such 
as poly(lactic-co-glycolic acid) (PLGA) (22, 25, 27, 28, 36, 38, 39), 
poly(butylcyanoacrylate) (PBCA) (29, 40, 41), and poly-E:-caprolactone (PCL) (6) have 
been commonly used for nanoparticle formulations in nCmP systems. 
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Figure 5.1. Schematic of (A) the preparation of curcumin nanoparticles (CUR NP) via 
emulsion/solvent evaporation, (B) formation and collection of nanocomposite 
microparticles (nCrnP) via spray drying, and (C and D) an aerosol nCmP system 
interacting with the pulmonary mucosa where (C) a patient breathes the nCmP into their 
lungs and (D) once the nCmP impact on the surface of the mucus coating the pulmonary 
epithelium they degrade to release the nanoparticles. 
Although many nCmP systems have been developed, few comprehensive studies 
have been completed to illustrate the effective engineering an optimal nCmP system for 
deep lung delivery of therapeutics. To date, the influence of parameters such as the spray 
drying inlet temperature, nanoparticle size, or the mass ratio of nanoparticles within the 
nCrnP system have been studied using one-factor-at-a-time optimization methods (38, 
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39). In one study, a factorial 2x2x3 experimental design was applied to evaluate the 
influence of the type of carbohydrate excipient, ratio of nanoparticles, and total 
concentration of carbohydrate excipient to NP in the feed solution on the produced nCmP 
(22). As the type of carbohydrate excipient is a categorical factor, limitations exist in the 
statistical analysis of the overall influence of the three factors. Since the parameters 
relevant for the nCmP preparation correlate with and depend on each other, a 
comprehensive consideration of the parameters should be taken. Design of experiment 
(DOE) has been widely used to screen relevant factors and study their influence on 
products, thus allowing for the determination of optimal manufacturing conditions (43, 
44). Response surface methodologies (RSM) such as central composite design (CCD) or 
Box-Behnken design (BBD) have been applied as optimization methods in the 
development and improvement of pharmaceutical formulations ( 45, 46). 
In the current study, Box-Behnken design was used to investigate the influence of 
the spray drying parameters: (1) weight ratio of NP (NP%), (2) total feed concentration of 
mannitol and NP (Fe), (3) and spray drying inlet temperature (Tin) in order to optimize 
the nCmP systems. These factors were selected as they have been proven to be significant 
in the successful formation of nCmP in previous research (22, 38, 39). Mannitol was 
used as excipient due to its ability to enhance the mucus penetration of nanoparticles by 
increasing the fluidity of mucus in the lungs (46). Acetalated dextran (Ac-Dex) was 
applied as the polymer to form nanoparticles as Ac-Dex is a novel, acid-sensitive, 
biodegradable, and biocompatible polymer that has attracted increasing attention in 
nanoparticle drug delivery applications. Compared to PLGA or other polyesters, Ac-Dex 
shows advantages including easily tunable degradation, minimal burst release at 
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physiological conditions (pH 7.4), degradation into neutral by-products avoiding 
undesirable changes of micro-environmental pH, and acid-sensitivity, facilitating the 
targeted delivery of therapeutics (47-49). Curcumin (CUR) was used as model drug 
owing to its hydrophobic nature and fluorescent properties. The goal of this research was 
to identify the optimal spray drying condition(s) in order to prepare nCmP systems 
comprised of CUR-loaded Ac-Dex nanoparticles. The optimal nCmP should show 
favorable properties including: small aerodynamic diameter, effective nanoparticle 
redispersion, high drug loading, and low water content. 
5.2. Materials and Methods 
5.2.1 Materials 
Dextran from Leuconostoc mesenteroides (9000-11000 MW), pyridinium p-
toluenesulfonate (PPTS, 98%), D-mannitol (2 98%), 2-methoxypropene (2-MOP, 97%), 
triethylamine (TEA, 2 99%), anhydrous dimethyl sulfoxide (DMSO, 2 99.9%), 
poly(vinyl alcohol) (PVA, MW 13,000-23,000, 87-89% hydrolyzed), dichloromethane 
(DCM, anhydrous, 2 99.8%), deuterium chloride (DCl, 35 weight% in D20, 99 atom% 
D), Tween® 80, curcumin, and methanol (anhydrous, 2 99.9%) were obtained from 
Sigma-Aldrich (St. Louis, MO). Deuterium oxide (D20, 99.8% atom D) was obtained 
from Acros Organics (Geel, Belgium). Phosphate buffered saline (PBS) was obtained 
from Fisher Scientific (Somerville, NJ). Hydranal® KF reagent was obtained from Fluka 
Analytical. 
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5.2.2 Synthesis and NMR Analysis of Acetalated Dextran (Ac-Dex) 
Ac-Dex was synthesized as described previously (49) with minor modifications. 
Briefly, 1 g of lyophilized dextran and 25 mg of PPTS were dissolved in 10 mL 
anhydrous DMSO. 5 mL of 2-MOP was added into the solution to initiate the reaction 
and 1 mL of TEA was added after 5 minutes to quench the reaction. The resulting 
mixture was then precipitated in basic water (water and TEA, pH 9), vacuum filtered, and 
lyophilized (-50 °C, 0.023 mbar) for 24 hours to yield a solid product. 
The cyclic-to-acyclic (CAC) ratio of acetal coverage and the total acetal coverage 
was confirmed by lH NMR spectroscopy (Bruker 300 MHz NMR, MA). 10 mg of Ac-
Dex was added to 700 µL of D20 and was hydrolyzed with 30 µL of DCl prior to 
analysis. The hydrolysis of one cyclic acetal group produces one acetone whereas one 
acyclic acetal produces one acetone and one methanol. Consequently, from the 
normalized integrations of peaks related to acetone, methanol, and the carbon ring of 
dextran, the CAC ratio of acetal coverage and total acetal coverage per 100 glucoses were 
determined. 
5.2.3 Formation of CUR-Loaded Ac-Dex Nanoparticles (CUR NP) 
Curcumin-loaded nanoparticles (CUR NP) were prepared via oil-in-water 
emulsion solvent evaporation. 49 mg of Ac-Dex and 1 mg of CUR were dissolved in 1 
mL of DCM over an ice bath, establishing the organic phase. The aqueous phase, 
comprised of 6 ml of 3% PVA in PBS, was added to the organic phase. The resulting 
mixture was sonicated (Q500 Sonicator, Qsonica, Newtown, CT) for 30 seconds with a 1 
second on/off pulse at 70% amplitude. The emulsion was transferred to a spinning 
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solution of 0.3% PVA in PBS and stirred for 3 hours to allow for evaporation of the 
organic solvent and particle hardening. The solution was then centrifuged at 19802 xg for 
20 minutes to collect the nanoparticles. The nanoparticles were then washed once with DI 
water, redispersed in 0.1 % PV A, and lyophilized (-50 °C, 0.023 mbar) for 48 hours. 
5.2.4 Formulation of Nanocomposite Microparticles (nCmP) Via Spray Drying 
nCmP were prepared via the spray drying an aqueous suspension of a CUR NP 
and mannitol using a Buchi B-290 spray dryer (Buchi Labortechnik, AG, Switzerland) in 
open mode. The CUR NP/mannitol suspension was sonicated for 10 minutes before spray 
drying. The spray drying conditions were as follows: 0.7 mm nozzle diameter, 
atomization gas flow rate of 414 L/h using UHP dry nitrogen, aspiration rate of 28 m3/h, 
pump rate of 0. 9 mL/min, and nozzle cleaner rate of 3. The spray dryer inlet temperature, 
feed concentration, and nanoparticle loading were varied as seen in Table 1. The 
resulting nCmP were separated in a high-performance cyclone, dried for 15 minutes in 
the spray dryer, collected in a sample collector, and stored in amber glass vials in 
desiccators at -20°C. 
5.2.5 Design of Experiment 
The spray drying parameters evaluated by design of experiment (DOE) were: the 
weight ratio of NP (NP%), total feed concentration of excipient and NP (F c ), and spray 
dryer inlet temperature (Tin) (Table 1). BBD was applied to determine the experimental 
conditions using Design Expert (Version 8 Stat-Ease, Inc.). The DOE responses including 
the aerodynamic diameter, properties of the nanoparticles following redispersion 
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(characterized by particle size and PDI), drug loading, and water content were analyzed 
in Design Expert software using an analysis of variance (ANOVA) approach. The 
complete design and formulation parameters that were varied are shown in Table 2. 
Table 5.1. Factors and levels for the Box-Behnken design of dry powder aerosol 
nanocomposite microparticle (nCmP) formulations corresponding to the spray drying 
parameters utilized. 
Factors Level 
Low Center High 
Inlet Temperature, Tin (°C) 50 90 130 
NP ratio, NP% (% w/w) 20 50 80 
Total Feed Concentration, Tc(% w/v) 0.5 1.5 2.5 
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Table 5.2. Spray drying formulation parameters of the nanocomposite microparticle 
(nCmP) system including the inlet temperature (Tin), nanoparticle loading in weight % 
(NP%), and feed concentration (Fe). 
Factors 
Run Tin (°C) NP(%) Fe(%) 
1 130 80 1.5 
2 50 50 0.5 
3 50 50 2.5 
4 90 50 1.5 
5 90 80 0.5 
6 90 50 1.5 
7 50 20 1.5 
8 90 80 2.5 
9 130 50 0.5 
10 90 20 2.5 
11 130 50 2.5 
12 90 50 1.5 
13 50 80 1.5 
14 90 20 0.5 
15 130 20 1.5 
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5.2.6 Particle Morphology and Shape Analysis via Scanning Electron Microscopy 
(SEM) 
The shape and surface morphology of the NP and nCmP were evaluated by SEM 
using a Zeiss SIGMA VP Field Emission Scanning Electron Microscope (FE-SEM) 
(Germany). nCmP samples were placed on aluminum SEM stubs (Ted Pella, Inc., 
Redding, CA) with double-sided adhesive carbon tabs. Nanoparticles were dispersed in 
DI water (pH 7, 10 mg/mL) and the suspensions were dropped onto aluminum SEM stubs 
and then dried at room temperature. The samples were coated with a thin film of a 
gold/palladium alloy using a BIO-RAD sputter coating system at 20 µA for 60 seconds 
under argon gas. Images were captured at 5 kV at various magnifications. 
5.2.7 Analysis of Nanoparticles Following Redispersion in Aqueous Solution 
Following nCmP formation, the properties of the NP entrapped m and 
subsequently released from the nCmP were analyzed. The nCmP were dispersed in DI 
water (pH 7, 0.3 mg/mL) and the size, PDI, and zeta potential of the particles were 
measured by dynamic light scattering (DLS) using a Malvern Nano Zetasizer (Malvern 
Instruments, Worcestershire, UK). All experiments were performed in triplicate with a 
scattering angle of 173 ° at 25 °C. This study characterized the ability of the nCmP 
systems to be redispersed back to individual nanoparticles in an aqueous environment. 
Two values were applied to quantify the redispersion potential of the particles: (1) the 
ratio of nanoparticle size change after redispersion to the original nanoparticle size to 
denote the increase of nanoparticle average size, and (2) the ratio of PDI change after 
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redispersion to the original nanoparticle PDI to denote the change of nanoparticle size 
distribution. These values were determined by the following equations: 
. h O/ Final NP size - Original NP size x 1000/0 Size c ange /o = _______ __;;:_____ ,,< 
Original NP size 
PDI change%= Final NP PDI - Original NP PDI x lOO% 
Original NP PDI 
In addition, the influence of the spray dryer inlet temperature on size and PDI at higher 
spray drying temperatures was evaluated by spray drying CUR NP without mannitol (100 
nCmP) at 50, 90, 130, 160, 190, and 220 °C. The resulting particle samples were 
sonicated for 1, 2, and 15 minutes prior to DLS measurement. 
5.2.8 Analysis of Drug Loading of CUR NP and CUR nCmP 
Drug loading and encapsulation efficiency of CUR NP and CUR nCmP were 
determined via fluorescence spectroscopy (Biotek Cytation 3, Winooski, VT). The 
particle samples were dissolved in DMSO and evaluated at 420 nm (excitation) and 540 
nm (emission). The CUR loading of NP, CUR loading of nCmP, NP loading in nCmP, 
CUR encapsulation efficiency (EE) of NP, and NP encapsulation efficiency of nCmP 
were determined by the following equations: 
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l d. f NP mass of drug loaded in NP x l ooo"o Drug oa mg o = ---------- ,< 
mass ofNP 
l d. f C p mass of drug loaded in nCmP x 1000"0 Drug oa mg o n m = -----=-------- /( 
mass ofnCmP 
. . mass of drug loaded in NP Encapsulation efficiency (EE) = x 100% 
initial mass of drug in NP formulation 
Nanoparticle loading mass of NP loaded in nCmP x 100% 
mass ofnCmP 
NP loading efficiency mass ofNP loaded in nCmP x 100% 
initial mass of NP in nCmP formulation 
5.2.9 Karl Fischer Coulometric Titration 
The water content of the nCmP was quantified by Karl Fischer (KF) titration 
using a 737 KF coulometer (Metrohm, Riverview, FL). 3 mg of powder was dissolved in 
anhydrous methanol. The resulting solution was injected into the KF reaction cell filled 
with Hydranal® KF reagent and then the amount of water was analyzed. Pure solvent 
was also injected for use as a background sample. 
5.2.10 Differential Scanning Calorimetry (DSC) 
The thermal phase transitions of the raw particle components were determined via 
DSC using a TA QIO DSC system (TA Instruments, New Castle, DE, USA) equipped 
with an automated computer-controlled TA instruments DSC refrigerated cooling system. 
1 - 3 mg of sample was weighed into Tzero TM alodined aluminum pans that were 
hermetically sealed. The sealed pans were placed into the DSC furnace along with an 
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empty sealed reference pan. The samples were analyzed at a heating range of 0 - 250 °C 
and heating rate of 10 °C/min. 
5.2.11 In Vitro Aerosol Dispersion Performance with the Next Generation Impactor 
(NGI) 
The in vitro aerosol dispersion performance of nCmP was evaluated using a Next 
Generation Impactor™ (NGI™, MSP Corporation, Shoreview, MN) equipped with a 
stainless steel induction port (USP throat adaptor) attachment and stainless steel 
gravimetric insert cups. The NGI™ was coupled with a Copley TPK 2000 critical flow 
controller, which was connected to a Copley HCP5 vacuum pump (Copley Scientific, 
United Kingdom). The airflow rate (Q) was measured and adjusted to 60 Umin in order 
to model the flow rate in a healthy adult lung before each experiment. Glass fiber filters 
(55 mm, Type A/E, Pall Life Sciences, PA) were placed in the gravimetric insert cups for 
stages 1 through 7 to minimize bounce or re-entrapment (50) and these filters were 
weighed before and after the experiment to determine the particle mass deposited on each 
stage. Approximately 10 mg of powder was loaded into a hydroxypropyl methylcellulose 
(HPMC, size 3, Quali-V®, Qualicaps® Inc. , Whitsett, NC, USA) capsule and the capsule 
was placed in a human dry powder inhaler device (HandiHaler, Boehringer Ingelheim 
Pharmaceuticals, CT) attached to a customized rubber mouthpiece connected to the 
NGI™. Three HPMC capsules were loaded and released in each measurement and 
experiments were performed in triplicate. The NGI™ was run with a delay time of 10 s 
and running time of 10 s. For Q = 60 Umin, the effective cutoff diameters for each stage 
of the impactor were given from the manufacturer as: stage 1 (8.06 µm); stage 2 (4.46 
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µm); stage 3 (2.82 µm); stage 4 (1.66 µm); stage 5 (0.94 µm); stage 6 (0.55 µm); and 
stage 7 (0.34 µm). The fine particle dose (FPD), fine particle fraction (FPF), respirable 
fraction (RF), and emitted dose (ED) were calculated as follows: 
F. . 1 fi . (FPF) mass of particles on Stages 2 through 7 x 100010 me part1c es ract10n = -------------- /c 
initial particle mass loaded into capsules 
R . bl fi . (RF) mass of particles on Stages 2 through 7 x 100010 espira e ract1on = -------------- /c 
total particle mass on all stages 
E . d D (ED) initial mass in capsules - final mass remaining in capsules m1tte ose = x 100% 
initial mass in capsules 
The mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) for the particles were determined using a Mathematica® program 
written by Dr. Warren Finlay (50, 51). 
5.2.12 Statistical analysis 
All measurements were performed in at least triplicate. Values are given in the 
form of mean ± standard deviation. The statistical significance of the results was 
determined using analysis of variance (ANOV A). A p-value less than 0.05 was 
considered statistically significant. 
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5.3. Results and Discussion 
5.3.1 Preparation and Characterization of Curcumin-Loaded Nanoparticles (CUR 
NP) 
5.3.1.1 Preparation and Characterization of Acetalated Dextran (Ac-Dex) 
Successful synthesis of Ac-Dex was confirmed by lH NMR where the polymer 
exhibited 61.3% cyclic acetal coverage and 77.1% total conversion of -OH groups. A 
high CAC is known to decrease the degradation rate of Ac-Dex (50), and a high total 
acetal coverage is required to stabilize the PV A coating of nanoparticles, which ensures 
small particle size and narrow particle size distribution. 
5.3.1.2 Preparation and Characterization of Original CUR NP 
The average nanoparticle size, size distribution/polydispersion index (PDI), zeta 
potential, drug loading, and encapsulation efficiency of curcumin-loaded nanoparticles 
(CUR NP) are shown in Table 5.3. The original CUR NP exhibited an average diameter 
of approximately 200 nm, which is in the desirable range to avoid macrophage clearance 
and mucus entrapment (14). The low PDI value denotes a narrow size distribution of 
nanoparticles. The surface of nanoparticles was slightly negative, which is suitable to 
reduce the interaction of the NP with negatively charged mucin fibers present in airway 
mucus (52). Curcumin was successfully encapsulated into the CUR NP and the amount of 
the drug in CUR NP was sufficient for the quantification of CUR and NP in nCmP 
samples. 
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Table 5.3. Properties of curcumin nanoparticles (CUR NP) including their size (as 
measured by dynamic light scattering), polydispersity index (PDI), zeta potential, drug 
loading, and encapsulation efficiency (EE) (mean± standard deviation, n = 3). 
Diameter Zeta Potential Drug Loading System (nm) PDI (mV) (mg drug/lOOmg EE(%) NP) 
CUR NP 204.l ± 0.07± -6.98 ± 0.73 0.64 ± 0.04 31.99 ± 4.4 0.02 3.69 
5.3.2 Design of Experiment and nCmP Characterization 
5.3 .2.1 Box-Behnken Design 
The results of the Box-Behnken design are shown in Table 5.4. Analysis of 
variance (ANOVA) was performed to evaluate the influence of the factors on the 
responses. The statistical significance and the magnitude of the exerted effects 
(coefficient estimates) of each factor are shown in Table 5.5. The interaction of 
parameters was not included, as its effect on the results was negligible. The sign of the 
coefficient estimates signifies a positive or negative influence of the factor on 
the corresponding response. Since this study was designed to qualify the effects of the 
formulation parameters on particle properties and the final model will not be used for 
prediction purposes at this point, a lack of fit test was not a major consideration in model 
selection. 
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5.3.2.2 Drug Loading and Encapsulation Efficiency (EE) 
The drug loading of CUR nCmP was only affected by the nanoparticle loading 
(NP%, p < 0.0001) and no other factors had a significant influence on this parameter. 
Since the drug loading of the CUR NP was constant in this study, the NP% was the only 
parameter that should definitively affect the drug loading of nCmP. Therefore, either 
increasing the NP% in the nCmP formulation or using original NP with higher drug 
loading can be applied to achieve higher drug loading in the nCmP system. Unlike the 
formation of traditional spray-dried particles (53, 54) composed of a mixture of drug and 
excipient, the drug loading capacity of nCmP can be optimized beforehand during 
nanoparticle preparation. By providing an optimal nanoparticle system, drug loading 
optimization during spray drying can be remarkably simplified. 
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Table 5.4. Responses of the Box-Behnken design for the nanocomposite microparticle 
(nCmP) systems including drug loading, encapsulation efficiency (EE), water content, 
mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine 
particle fraction (FPF), respirable fraction (RF), emitted dose (ED), percent size change, 
and percent polydispersity index (PDI) change. The corresponding particle conditions can 
be seen in Table 2. 
Responses 
Drug EE Water MMAD GSD FPF RF EF Size PDI Run Loading Content Change Change (%) (%) (µm) (µm) (%) (%) (%) (%) (%) (%) 
1 0.372 72.74 4.51% 2.44 2.34 98.6% 76.0% 97.7% 0.2% -2.9% 
2 0.201 62.78 5.71% 1.69 2.79 99.4% 77.2% 98.0% 5.6% 20.0% 
3 0.192 60.14 3.82% 4.49 1.95 85.0% 57.9% 99.0% 0.0% 31.4% 
4 0.201 62.83 2.95% 4.28 1.70 84.4% 60.9% 99.6% 2.5% 14.3% 
5 0.357 69.79 5.94% 1.50 2.57 98.8% 86.0% 96.3% 9.7% 17.1% 
6 0.087 58.45 3.41% 4.05 2.34 86.1 % 67.4% 99.6% 4.9% 14.3% 
7 0.074 58.12 5.43% 7.44 2.34 54.2% 48.4% 99.8% 1.0% -21.4% 
8 0.402 78.70 4.69% 2.48 2.77 97.5% 70.0% 94.6% 4.9% 57.1% 
9 0.195 61.09 5.66% 3.69 2.81 83.6% 73.0% 98.8% 7.5% 30.0% 
10 0.083 65.33 2.63% 7.20 2.81 62.2% 38.0% 100.1 % 4.8% 20.0% 
11 0.172 53.71 3.84% 5.78 2.50 66.2% 55.8% 99.2% 1.1% -20.0% 
12 0.193 60.34 3.23% 4.11 1.88 85.3% 61.6% 99.9% 2.3% -1.4% 
13 0.288 56.43 4.68% 2.38 2.71 98.1% 82.2% 95.7% 4.2% 15.7% 
14 0.093 72.93 6.72% 3.24 3.00 83.3% 64.4% 97.1 % -0.2% 32.9% 
15 0.113 88.07 4.13% 5.46 1.88 68.8% 46.2% 100.0% 8.3% 22.9% 
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Table 5.5. Statistical significance (p-value and coefficient estimation) of nanocomposite 
microparticle (nCmP) formulation parameters including drug loading (DL), encapsulation 
efficiency (EE), size change, polydispersity (PDI) change, mass median aerodynamic 
diameter (MMAD), fine particle fraction (FPF), respirable fraction (RF), emitted dose 
(ED), and water content (WC) with respect to the spray dryer inlet temperature (Tin), 
nanoparticle loading (NP%), and feed concentration (Fe). 
Factors Drug Loading Capacity Re-dispersity 
DL(%) EE(%) Size change (%) PDI change (%) 
p-Value Coef. Est. p-Value Coef. Est. p-Value Coef. Est. p-Value Coef. Est. 
Tin -
NP% I< 0.0001 
Fe% I 
Factors 
-
0.13 
MMAD (µm) 
p- Coef. 
Value Est. 
Tin - -
- - - -
In Vitro Aerosol Performance 
FPF (%) RF(%) ED ( % ) 
p- Coef. p- Coef. p- Coef. 
Value Est. Value Est. Value Est. 
< 4.07E-
- - - - 0.0001 03 
-1.8210.0001 0.16 lo.o~ol 0.15 10.0036 -0.016 I 
- -
Water 
Content 
WC(%) 
p- Coef. 
Value Est. 
- -
NP% 10.0002 
Fe% 0.0026 < < 3.26E-l.23 0.0258 -0.068 0.0001 -0.099 0.0001 03 0.0009 -0.011 
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5.3.2.3 Analysis of Properties Following Redispersion of CUR NP from CUR nCmP 
The average size and PDI of CUR NP before and after spray drying (and 
subsequent redispersion in water) were measured by DLS. No significant differences 
were found in the NP properties before and after nCmP formation (p < 0.05), which 
indicates that the NP from the nCmP systems can be fully redispersed with no adverse 
effects. The ANOVA analysis of the DOE results showed that Tin, NP%, and Fe had no 
effect on the redispersion properties of CUR NP. In previous studies, NP%, Fe, and the 
type of excipient have been reported to have no impact on the redispersion of PLGA NP 
from prepared at a low spray drying inlet temperature (50 °C). However, in a study 
by Tomoda et al., the inlet temperature was an important factor affecting the redispersion 
of NP from nCmP comprised of PLGA NP and trehalose or lactose (20, 55). In that study, 
a higher Tin (100 °C) resulted in poor NP redispersion due to the aggregation or fusion of 
the primary nanoparticles during spray drying. The authors claimed that the aggregation 
of the NP could be attributed to the low melting temperature of PLGA (Tm = 
45 °C). Since Ac-Dex has a higher melting point (170 °C) and no thermal transitions 
before melting, we hypothesize that the nCmP comprised of Ac-Dex NP can be 
completely redispersed when the outlet temperature during spray drying is lower than the 
melting point of Ac-Dex. The spray drying outlet temperatures were approximately half 
of the inlet temperatures in the present study (Table B.1), so even the maximum Tin 
(220 °C) capable by a Bilchi B-290 spray dryer should be within an acceptable 
temperature range to allow for effective nCmP formation and NP redispersion. 
nCmP systems with 100% NP loading were formulated to evaluate the influence 
of higher Tin values on NP redispersion, since the NP% showed no influence on the 
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redispersion of NP in the initial formulations. The influence of the spray dryer inlet 
temperature on the redispersed nanoparticles is shown in Figure 5.2. NP from 100% 
nCmP manufactured at 50, 90, and 130°C were fully redispersed upon dissolving in DI 
water. NP from 100% nCmP manufactured at 160, 190, and 220 °C exhibited an increase 
in both size and PDI due to NP agglomeration. By sonicating the nCmP samples prior to 
DLS measurement, both the average size and PDI can be reduced and higher 
manufacturing temperatures required more sonication to effectively redisperse the NP. 
DSC analysis was performed on the raw NP and nCmP materials (Figure 5.3). 
The melting points of PVA, Ac-Dex, curcumin, and mannitol were 175, 170, 172, and 
167 °C, respectively, which were all higher than the spray drying outlet temperature 
(112 °C). PVA exhibited a glass transition temperature at 49 °C, which should have no 
effect on nanoparticle agglomeration, as NP from 100% NP-loaded nCmP prepared at 90 
and 130 °C could be completely redispersed. The aforementioned results failed to support 
our initial hypothesis. In summary, manufacturing nCmP at temperatures lower than the 
melting point of the raw materials cannot necessarily ensure the avoidance of 
nanoparticle fusion and agglomeration. A reasonable explanation is that the high pressure 
during the quick drying process at high temperatures may cause nanoparticle 
agglomeration. Further studies will be carried out to determine the influence of the drying 
rate on nanoparticle redispersion. 
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Figure 5.2. Influence of spray dryer inlet temperature (Tin) on the size and polydispersity 
index (PDI) of nanoparticles redispersed from nanocomposite microparticles comprised 
of 100% NP loading. 
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Figure 5.3. Representative differential scanning calorimetry (DSC) thermograms of raw 
Ac-Dex, PVA, curcumin, and mannitol. 
5 .3 .2.4 Water Content of CUR nCmP 
The CUR nCmP samples exhibited water content in the range of 2.6 - 6.7% 
(Table 5.4). The water content of the nCmP was affected only by the feed solution 
concentration (p = 0.0009). Higher feed solution concentration resulted in lower water 
content in the particles, which corresponds to previous research on nCmP systems (22) 
and traditional spray-dried particles (56). However, unlike previous studies (22, 56), Tin 
and NP% showed no effect on water content. The reason for this is likely the post drying 
process, which further removed water from the nCmP, thus reducing the difference in 
water content among the samples. Low water content is highly favorable in inhalable dry 
powders to allow for efficient aerosolization and particle delivery as it improves particle 
dispersion properties during aerosolization by reducing the interparticulate capillary 
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forces acting at the solid-solid interface between particles (53, 57). Furthermore, low 
water content enhances the stability of dry powders during storage (58). Since the water 
content of all of the samples were acceptable in this study, the post drying process can be 
applied to simplify optimization in future studies. 
5.3.2.5 Morphology of CUR nCmP 
As seen in the representative SEM images in Figure 5.4 (SEM images of all 
nCmP systems are available in Figure B.1), nCmP showed two kinds of morphology: (1) 
raisin-like particles with wrinkled surfaces and (2) spherical particles with cracks on the 
surface. nCmP with 80% NP (Figure 5.4C) exhibited raisin-like morphology, while 
nCmP with 20% NP (Figure 5.4A) were cracked spheres. Particles with surface 
morphology of both types can be seen in the 50% NP sample (Figure 5.4B). The 
corrugated surface of the nCmP systems facilitate aerosol performance by reducing the 
contact area between particles during aerosolization. As a result, aggregation of the 
nCmP can be reduced, thus improving the redispersion of NP from nCmP formulations. 
The raisin-like morphology of nCmP may be attributed to the early formation of 
nanoparticle shells in droplets during the spray drying process, during which · the 
geometric size of nCmP is determined. As the drying process proceeds, the remaining 
water evaporates from the droplet center and the newly precipitated dry materials cannot 
fill the hollow interior of the nCmP, which results in shrinkage of the particles (59, 60). 
The spherical particle systems with cracks in their surface are the typical morphology of 
particles with mannitol shells. The cracks evident on these types of particles were not 
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caused by the spray drying process but instead were generated during SEM imaging due 
to the high energy of the electron beam (Figure B.2). 
Figure 5.4. Representative SEM micrographs of curcumin-loaded nanocomposite 
microparticles (CUR nCmP) spray dried with varying conditions such as inlet 
temperature (Tin), nanoparticle loading (NP%), and feed concentration (Fe), including: (A) 
Tin = 50 °C, NP% = 20%, Fe = 1.5%, (B) Tin = 90 °C, NP% = 50%, Fe = 1.5%, and (C) 
Tin= 90 °C, NP%= 80%, Fe= 0.5%. Scale bar= 5 µm. 
5.3.2.6 In Vitro Aerosol Dispersion Performance Using the Next Generation Impactor 
(NGI) 
In vitro aerosol dispersion performance properties of the nCmP were evaluated 
using a Next Generation Impactor™ coupled with a human DPI device. Mass mean 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), respirable fraction 
(RF), fine particle fraction (FPF), and emitted dose (ED) were calculated (Table 5.4). 
None of the spray drying parameters exhibited a significant influence on the GSD values 
(p > 0.05). Both NP% and Fe showed a significant effect on the MMAD, RF, FPF, and 
ED. Higher NP% resulted in smaller MMAD, higher RF, and higher FPF, which are all 
beneficial for effective delivery of payloads into the lungs by nCmP. A MMAD in the 
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range of 1 - 5 µm is required for predominant deposition of nCmP into the deep lung 
(alveolar) region, and particles with higher MMAD tend to deposit in the upper airways 
and throat. NP% had a negative influence on the ED, however, the ED of all of the 
samples was within a high range of 94.6% - 100%, which makes it acceptable to apply 
high NP% in the optimization of aerosol dispersion properties. 
The feed solution concentration (Fe) showed a negative influence on the RF and 
FPF but positive influence on the MMAD. As a result, low Fe should be applied to 
achieve an optimal nCmP system. Fe and Tin had a negligible positive influence on ED 
(Table 5.5), which was not taken into consideration. The aerosol distribution 
performance of a representative nCmP system is shown in Figure 5.5. The three nCmP 
samples analyzed correspond to the three SEM micrographs in Figure 5.4. The nCmP 
sample with more wrinkled particles deposited in the lower NGI stages, indicating the 
potential for predominant particle deposition into the lower airways. This phenomenon 
was in accordance with the negative influence of NP% on the MMAD. As the increased 
NP% can result in more wrinkled and hollow particles with low density and favorable 
aerosol dispersion, the MMAD was thus reduced. Fe had positive influence on the 
MMAD, as more dry material exists in the droplets during spray drying, which increases 
the density of resulting particles. 
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Figure 5.5. Nanocomposite microparticle (nCmP) aerosol dispersion performance as % 
deposited on each stage of the Next Generation Impactor™ (NGI™) for representative 
CUR nCmP systems. For Q = 60 Umin, the effective cutoff diameters (Dso) for each 
impaction stage are as follows: stage 1 (8.06 µm), stage 2 ( 4.46 µm), stage 3 (2.82 µm), 
stage 4 (1.66 µm), stage 5 (0.94 µm), stage 6 (0.55 µm), and stage 7 (0.34 µm). (mean± 
standard deviation, n = 3). 
5.4 Conclusions 
The current study identified the optimal spray drying conditions to prepare Ac-
Dex nanoparticles-based nCmP systems with favorable properties including: small 
aerodynamic diameter, effective nanoparticle redispersion, high drug loading, and low 
water content. Higher NP% resulted in nCmP systems with smaller MMAD, high FPF, 
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higher RF, and higher drug loading. Lower Fe lead to smaller MMAD, higher FPF, and 
high RF, while higher Fe was beneficial for lower water content. Tin had a negligible 
influence on the nCmP properties in the design range, while in higher range it will hinder 
the redispersion of NP from the nCmP. The drug loading was only affected by the NP% 
of nCmP, which simplifies the optimization of spray drying nCmP given that high drug 
loading of NP can be achieved. The influence of each spray drying parameter on the 
properties of the resulting particles is summarized in Figure 5.6. The optimal condition 
to prepare nCmP with a small aerodynamic diameter, desirable nanoparticle redispersion, 
high drug loading, and low water content is via high NP%, low Fe, and a Tin under 
130 °C. 
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ABSTRACT 
Biocompatible, biodegradable polymers are commonly used as excipients to 
improve the drug delivery properties of aerosol formulations, in which acetalated dextran 
(Ac-Dex) exhibits promising potential as a polymer in various therapeutic applications. 
Despite this promise, there is no comprehensive study on the use of Ac-Dex as an 
excipient for dry powder aerosol formulations. In this study, we developed and 
characterized pulmonary drug delivery aerosol microparticle systems based on spray-
dried Ac-Dex with capabilities of (1) delivering therapeutics to the deep lung, (2) 
targeting the particles to a desired location, and (3) releasing the therapeutics in a 
controlled fashion. Two types of Ac-Dex, with either rapid or slow degradation rates, 
were synthesized. Nanocomposite microparticle (nCmP) and microparticle (MP) systems 
were successfully formulated using both kinds of Ac-Dex as an excipient and curcumin 
as a model drug. The resulting MP were collapsed spheres approximately 1 µm in 
diameter, while the nCmP were similar in size, with wrinkled surfaces, and these systems 
dissociated into 200 nm nanoparticles upon reconstitution in water. The dug release rates 
of the Ac-Dex particles were tuned by modifying the Ac-Dex reaction time, particle size, 
and ratio of fast to slow degrading Ac-Dex. The pH of the environment was also a 
significant factor that influenced the drug release rate. All nCmP and MP systems 
exhibited desirable aerodynamic diameters that are suitable for deep lung delivery (e.g. 
below 5 µm). Overall, the engineered Ac-Dex aerosol particle systems have the potential 
to provide targeted and effective delivery of therapeutics into the deep lung. 
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6.1 Introduction 
Pulmonary drug delivery has exhibited promising potential in the treatment of 
lung diseases, as it allows for the delivery of a wide range of therapeutics directly and 
efficiently to the lungs, thereby increasing local drug concentration, reducing systemic 
side effects, providing a rapid onset of pharmaceutical action, and avoiding the first-pass 
metabolism associated with the liver (1-4). The deep lung (alveolar) region can be 
utilized as a route for systematic drug delivery due to the enormous surface area available 
and nearby plentiful capillary vessels that facilitate drug absorption, the very thin 
(approximately 0.1 µm) liquid layer over the alveoli that ensures rapid and unhindered 
drug absorption, and low enzymatic activity, which enhances drug availability (1, 5, 6). 
As a result, various therapeutics such as antibiotics, proteins, peptides, anti-cancer drugs 
(7), plasmid DNA (8), siRNA (9), and anti-tuberculosis (TB) drugs have been employed 
in the inhalation forms for the treatment of pulmonary diseases such as asthma, chronic 
obstructive pulmonary disease (COPD), cystic fibrosis (CF)-related pulmonary 
infections, and lung cancer (7, 10). 
Dry powders is a dosage form that delivers therapeutics to the lung, in the form of 
particles, using a dry powder inhaler (7). Compared with liquid aerosols, these 
formulations offer additional benefits such as enhanced stability of the formulation, 
controllable particle size for targeting different regions of the lung, and increased drug 
loading of hydrophobic payloads (10, 11 ). Spray drying has proven to be a suitable 
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technology in the preparation of dry powder therapeutics ( 10), as it is capable of 
producing respirable microparticles for deep lung delivery with acceptable aerosol 
dispersion properties (4). The properties of dry powder particles such as particle size, 
particle shape, and surface morphology can be modified by controlling the production 
process, thus providing desirable particle characteristics ( 4, 7). 
Biocompatible, biodegradable polymers such as poly( E-caprolactone) (PCL) and 
poly(lactic-co-glycolic acid) (PLGA) have been used as dry powder formulation 
excipients to carry drug molecules, protect drugs from degradation, and impart sustained 
release to aerosol formulations (3). However, the PLGA and PCL delivery systems show 
significant bolus release of their payloads due to bulk erosion of the polymers, and it is 
difficult to control the polymer degradation rate and modulate their release profiles (12) 
(Acetalated dextran (Ac-Dex) is an acid-sensitive, biodegradable, biocompatible polymer 
prepared via a one-step reaction by reversibly modifying dextran with acetal groups. This 
modification reverses the solubility properties of dextran from hydrophilic to 
hydrophobic, making it possible to form polymeric particles using standard emulsion or 
nanoprecipitation techniques. In contrast to other commonly used polymers such as 
PLGA, polylactic acid, and PCL, Ac-Dex exhibits attractive properties suitable for the 
controlled release of the payloads. By controlling the reaction time during the formation 
of Ac-Dex, the ratio of cyclic acetal groups with a slower degradation rate to acyclic 
acetal groups with a faster degradation rate can be adjusted. As a result, the degradation 
rate of the resulting Ac-Dex can be tuned from hours to months to suit various 
applications. Moreover, the acid-sensitivity of Ac-Dex enables it to degrade faster in 
lower pH environments, such as lysosomes in macrophage or tumor cells, allowing for 
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controlled release of drug. Furthermore, Ac-Dex degrades into neutral by-products, 
which avoids undesirable changes in the micro-environmental pH in the body. Finally, 
Ac-Dex offers the potential of targeted delivery, due to the dextran chains present that 
can be further modified with a variety of functional moieties, which can enhance the 
efficacy of therapeutic delivery to a targeted site (13-15). 
Owing to aforementioned advantages, Ac-Dex has been widely applied in the 
formation of polymeric carriers for drug delivery. Porous Ac-Dex microparticles loaded 
with the chemotherapeutic camptothecin for pulmonary delivery were developed using 
emulsion techniques, which exhibited in a respirable fraction of 37% and experimental 
mass mean aerodynamic diameters from 5.3 - 11.9 µm (2). Ac-Dex nanoparticle systems 
have also been investigated in the application of protein delivery for imrnunotherapy 
(13), gene delivery to phagocytic and non-phagocytic cells (11), tandem delivery of 
peptide and chemotherapeutic for controlled combination chemotherapy (1 ), delivery of 
the host-mediated compound AR-12 (Arno Therapeutics; formerly known as OSU-
03012) for the treatment of Leishmania donovani (6), and the control of Salmonella 
infection (6). Both Ac-Dex nanoparticles and microparticles loaded with horseradish 
peroxidase have been evaluated to improve vaccine stability outside cold chain 
conditions (16). 
Despite this work, there is no comprehensive study on using Ac-Dex as an 
excipient for dry powder aerosol formulations. In this study, we aimed to develop and 
characterize pulmonary delivery systems based on spray-dried Ac-Dex particles with 
capabilities of (a) delivering therapeutics to the deep lung, (b) targeting the particles to a 
particular location in the lungs, and ( c) releasing therapeutics in controlled rate. Previous 
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studies have shown that: (a) aerodynamic diameter (da) determines the region of the lungs 
where particles will deposit, where particles with an da of 1 - 5 µm tend to deposit in the 
deep lung region (10); (b) geometric size plays an important role in the cellular uptake of 
particles, where nanoscale particles (approximately 150 nm) tend to escape phagocytic 
uptake ( 17), while particles larger than 1 µm will suffer from macrophage clearance in 
the alveoli (18); and (c) the drug release rate of Ac-Dex particles can be tuned by 
modifying the synthesis time of the Ac-Dex polymer (2, 15). 
To prepare the engineered particle systems, two types of Ac-Dex with rapid or 
slow degradation rates were synthesized. Nanocomposite microparticle (nCmP) and 
microparticle (MP) systems were successfully formulated using both kinds of Ac-Dex as 
the excipient and curcumin (CUR) as the model drug. The nCmP were prepared by spray 
drying an aqueous suspension of CUR-loaded Ac-Dex nanoparticles (200 nm) and the 
MP were formulated by spray drying a solution of Ac-Dex and CUR in a solution of 
tetrahydrofuran (THF) and acetone. We hypothesize that upon pulmonary administration, 
the nCmP will deposit in the deep lung, decompose into free NP, and will facilitate the 
sustained release of drug to the targeted site, while the MP will remain the original size 
after deposition in the deep lung region. A schematic of particle preparation and design is 
shown in Figure 6.1. Overall, the goal of the described research was the initial 
development and physicochemical characterization of dry powder Ac-Dex aerosol 
particle systems with the potential for effective delivery of therapeutics in to the deep 
lung, targeting at desired pulmonary location, and continuous controlled release of a 
drug. 
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Figure 6.1. Schematic depicting the of synthesis of Ac-Dex (Left) and preparation of 
nanoparticles and formation of nanocomposite microparticles (nCmP) and microparticles 
(MP) (Right). 
6.2. Materials and Methods 
6.2.1 Materials 
Dextran from Leuconostoc mesenteroides (9000-11000 MW), pyridinium p-
toluenesulfonate (PPTS, 98%), 2-methoxypropene (2-MOP, 97%), triethylamine (TEA, 2: 
99%), anhydrous dimethyl sulfoxide (DMSO, 2: 99.9%), poly(vinyl alcohol) (PVA, MW 
13,000-23 ,000, 87-89% hydrolyzed), dichloromethane (DCM, anhydrous, 2: 99.8%), 
deuterium chloride (DCl, 35 weight% in D20 , 99 atom% D), Tween® 80, curcumin, 
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sodium acetate (2: 99%), acetic acid solution (1.0 N), acetone (2: 99.8%), tetrahydrofuran 
(THF, 2: 99%), and methanol (anhydrous, 2: 99.9%) were obtained from Sigma-Aldrich 
(St. Louis, MO). Deuterium oxide (D20, 99.8% atom D) was obtained from Acros 
Organics (Geel, Belgium). Phosphate buffered saline (PBS) was obtained from Fisher 
Scientific (Somerville, NJ). Hydranal® KF reagent was obtained from Fluka Analytical. 
6.2.2 Synthesis and NMR Analysis of Acetalated Dextran (Ac-Dex) 
Ac-Dex was synthesized as described previously (14) with minor modifications. 1 
g of lyophilized dextran and 25 mg of PPTS were dissolved in 10 mL of anhydrous 
DMSO. The resulting solution was reacted with 5 mL of 2-MOP under nitrogen gas for 5 
minutes to prepare Ac-Dex with a rapid degradation rate (Ac-Dex-5min) or for 3 hours to 
prepare Ac-Dex with a slower degradation rate (Ac-Dex-3h). The reaction was quenched 
with 1 mL of TEA. The reaction mixture was then precipitated in basic water (water and 
TEA, pH 9), vacuum filtered, and lyophilized (-50 °C, 0.023 mbar) for 24 hours to yield 
a solid product. 
The cyclic-to-acyclic (CAC) ratio of acetal coverage and degrees of total acetal 
coverage per 100 glucose molecules was confirmed by 1 H NMR spectroscopy (Bruker 
300 MHz NMR, MA). 10 mg of Ac-Dex was added to 700 µL of D20 and was 
hydrolyzed with 30 µL of DCl prior to analysis. The hydrolysis of one cyclic acetal group 
produces one acetone molecule whereas one acyclic acetal produces one acetone and one 
methanol molecule each. Consequently, from the normalized integration of peaks related 
to acetone, methanol, and the carbon ring of dextran, the CAC ratio of acetal coverage 
and degrees of total acetal coverage per 100 glucoses were determined. 
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6.2.3 Formation of CUR-Loaded Ac-Dex Nanoparticles (CUR NP) 
Curcumin-lo.aded nanoparticles (CUR NP) were prepared via an oil/water 
emulsion solvent evaporation using Ac-Dex-5min, Ac-Dex-3h, or a mixture of both types 
of Ac-Dex (5U % w/w). 49 mg of Ac-Dex and 1 mg of CUR were dissolved in 1 mL of 
DCM over an ice bath, establishing the organic phase. The aqueous phase was comprised 
of 6 ml of 3% PVA in PBS and was added to the organic phase. The resulting mixture 
was sonicated (Q500 Sonicator, Qsonica, Newtown, CT) for 30 seconds with a 1 second 
on/off pulse at 70% amplitude. The emulsion was transferred to a spinning solution of 
0.3% PV A in PBS and was stirred for 3 hours to allow for evaporation of the organic 
solvent and particle hardening. The solution was then centrifuged at 19802 xg for 20 
minutes to collect the nanoparticles. Nanoparticles were washed once with DI water, 
redispersed in 0.1 % PV A, and lyophilized (-50 °C, 0.023 mbar) for 48 hours. The 
resulting NP systems were: CUR NP-5min (made of Ac-Dex-5min), CUR NP-3h (made 
of Ac-Dex-3h), and CUR NP-h (50 wt% Ac-Dex-5min and 50 wt% Ac-Dex-3h). 
6.2.4 Formulation of CUR Nanocomposite Microparticles (nCmP) Via Spray Drying 
CUR nCmP were prepared via the spray drying of an aqueous suspension of each 
type of CUR NP (0.5%, w/v) using a Biichi B-290 spray dryer (Biichi Labortechnik, AG, 
Switzerland) in open mode. The CUR-NP suspension was sonicated for 10 minutes 
before spray drying. The spray drying conditions were as follows: 0. 7 mm nozzle 
diameter, atomization gas flow rate of 414 L/h using dry nitrogen, aspiration rate of 28 
m3/h, pump rate of 0.9 mL/min, and nozzle cleaner rate of 3. The resulting nCmP were 
separated in a high-performance cyclone, dried for 15 minutes in the spray dryer, 
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collected in a sample collector, and stored in amber glass vials in a desiccator at -20°C. 
nCmP comprised of each kind of NP described previously were produced: nCmP-5min, 
nCmP-3h, and nCmP-h, correspondingly. 
6.2.5 Formulation of CUR Microparticles (MP) Via Spray Drying 
CUR MP were prepared via the spray drying of an organic solution of a mixture 
of Ac-Dex and CUR (2 %, w/v) using a Buchi B-290 spray dryer in closed mode. The 
organic solutions were prepared by dissolving CUR and Ac-Dex (2:98 w/w) in an organic 
solvent comprised of 85% acetone and 15% THF (v/v) at a solids concentration of 2% 
(w/v). The spray drying conditions were as follows: 0.7 mm nozzle diameter, atomization 
gas flow rate of 414 L/h using UHP dry nitrogen, aspiration rate of 40 m3 /h, pump rate of 
3 mL/min, and nozzle cleaner rate of 0. The resulting MP were separated in a high-
performance cyclone, dried for 15 minutes in the spray dryer, collected in a sample 
collector, and stored in amber glass vials in a desiccator at -20°C. The resulting MP 
were: MP-5min (from Ac-Dex-5min), MP-3h (from Ac-Dex-3h), and MP-h (from 50 
wt% Ac-Dex-5min and 50 wt% Ac-Dex-3h). 
6.2.6 Particle Size, Size Distribution, and Zeta Potential Analysis 
The average diameter, size distribution, and zeta potential of the original NP and 
the NP entrapped in the nCmP were measured by dynamic light scattering (DLS) using a 
Malvern Nano Zetasizer (Malvern Instruments, Worcestershire, UK). Original NP were 
dispersed in DI water (pH= 7, 0.3 mg/mL), and nCmP were dispersed in DI water as well 
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to recover the entrapped NP. All experiments were performed m triplicate with a 
scattering angle of 173 ° at 25 °C. 
6.2. 7 Particle Morphology and Shape Analysis via Scanning Electron Microscopy 
(SEM) 
The shape and surface morphology of the nCmP and MP were evaluated by SEM 
usmg a Zeiss SIGMA VP Field Emission-Scanning Electron Microscope (FE-SEM) 
(Germany). Particle samples were placed on aluminum SEM stubs (Ted Pella, Inc., 
Redding, CA) with double-sided adhesive carbon tabs. Both the nCmP and MP samples 
were coated with a thin film of a gold/palladium alloy using a BIO-RAD sputter coating 
system at 20 µA for 60 seconds under argon gas. Images were captured at 8 kV at various 
magnifications. The geometric mean diameter and standard deviation of the MP were 
measured digitally from SEM images using ImageJ software (19). Representative 
micrographs (5000x magnification) for each sample were analyzed by measuring the 
diameter of at least 100 particles. 
6.2.8 Tapped Density Evaluation 
The tapped density of the particles was measured as described previously with 
minor modifications (20). 3 5 - 40 mg of nCrnP or MP was weighed into a glass tube. The 
tube was tapped 200 times to ensure efficient packing of the nCmP and then the volume 
occupied by the particles was measured using calipers. The density was determined by 
the following equation: 
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m p=-
v 
where p is the tapped density, m is the particles mass, and V is the volume occupies by 
the particles as determined by measuring the height of the particles in the tube with a 
known diameter (5 mm). The theoretical MMAD (MMADT) of the particles was then 
calculated using the following equation: 
where d is the geometric diameter determined by ImageJ, p is the tapped density of the 
particles, and p * = 1 g/cm3, which is the reference density of solid polymer. 
6.2.9 Drug Loading Analysis of CUR nCmP and CUR MP 
Drug loading and encapsulation efficiency of CUR nCmP and CUR MP were 
determined via fluorescence spectroscopy (Biotek Cytation 3, Winooski, VT). All 
particle samples were dissolved in DMSO and were evaluated at 420 nm (excitation) and 
520 nm (emission). The CUR drug loading and encapsulation efficiency (EE) of the 
particles were determined by the following equations: 
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D l d. mass of CUR loaded in particles rug oa mg = ---------=----
mass of particles 
E l . ffi . (EE) mass of CUR loaded in particles x 1000/0 ncapsu at1on e ic1ency = ----------- ;re 
initial mass of CUR in particles 
6.2.10 In Vitro Drug Release from nCmP and MP 
The in vitro release profiles of CUR from nCmP and MP were determined via the 
release of suspended particles (0.5 mg/rnL, 1.5 mL) in modified phosphate buffer (0.1 M, 
pH= 7.4, 0.5 wt% Tween® 80) and modified acetate buffer (0.1 M, pH= 5, 0.5 wt% 
Tween® 80). The particle suspension was incubated at 3 7 °C and 100 rpm. At various 
time points, particle samples were centrifuged at 23102 x g for 5 minutes at 4 °C to 
isolate the NP. 200 µL of supernatant was withdrawn and replaced by the same amount of 
fresh modified buffer in each sample. The withdrawn solutions were mixed with same 
volume of DMSO and analyzed for CUR content via fluorescence spectroscopy using the 
same method described for drug loading. The release data was fitted to several commonly 
utilized drug release models (S.6.1) to study the mechanism of drug release of Ac-Dex 
particles. The coefficient of determination (R2) was applied to test the applicability of the 
release models. 
6.2.11 Differential Scanning Calorimetry (DSC) 
The thermal phase transitions of the nCmP, MP, and their raw components were 
determined via DSC using a TA QlO DSC system (TA Instruments, New Castle, DE, 
USA) equipped with an automated computer-controlled TA instruments DSC refrigerated 
cooling system. 1 - 3 mg of sample was weighed into Tzero ™ alodine-coated aluminum 
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pans that were hermetically sealed. The sealed pans were placed into the DSC furnace 
along with an empty sealed reference pan. The heating range was 0 - 200 °C at a heating 
rate of 10 °C/min. 
6.2.12 Powder X-Ray Diffraction (PXRD) 
The crystalline states of the nCmP, MP, and its raw components were examined 
by PXRD using a Rigaku Multiflex X-ray diffractometer (The Woodlands, TX) with a Cu 
Ka radiation source (40 kV, 44 mA). The samples were placed on a horizontal quartz 
glass sample holder (3 mm) prior to analysis. The scan range was 5 - 60° in 28 with a 
step width of 0.1 and scan rate of 1 ° /min. 
6.2.13 Karl Fischer Coulometric Titration 
The water content of the nCmP and MP was quantified by Karl Fischer (KF) 
titration using a 737 KF coulometer (Metrohm, Riverview, FL). 5 mg of powder was 
dissolved in anhydrous methanol. The resulting solution was injected into the KF reaction 
cell filled with Hydranal® KF reagent and then the amount of water was analyzed. Pure 
solvent was also injected for use as a background sample. 
6.2.14 In Vitro Aerosol Dispersion Performance with the Next Generation Impactor 
(NGI) 
In vitro aerosol dispersion performance of the nCmP and MP was evaluated using 
a Next Generation Impactor™ (NGI™, MSP Corporation, Shoreview, MN) equipped 
with a stainless steel induction port (USP throat adaptor) attachment and stainless steel 
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gravimetric insert cups. The NGI™ was coupled with a Copley TPK 2000 critical flow 
controller, which was connected to a Copley HCP5 vacuum pump (Copley Scientific, 
United Kingdom). The air flow rate (Q) was measured and adjusted to 60 Umin in order 
to model the flow rate in a healthy adult lung before each experiment. Glass fiber filters 
(55 mm, Type AJE, Pall Life Sciences, PA) were placed in the gravimetric insert cups for 
stages 1 through 7 to minimize particle bounce or re-entrapment (10) and these filters 
were weighed before and after the experiment to determine the particle mass deposited on 
each stage. Approximately 10 mg of powder was loaded into a hydroxypropyl 
methylcellulose (HPMC, size 3, Quali-V®, Qualicaps® Inc., Whitsett, NC, USA) capsule 
and the capsule was placed into a human dry powder inhaler device (HandiHaler, 
Boehringer Ingelheim Pharmaceuticals, CT) attached to a customized rubber mouthpiece 
connected to the NGI™. Three HPMC capsules were loaded and released in each 
measurement and experiments were performed in triplicate. The NGI™ was run with a 
delay time of 10 s and running time of 10 s. For Q = 60 Umin, the effective cutoff 
diameters for each stage of the impactor were given from the manufacturer as: stage 1 
(8.06 µm); stage 2 ( 4.46 µm); stage 3 (2.82 µm); stage 4 (1.66 µm); stage 5 (0.94 µm); 
stage 6 (0.55 µm); and stage 7 (0.34 µm). The fine particle dose (FPD), fine particle 
fraction (FPF), respirable fraction (RF), and emitted dose (ED) were calculated as 
follows: 
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initial particle mass loaded into capsules 
R . bl fr . (RF) mass of particles on Stages 2 through 7 x 100010 esprra e act10n = ---"-------------- :tc 
total particle mass on all stages 
Emitted Dose (ED)= initial mass in capsules - final mass remaining in capsules x lOO% 
initial mass in capsules 
The experimental mass median aerodynamic diameter (MMADr) and geometric 
standard deviation (GSD) for the particles were determined using a Mathematica® 
program written by Dr. Warren Finlay (10, 21). 
6.2.15 Statistical analysis 
All measurements were performed in at least triplicate. Values are given in the 
form of mean ± standard deviation. The statistical significance of the results was 
determined using analysis of variance (ANOV A) and student's t-test. A p-value of <0.05 
was considered statistically significant. 
6.3. Results and Discussion 
6.3.1 Preparation and Characterization of Ac-Dex and Curcumin Nanoparticles 
6.3.1.1 NMR Analysis of Ac-Dex 
Successful synthesis of Ac-Dex was confirmed by 1H NMR. Ac-Dex-5min 
exhibited 61.2% cyclic acetal coverage (CAC) and 71.6% total conversion of -OH 
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groups, while Ac-Dex-3h exhibited 82.5% CAC and 80.0% total conversion of -OH 
groups. The Ac-Dex with longer synthesis time (Ac-Dex-3h) exhibited a higher CAC, 
which was in accordance with previous studies. An increase in CAC is known to decrease 
polymer degradation and ultimately, the drug release rate, due to the slower degradation 
of the cyclic acetal groups on the Ac-Dex backbone (13, 14). Ac-Dex-3h also showed a 
higher total conversion of -OH groups, which could be a result of elongated reaction 
time. This higher total acetal coverage is favorable in the enhancement of the stability of 
the PV A coating of nanoparticles (data not shown), thus ensuring small particle size and 
narrow size distribution. 
6.3 .1.2 Dynamic Light Scattering (DLS) Analysis of Original and Redispersed CUR NP 
Average nanoparticle (NP) size, size distribution/polydispersion index (PDI), and 
zeta potential are shown in Table 6.1. No significant changes in NP size, PDI, or zeta 
potential was found between the original and redispersed NP (p < 0.05), indicating that 
the CUR NP maintained their desirable properties after redispersion. The original and 
redispersed NP exhibited an average diameter of approximately 200 nm, which is in the 
desirable range to avoid macrophage clearance and mucus entrapment (18). The low PDI 
value denotes a narrow size distribution of the NP, and the slightly negatively charged 
surface of nanoparticles, as measured by zeta potential, is desirable in order to reduce the 
interactions with negatively charged mucin fibers in the airway mucus (22). According to 
our preliminary experiments (data not shown), a low total conversion of -OH groups on 
the Ac-Dex results in NP with larger sizes and PDI due to NP agglomeration. This 
phenomenon could be a result of the lessened hydrophobicity of Ac-Dex with fewer -OH 
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groups converted to acetal groups, which leads to insufficient absorption of PV A on the 
NP surface. However, the Ac-Dex in this study was prepared to produce NP with small 
sizes and low PDI, as the total conversion of -OH groups was kept in a higher range to 
prevent NP agglomeration. 
Table 6.1. Average diameter (as measured by dynamic light scattering), polydispersity 
index (PDI), and zeta potential (ZP) of CUR-loaded nanoparticles before spray drying 
(NP) and after redispersion from nanocomposite microparticles (nCmP) (mean± standard 
deviation, n = 3). 
Average PDI ZP (mV) Diameter (nm) 
NP-Smin 192.2 ± 2.7 0.07 ± 0.03 -8.4 ± 4.1 
NP-h 201.1±1.5 0.02 ± 0.01 -8.0± 3.7 
NP-3h 206.l ± 1.3 0.03 ± 0.03 -7.0 ± 1.6 
nCmP-Smin 199.3 ± 1.3 0.09 ± 0.02 -14.5 ± 1.0 
nCmP-h 210.2 ± 2.5 0.07 ± 0.01 -13.3 ± 1.9 
nCmP-3h 213.5 ± 2.4 0.02 ± 0.00 -11.2±1.6 
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Figure 6.2. SEM micrographs of curcumin-loaded nanocomposite microparticles (CUR 
nCrnP) and microparticles (CUR MP) including: (A) CUR nCmP-5min, (B) CUR nCmP-
h, (C) CUR nCmP-3h, (D) CUR M~-5min, (E) CUR MP-h, and (F) CUR MP-3h 
systems. Scale bar = 2 µm. 
6.3.2 Preparation and Characterization of Nanocomposite Microparticles (nCmP) 
and Microparticles (MP) 
6.3.2.1 Morphology, Sizing, and Size Distribution 
CUR nCmP displayed a wrinkled and raisin-like surface with visibly encapsulated 
NP as seen in Figures 6.2A-C. The raisin-like morphology of the nCrnP can be attributed 
to the early formation of nanoparticle shells in the solution droplets during spray drying, 
which determines the geometric size of nCmP during spray drying. As the drying process 
proceeds, the remaining solvent evaporates from the droplet center, resulting in hollow 
particles that tend to shrink (23 , 24). 
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CUR MP were collapsed spheres with smooth surfaces as seen in Figures 6.2D-F. 
Differing the Ac-Dex composition of particles had no impact on particle morphology. 
The geometric diameters ( dg) of the CUR nCmP and MP system are shown in Table 6.2. 
All of the MP dg were approximately 1 µm in size, which is reported to make the particles 
vulnerable to macrophage uptake (25). On the contrary, the nCmP system can escape 
macrophage clearance as they dissociate into NP upon reaching the deep lung. 
Table 6.2. Geometric diameter (as measured by SEM imaging and ImageJ analysis), 
water content, tapped density, theoretical mean mass aerodynamic diameter (MMADT), 
drug loading, and drug encapsulation efficiency of nCmP and MP (mean ± standard 
deviation, n = 3). 
Drug 
Geometric Water Tapped Loading 
Encapsulation 
Particle Diameter Content Density MMADT (mg/100 Efficiency System (µ.m) (%) (g/cm3) (µ.m) mg (%) 
particle) 
nCmP- 7.69± 0.122 ± 0.52 ± 0.57± 28.7 ± 0.32 
Sm in 1.50 ± 0.52 0.76 0.001 0.09 0.006 
nCmP- 7.89 ± 0.115 ± 0.60 ± 0.58 ± 28.4 ± 0.42 
h 1.78 ± 0.67 1.56 0.004 0.09 0.008 
nCmP- 7.86 ± 0.133 ± 0.64± 0.62± 31.2 ± 0.63 
3h 1.77 ± 0.87 0.43 0.002 0.12 0.013 
MP- 6.12 ± 0.050 ± 0.21 ± 1.33 ± 66.3 ± 4.62 
Sm in 0.93 ± 0.34 1.33 0.001 0.03 0.092 
5.87± 0.050 ± 0.29± 1.03 ± 51.6 ± 1.48 MP-h 1.29 ± 0.42 1.85 0.001 0.32 0.030 
5.23 ± 0.052 ± 0.23 ± 1.12 ± 55.8 ± 0.61 MP-3h 1.03 ± 0.45 1.13 0.001 0.03 0.012 
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6.3.2.2 Analysis of Particle Density 
The density of the particles was determined via tapped density measurements, as 
shown in Table 6.2. CUR nCmP exhibited tapped density values around 0.12 g/cm3, 
while the MP system showed values around 0.05 g/cm3• These density values are 
relatively low compared with the raw materials ( ~ 1 g/cm3), which can be attributed to the 
wrinkled morphology and hollow structures of the particle systems. It has been reported 
that particles > 1 µm in diameter and having greater density will get deposited in the lung 
by sedimentation (26). Therefore, the increased density of CUR nCmP system as 
compared to MP will enhance their rate of deposition into the deep lung. 
6.3.2.3 CUR Loading and in Vitro Release of CUR 
CUR was successfully encapsulated into both the nCmP and MP systems as seen 
in Table 6.2. The MP systems prepared via closed mode, organic spray drying exhibited 
higher encapsulation efficiency (EE, > 50%) than the nCmP systems (approximately 
30%) prepared in open mode in aqueous solutions. The lower EE of the nCmP can be 
attributed to the low EE of the original CUR-loaded NP, which was also approximately 
30%. The spray drying process had no influence on the CUR loading and EE for the 
nCmP systems (p < 0.05), which indicates that the drug loading of nCmP systems can be 
determined during NP preparation. 
Results of the in vitro release of CUR from nCmP and MP systems in modified 
phosphate (pH 7.4) and acetate (pH 5) buffers at physiological temperature (37°C) are 
reported in Figure 6.3 as the percentage of cumulative drug released over time. As shown 
in Table C.1, all particle systems exhibited shorter release duration and increased release 
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of CUR (p < 0.05) at acidic pH (except nCmP-5min), which is in accordance with 
previous studies (2, 27). The pH-sensitive release profiles suggest that the drug will be 
released at significantly higher rates once the carrier particles reaches an acidic 
environment. This can allow the Ac-Dex particles the ability to provide the controlled 
release of a therapeutic payload in cells and tissue with lower pH values, such as tumor 
cells and macrophages. On the contrary, if the carrier particles remain in the extracellular 
or neutral pH environments, the release rate can be reduced, which will minimize 
systemic and local cytotoxicity (2). 
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Figure 6.3. In vitro drug release profiles for curcumin (CUR) nanocomposite 
microparticle (nCmP) and microparticle (MP) systems including CUR nCmP-5min, CUR 
nCrnP-h, CUR nCrnP-3h, CUR MP-5min, CUR MP-h, and CUR MP-3h at pH 5 and 7.4. 
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In addition, the nCmP systems exhibited faster release than MP systems, which is 
likely due to the larger surface area available in the nano-sized delivery systems. Upon 
reaching an aqueous environment, the nCmP dissociate into nanoparticles with large 
surface area and a PVA coating that facilitates particle dispersity, while the MP may 
agglomerate due to their highly hydrophobic surfaces. As a result, the nCmP systems 
undergo faster polymer degradation and drug diffusion, resulting in a faster release of 
payloads than MP at both acidic and physiologic pH. Particles made of Ac-Dex-3h 
exhibited slower release rates than those comprised of Ac-Dex-5min, indicating that the 
drug release rate can be controlled by the polymer reaction time. At pH 7.4, particles 
made of Ac-Dex-h exhibited a drug release rate between Ac-Dex-5 min and Ac-Dex-3h, 
suggesting that the ratio of different types of Ac-Dex can also act as an important factor 
in adjusting the release profiles of particle systems. However, the drug release rates of the 
Ac-Dex particles at pH 5 did not follow this trend, which could be explained by the 
following two mechanisms: (1) The release profile of Ac-Dex particles is polymer 
degradation/erosion controlled, and the decomposition of the Ac-Dex matrix is greatly 
impacted by buffer pH. A study based on design of experiment will be conducted in our 
further research to illustrate the influence of potential factors (reaction time, polymer 
ratio, particle size, and pH) on the drug release profile of particle systems. (2) The release 
profile of Ac-Dex particles is both polymer degradation/erosion and drug diffusion 
controlled. In previous studies, the drug release of Ac-Dex particles is believed to be 
associated with Ac-Dex degradation (2, 14, 15). However, Ac-Dex degradation may 
cause surface erosion of particles, formation of large pores in the particles that facilitate 
drug diffusion, or both at the same time. As a result, the drug release profile could be 
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controlled by drug diffusion through water-filled pores (diffusion controlled), polymer 
erosion on the particle surface (erosion controlled), or both drug diffusion and surface 
erosion (diffusion and erosion controlled), respectively (13). 
In order to further illustrate the mechanism of drug release of Ac-Dex particles, 
we fit the release data to several commonly utilized drug release models, including: (1) a 
first order model and (2) Hixson-Crowell model for drug dissolution controlled release, 
(3) Higuchi model modified to fit the burst release at time 0, ( 4) Korsmeyer-Peppas 
model and (5) Baker-Lonsdale for drug diffusion controlled release, (6) Hopfenberg 
model for surface erosion controlled, (7) Baker's model for both degradation and 
diffusion controlled, and (8) Weibull model as a general empirical equation to describe a 
dissolution or release process (28-32). The coefficient of determinations (R2) of all the 
models are summarized in Table C.2, and the modified Higuchi and Baker-Lonsdale 
models exhibited higher R2 compared with other models, indicating that the drug release 
profile of Ac-Dex particles in both pH buffers was due primarily to drug diffusion. For 
Baker's model (28) that describes a degradation and diffusion process, the optimal 
coefficient k was 0, making the Baker's model the same with Higuchi model. 
Considering that the degradation of Ac-Dex was observable during the release test, the 
release profile of Ac-Dex particles can be explained by the mechanism of drug diffusion 
through water-filled pores (32). In this process, water was absorbed by Ac-Dex particles 
and filled in the pores of the polymer matrix, through which the drug diffused into the 
buffer. As polymer degraded, both pore size and number increased, leading enhanced 
drug release. Therefore, the reaction time of Ac-Dex affected the drug release rate 
significantly by controlling the formation of pores of particle matrix but not polymer 
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degradation on the surface. Meanwhile, the water absorption into the particles may also 
influence the drug release rate, which can be supported by the fact that Ac-Dex-3h had a 
higher ratio of total hydrophobic acetalated group conversion than Ac-Dex-5min. The 
fitted release curves using modified Higuchi model are shown in Figure S6.1 along with 
the original data points. The model was modified to fit the burst release at time 0 of some 
of the particle systems, which is attributed to the CUR initially available on the surface of 
particles. The nCmP systems exhibited a higher release at time 0 because that the 
nanoparticle suspension was sonicated before spray drying to form a uniform dispersion, 
which may lead to CUR release in to the suspension. 
3.3.2.4 Karl Fischer Titration 
The residual water content of CUR nCmP and MP is shown in Table 6.2. The 
water content of nCmP system was approximately 8%, while that of MP system was 
approximately 6%. The lower water content of MP samples is likely due to the absence of 
water during the closed mode spray drying process. All the particle systems showed 
acceptable water content. In general, reducing the water content in inhalable dry powders 
can significantly improve their dispersion properties and enhance the stability of the 
powders during storage (33, 34). Correspondingly, low water content in inhalable dry 
powders is highly favorable for efficient dry powder aerosolization and effective particle 
delivery (34, 35). 
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6.3.2.5 Differential Scanning Calorimetry 
Figure 6.4 shows DSC thermograms of the raw materials used in particle 
preparation and the final CUR nCmP and CUR MP systems. Both the raw Ac-Dex-5min 
and Ac-Dex-3h displayed endothermic main phase transition peaks (Tm) near 170 °C. 
The peaks were broad because of the wide size distribution of Ac-Dex polymer 
crystallites. The raw CUR powder displayed a sharp peak at 180 °C corresponding to the 
melting point of crystalline CUR, which is consistent with earlier studies (36). None of 
the CUR nCmP systems exhibited a peak corresponding to Ac-Dex melting, which 
indicates that the Ac-Dex was turned amorphous by rapid precipitation during NP 
formation. All of the CUR MP systems exhibited a broad peak near 160 °C, which 
corresponds to the melting of Ac-Dex. This phase transition shifted to the lower 
temperature range, indicating an increase in the amorphous state of Ac-Dex after the 
spray drying process. None of the CUR nCmP or CUR MP displayed melting peaks that 
would correspond to raw CUR, indicating that the crystalline CUR was converted to an 
amorphous phase during particle preparation. 
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Figure 6.4. Representative differential scanning calorimetry (DSC) thermograms of raw 
curcumin (CUR), raw acetalated dextran-5min (Ac-Dex-5min), raw acetalated dextran-3h 
(Ac-Dex-3h), CUR nCmP-5min, CUR nCmP-h, CUR nCmP-3h, CUR MP-5min, CUR 
MP-h, and CUR MP-3h. 
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6.3.2.6 Powder X-ray Diffraction (PXRD) 
X-ray diffraction diffractograms of the raw materials, CUR nCmP, and CUR MP 
are shown in Figure 6.5. Strong peaks were present for raw CUR indicating that it is in a 
crystalline form prior to spray drying. No peaks were present for either raw Ac-Dex 
samples, suggesting an irregular distribution of Ac-Dex crystallites. The absence of 
diffraction peaks from Ac-Dex is quite different from commercialized polymers such as 
PLGA, which exhibits strong XRD characterization peaks (34). This phenomenon is 
likely because the Ac-Dex was collected by rapid precipitation in water, which prevents 
the formation of large polymer crystallites. XRD diffractograms of the CUR nCmP and 
CUR MP were absent in any diffraction peaks corresponding to raw CUR, indicating that 
the crystalline CUR was converted to an amorphous phase in the spray drying or 
emulsion evaporation process. The amorphization of raw payloads into the particle 
matrix is suitable for the improvement in solubility of hydrophobic drugs in physiological 
conditions. The results obtained from the XRD diffractograms confirmed those from 
DSC thermograms, which proves that raw CUR was converted to amorphous forms 
during the particle manufacturing process. 
6.3.2.8 In Vitro Aerosol Dispersion Performance Using Next Generation Impactor (NGI) 
In vitro aerosol dispersion performance properties of the nCmP were evaluated 
using a Next Generation Impactor™ coupled with a human DPI device (Figure 6.6 and 
Figure 6. 7). The results indicated that the formulated nCmP and MP are favorable for 
efficient dry powder aerosolization and effective targeted pulmonary delivery. The mass 
mean aerodynamic diameter (MMAD) value of all particle systems were approximately 2 
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µm, while the geometric standard deviation (GSD) value was 2 -3 µm. The MMAD value 
is within the range of 1 - 5 µm that is required for predominant deposition of particles 
into the deep lung region (3 7), which would be desirable to deliver therapeutics for the 
treatment of both local pulmonary and systematic diseases through the lung. The 
theoretical MMAD (MMADr, shown in Table 2), calculated using the geometric 
diameter and tapped density, was lower than the experimental results (MMAD1). This 
could be due to particle agglomeration, which increased the geometric size of the dry 
powder. The GSD values were within the range of those previously reported and the 
respirable fraction (RF), fine particle fraction (FPF), and emitted dose (ED) values were 
all higher than reports from similar systems (10, 37, 38). The formulated Ac-Dex particle 
systems are expected to achieve an improved therapeutic effect with a reduced amount of 
payloads by effectively delivering the drug into deep lung region. 
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Figure 6.5. Representative powder X-ray diffractograms (PXRD) of raw curcumin 
(CUR), raw acetalated dextran-5min (Ac-Dex-5min), raw acetalated dextran-3h (Ac-Dex-
3h), CUR nCmP-5min, CUR nCmP-h, CUR nCrnP-3h, CUR MP-5min, CUR MP-h, and 
CURMP-3h. 
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Figure 6.6. Aerosol dispersion performance of curcumin-loaded nanocomposite 
microparticles (CUR nCmP) and microparticles (CUR MP) as % particles deposited on 
each stage of the Next Generation Impactor™ (NGI™). For Q = 60 L/min, the effective 
cutoff diameters (D5o) for each impaction stage are as follows: stage 1 (8.06 µm), stage 2 
(4.46 µm), stage 3 (2.82 µm), stage 4 (1.66 µm), stage 5 (0.94 µm), stage 6 (0.55 µm), 
and stage 7 (0.34 µm) (mean± standard deviation, n = 3). 
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Figure 6.7. Jn vitro aerosol dispersion performance properties including fine particle dose 
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curcumin loaded nanocomposite microparticles (CUR nCmP) and microparticles (CUR 
MP) (mean± standard deviation, n = 3). 
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6.4. Conclusions 
Two types of pulmonary delivery systems were successfully formulated using Ac-
Dex with two different degradation rates. MP were wrinkled spheres (approximately 1 
µm) with smooth surfaces, while nCmP were 1.5 µm with wrinkled surfaces that 
dissociated into 200 nm nanoparticles upon being reconstituted in water. The variation in 
the drug release rates from the Ac-Dex particles were determined by the Ac-Dex reaction 
time, ratio of two types of Ac-Dex, and the particle size, which could be easily tuned 
during the manufacturing process. The pH value of environment also had a significant 
influence on the release profiles, allowing the Ac-Dex particles to release the payload in a 
controlled fashion. All nCmP and MP systems exhibited desirable properties as dry 
powder inhalation therapeutics, including small aerodynamic diameters, which is suitable 
for deep lung delivery, low water content, which is favorable for particle storage, and 
amorphization of a crystalline payload, which improves the efficiency of drug 
dissolution. Overall, the engineered Ac-Dex aerosol particle systems have the potential 
for targeted delivery of therapeutics in to the deep lung. Meanwhile, these dry powder 
formulations also provide more convenient administration, more flexible storage 
conditions, and lower risk of contamination in the device. 
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CHAPTER 7 
Conclusions and Future Work 
7.1 Conclusions 
This dissertation focuses on the development, characterization, and optimization 
of dry powder aerosol nanocomposite microparticle systems for the treatment of 
pulmonary diseases. Azithromycin and rapamycin were encapsulated in Ac-Dex 
nanoparticles for potential application in the treatment of cystic fibrosis-related lung 
infections. These nanoparticles were coated with VP5k to ensure effective dispersion in 
and facilitate penetrating through viscous mucus caused by cystic fibrosis. Nanoparticles 
coated with PV A were able to maintain a favorable dispersion and can be used to deliver 
tacrolimus for the treatment of pulmonary arterial hypertension. 
In the production of nanoscale carriers, Ac-Dex with different degradation rates 
were applied to form polymer matrices with tunable release profiles. The drug release 
rates of the Ac-Dex particles were determined by the Ac-Dex reaction time, ratio of two 
types of Ac-Dex, and particle size, which could be easily tuned during the manufacturing 
process. The pH value of environment also had a significant influence on the release 
profiles, allowing the Ac-Dex particles to release the payload in a controlled fashion. 
Nanocomposite microparticles were formulated using spray drying a suspension 
of nanoparticles. The optimal spray drying conditions were identified to prepare nCmP 
systems with favorable properties including: small aerodynamic diameter, effective 
nanoparticle redispersion, high drug loading, and low water content. Meanwhile, the safe 
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range of spray drying parameters were discussed to ensure the stability of therapeutics 
and formulations. 
This is the first time that the dry powder aerosol nanocomposite microparticle 
systems have been comprehensively studied for the treatment of pulmonary diseases. The 
dissertation presents a strategy to develop nanoscale carriers with capability of protecting 
of drugs from degradation, enhancing of the solubility of drugs, releasing payloads at 
controlled rate, and overcoming physiological barriers. In addition, the optimal 
conditions to formulate microscale carriers with advantages including targeted deposition 
in the airways, high drug loading, enhanced stability, and maintenance of the favorable 
properties of embedded nanoparticles were elucidated. 
7.2 Future Work 
This dissertation provides the first comprehensive study on developing and 
optimizing dry powder aerosol nanocomposite microparticle systems for the treatment of 
pulmonary diseases. Many opportunities exist to conduct further research based on this 
delivery system, which may include, but are not limited to: 
• Investigation of the safety and antibacterial efficacy of azithromycin-loaded Ac-
dex nanoparticle with VP5k coating for the treatment of cystic fibrosis-related 
infections. 
• Development of Ac-dex nanoparticles with vanous coating materials and 
investigation of the safety of these nanoparticles, which could be used to targeted 
delivery of therapeutics. 
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• Optimization of the spray drying conditions to formulate nCmP encapsulated with 
Ac-dex nanoparticles with various coating materials for pulmonary delivery or 
systemic delivery of therapeutics through the lungs. 
• Investigation of the safety and efficacy of tacrolimus-loaded nCmP for the 
treatment of pulmonary arterial hypertension by in vivo study using an animal 
model. 
• Development of nCmP comprised of hydrophilic encapsulated nanoparticles and a 
hydrophobic excipient of microscale carriers, which could be applied to provide 
sustained release of hydrophilic drugs with short half-lives. 
• Application of the general-purpose nCmP system for protein, DNA, and RNA 
delivery to the lung. 
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Supplementary Material for Chapter 3 
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Table A.l. Characterization of nanoparticles after redispersion from nanocomposite 
microparticles in PBS including the size, polydispersity index (PDI), and zeta (~) 
potential. 
System 
AZI-NP 
RAP-NP 
Blank-NP 
Diameter (nm) 
327.6 ± 3.7 
348.2 ± 11.6 
270.8 ± 10.8 
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PDI 
0.32 ± 0.02 
0.43 ± 0.01 
0.26 ± 0.04 
~Potential (m V) 
-7.66 ± 0.68 
-5.99 ± 0.07 
-3.98 ± 0.67 
I 
0 
HO-s. -~. O 
HO . . .., \ $2 ~ ~ 
OH l 
+ o--._, 
·~. cx.·· C"3·~·· · · .·•. ·· .. o •.• H;,C'-. . \ 0 . 0 
HO HO 
6 PPTS (catalyst) 0 
' HO~..:::, OMSO 
0 
I 
0 
+ 
Figure A.1. Schematic of Ac-Dex synthesis 
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Figure A.2. NMR spectra of VP5k where (top) indicates entire spectra and (bottom) is an 
enlarged portion. 
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Figure A.3. NMR spectrum of acetalated dextran degradation products. 
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Figure A.4. Structure of azithromycin 
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Figure A.5. Structure of rapamycin 
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Figure A.6. Next generation impactor (NGI) is a high-performance, precision, particle 
classifying cascade impactor designed for testing MDis, DPis, nebulizers and aerosol and 
nasal sprays. (www.mspcorp.com) 
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Figure B.1. Structure of tacrolimus 
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Table C.l. Summary of curcumin-loaded nanocomposite microparticle (nCmP) systems 
and their corresponding inlet temperature (Tin), nanoparticle loading (NP %}, and feed 
concentration (Fe). 
nCmP Tin (°C) NP Fe(%) {%} 
A 50 50 2.5 
B 130 50 2.5 
c 90 20 2.5 
D 90 80 2.5 
E 50 20 1.5 
F 90 50 1.5 
G 50 80 1.5 
H 130 80 1.5 
I 130 20 1.5 
J 50 50 0.5 
K 90 80 0.5 
L 130 50 0.5 
M 90 20 0.5 
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Figure C.1. Representative SEM micrographs of curcumin-loaded nanocomposite 
microparticle systems (CUR nCmP) corresponding to Table B.l. Scale bar = 5 µm. 
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Figure C.2. Representative SEM micrographs showing the crack generation caused by 
the high energy electron beam where (A) was taken just after the initial focusing on the 
particles and (B) was taken 5 seconds after focusing. Scale bar = 5 µm. 
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Figure C.3. Structure of curcumin 
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Table C.2. Summary of the nCmP properties following spray drying. 
Factors Responses 
Tin NP Fe 
Water Size PDI Zeta Tout Yield Run Content change Potential (OC) (%) (%) 
_(o/<>)_ change(%) _(o/<>)_ Chan_ge_(%) (°C) (%) 
1 130 80 1.5 4.51% 0.2% -2.9% -2.9% 71.5 38.8 
2 50 50 0.5 5.71% 5.6% 20.0% 20.4% 30.5 59.3 
3 50 50 2.5 3.82% 0.0% 31.4% 13.3% 31.5 67.0 
4 90 50 1.5 2.95% 2.5% 14.3% -32.5% 51.0 60.6 
5 90 80 0.5 5.94% 9.7% 17.1% -22.3% 51.5 50.0 
6 90 50 1.5 3.41% 4.9% 14.3% -30.1% 50.5 62.0 
7 50 20 1.5 5.43% 1.0% -21.4% -62.2% 34.5 50.2 
8 90 80 2.5 4.69% 4.9% 57.1% -14.9% 52.5 65.9 
9 130 50 0.5 5.66% 7.5% 30.0% -61.0% 72.0 43.6 
10 90 20 2.5 2.63% 4.8% 20.0% -59.7% 49.5 41.2 
11 130 50 2.5 3.84% 1.1% -20.0% -1.1% 69.0 53.4 
12 90 50 1.5 3.23% 2.3% -1.4% -32.4% 50.5 60.1 
13 50 80 1.5 4.68% 4.2% 15.7% 8.9% 34.5 65.8 
14 90 20 0.5 6.72% -0.2% 32.9% -30.7% 49.0 43.4 
15 130 20 1.5 4.13% 8.3% 22.9% -38.2% 73.0 53.4 
Factors Responses 
Tin NP% Fe 
Drug EE MMAD GSD FPF RF EF 
Run Loading (°C) (%) (%) 
__{_o/<>)_ (%) (µm) (µm) (%) (%) (%) 
1 130 80 1.5 0.372 72.74 2.44 2.34 98.6% 76.0% 97.7% 
2 50 50 0.5 0.201 62.78 1.69 2.79 99.4% 77.2% 98.0% 
3 50 50 2.5 0.192 60.14 4.49 1.95 85.0% 57.9% 99.0% 
4 90 50 1.5 0.201 62.83 4.28 1.70 84.4% 60.9% 99.6% 
5 90 80 0.5 0.357 69.79 1.50 2.57 98.8% 86.0% 96.3% 
6 90 50 1.5 0.087 58.45 4.05 2.34 86.1% 67.4% 99.6% 
7 50 20 1.5 0.074 58.12 7.44 2.34 54.2% 48.4% 99.8% 
8 90 80 2.5 0.402 78.70 2.48 2.77 97.5% 70.0% 94.6% 
9 130 50 0.5 0.195 61.09 3.69 2.81 83.6% 73.0% 98.8% 
10 90 20 2.5 0.083 65.33 7.20 2.81 62.2% 38.0% 100.1% 
11 130 50 2.5 0.172 53.71 5.78 2.50 66.2% 55.8% 99.2% 
12 90 50 1.5 0.193 60.34 4.11 1.88 85.3% 61.6% 99.9% 
13 50 80 1.5 0.288 56.43 2.38" 2.71 98.1% 82.2% 95.7% 
14 90 20 0.5 0.093 72.93 3.24 3.00 83.3% 64.4% 97.1% 
15 130 20 1.5 0.113 88.07 5.46 1.88 68.8% 46.2% 100.0% 
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APPENDIXD 
Supplemental Material for Chapter 6 
D.1 Drug Release Model Description 
The drug release data of the particle systems was fitted to several models 
(equations shown below) to aid in the determination of the type of release the systems 
experienced. For the models that can be linearized (all models except for Baker's model), 
the coefficient of determination (R2) was utilized to determine the applicability of the 
release models. For Baker's model, Microsoft Excel with Solver add-in was applied to 
determine the parameters that minimize the sum of squares of the residues of the model. 
The models, equations, and their corresponding parameters for are as follows: 
First order model: K log Mi= logMo+--t 
2.303 
where Mt is the amount of drug released at time t, Mo is the initial amount of drug in the 
solution, and K is the first order release constant. 
Weibull model: 1 ( -(t-Ti)b) m= -exp 
a 
where m is the accumulated fraction of the drug released at time t, a is the scale 
parameter, which defines the time scale of the process, Ti is the location parameter, which 
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represents the lag time before the onset of the dissolution or release process, and b is the 
shape parameter, which characterizes the shape of release curve. 
Higuchi model: Mi= Kt 112 + b 
where Mt is the amount of drug released at time t, K is the Higuchi dissolution constant, 
and b is the amount of drug released at time 0. 
Hixson-Crowell model: w113 - w 113 =Kt 0 t 
where W 0 is the initial amount of drug in the particles, W1 is the remaining amount of 
drug in the particles at time t, and K is a constant characterizing the surface to volume 
relationship. 
Korsmeyer-Peppas model: m = atn 
where a is a constant characterizing the structural and geometric properties of the 
particles, n is the release exponent, indicating the drug release mechanism, and m is the 
accumulated fraction of the drug released at time t. 
Baker-Lonsdale model: 3 2/3 -[1- (1- m) ] - m = Kt 
2 
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where K is the release constant and m is the accumulated fraction of the drug released at 
time t. 
Hopfenberg model: m = 1- [1- Kt(t- l)r 
where K is a constant equal to k0/C0ao, where k0 is the erosion rate constant, Co is the 
initial concentration of drug in the matrix, and ao is the initial radius for particles. m is the 
accumulated fraction of the drug released at time t. 
where M1 is the amount of drug released in time t, Po is the drug permeability, A is the 
total area of the particle, Co is the drug concentration at the initial time, and k is the first-
order rate constant of bond cleavage of the polymer carrier. 
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Table D.1. The drug release duration and total released fraction of each particle system at 
both pH. 
pH=S pH= 7.4 
Particle Release Total Released Release Total Released 
System Duration (h) Fraction (%) Duration (h) Fraction (%) 
nCmP-5min 2 92.6 8 93.6 
nCmP-h 2 63.4 12 31.5 
nCmP-3h 4 73 24 23.7 
MP-5min 6 78 24 60.6 
MP-h 12 86.4 24 52.7 
MP-3h 24 68.5 168 24.9 
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Table D.2. Summary of the coefficient of determinations (R2) of all the models for all 
particle system. The model with relatively high R2 for all particle systems was regarded 
as applicable. 
pH=S 
Model nCmP - nCmP nCmP MP- MP-h MP-3h Sm in -h -3h Sm in 
First order 0.7835 0.8549 0.8511 0.573 0.4848 0.7517 
Hixson- 0.8615 0.9571 0.9613 0.847 0.8899 0.949 Crowell 
Higuchi 0.9468 0.9968 0.9989 0.9867 0.9748 0.9715 (modified) 
Korsmeyer- 0.9998 0.6906 0.505 0.81 0.8843 0.9882 
Peppas 
Baker-
Lonsdale 0.8729 0.9945 0.9799 0.9065 0.9595 0.9753 
Hopfenberg 0.5497 0.8743 0.9029 0.8925 0.849 0.9276 
Weibull 0.9098 0.5773 0.2538 0.9387 0.9936 0.9353 
pH= 7.4 
Model nCmP- nCmP nCmP- MP- MP-h MP-3h Sm in -h 3h Sm in 
First order 0.8084 0.7345 0.7574 0.3797 0.829 0.6414 
Hixson- 0.9312 0.8021 0.9482 0.7696 0.9117 0.8185 Crowell 
Higuchi 0.9573 0.8758 0.9732 0.9369 0.8288 0.9462 (modified) 
Korsmeyer- 0.899 0.5374 0.9457 0.8828 0.9349 0.9708 Peppas 
Baker- 0.9709 0.8172 0.9089 0.9283 0.9141 0.9079 Lonsdale 
Hopfenberg 0.8493 0.8678 0.9685 0.7462 0.8241 0.8526 
Weibull 1 0.5235 0.7905 0.9783 0.8897 0.8963 
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Figure D.1. Original data and fitted curves of in vitro drug release profiles for curcumin 
(CUR) nCmP and MP systems including CUR nCmP-5min, CUR nCmP-h, CUR nCmP-
3h, CUR MP-5min, CUR MP-h, and CUR MP-3h at pH= 5 and pH= 7.4. 
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